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1.0 Summary.
Dendritic cells (DCs) are antigen-presenting cells (APCs) which play a key role in 
the regulation of immune responses. DCs are unique APCs and are often referred 
to as “professional” APCs, since their primary function is to present antigens, 
e.g. from pathogens or malignant cells. DCs have the ability to induce a primary 
protective immune response to these antigens in resting naïve T lymphocytes. 
Consequently, there is a great deal of interest in how DCs might be exploited 
as a form of immunotherapy e.g. to induce immunity to cancers. However, 
DCs are also thought to play an important role in directing regulatory immune 
responses to innocuous antigens, which are targeted in autoimmune disease or 
during transplantation. Although fulfilling different roles, both responses are 
vitally important to maintain immune homeostasis. Soluble factors secreted by 
DCs are crucial mediators in determining this balance between the immunogenic 
and regulatory arms of the immune system. One such group of factors is 
cytokines. These cytokines are small proteins which are often grouped into 
different families based on structural similarities. One family which is gaining 
increasing attention is the IL-12 family. It is composed of four members; two 
are immunogenic and their expression has been very well characterised in DCs. 
The other two are regulatory, but relatively little is known about their regulation 
and expression in DC populations. In this thesis we aim to give a comprehensive 
overview of the expression and regulation of IL-12 family members in human 
DCs, with a particularly emphasis on IL-12, IL-27 and IL-35. We will discuss 
how the local cellular environment and normal physiological processes, such as 
clearance of dying cells can affect cytokine production and DC function. We 
will give a detailed analysis of the regulation of IL-12 family members in DCs 
using sterile and non-sterile stimuli, and describe the production of a novel 
anti-inflammatory cytokine, IL-35, by tolerogenic DCs. We will demonstrate a 
previously unidentified role for complement components, properdin and fH, in 
the stimulatory capacity of DCs and describe a role for IL-27 in their regulation. 
Finally, we will touch on the expression IL-12 family members in human kidney 
and discuss changes in their expression during renal allograft rejection. 
1.1 History of Dendritic cells.
Dendritic cells (DCs) represent a heterogeneous population of APCs that are 
found in virtually all tissues of the body1. They were first described by Paul 
Langerhans as a new epidermal cell in the paper published in 1868 entitled “On 
the nerves of the human skin”, and these epidermal DCs still bear his name today. 
Over a hundred years later, cells of a comparable nature were first described in 
mouse peripheral lymphoid organs by Ralph Steinman and Zanvil Cohn in 19732. 
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Although their function at that time was not known, their name was derived from 
the surface projections they possessed which resembled dendrites of neurons, 
and so coined the term “dendritic cell”. These days we know that these dendrite 
projections somewhat allude to the primary function of DCs, which is to constantly 
probe and sample their environment for signs of damage or infection, followed 
by ingestion and breakdown of antigen into peptide for presentation3. Interest in 
DCs gathered pace in the 1990s when a model was proposed that described two 
distinct subsets of DCs, immature and mature. It was thought that immature DCs 
were derived from bone marrow and had not yet encountered antigen, while the 
mature cells were derived from tissues and must have encountered Ag in order 
to have undergone maturation4. However, some debate was ongoing in the field 
to understand how a lymphocyte, upon engagement with a DC, determined when 
to proliferate and attack, and conversely, when not to, if antigen alone was the 
sole conveyor of this information. Research conducted a few years prior to the 
immature/mature findings demonstrated that although antigen was required, it 
was not sufficient to drive the adaptive immune response, and that accessory 
functions of DCs were crucial5,6 (signal 2). 
1.2 Dendritic cells initiate the immune response.
For much of this time the accepted idea was that the main goal of the immune 
system was to eliminate or attack foreign pathogens “non-self”, while remaining 
nonreactive to endogenous proteins in the body “self”. This theory of self-
nonself, although compelling, contradicted again with the observations discussed 
earlier, that antigen alone although required, is not sufficient to induce an immune 
response. Unlike T cells which may be able to discriminate between self and 
foreign antigen, DCs cannot, so how does an APC regulate immunity versus 
tolerance, and what controls signal 2? 
In 1989, Charles Janeway, reasoned that the adaptive immune system must rely 
on other receptors that unlike T and B cell receptors, are not randomly generated, 
and have been evolutionarily selected over time7. Janeway hypothesised the 
“Infectious-Nonself” model, which suggested that microbial components were 
recognised by innate cells and that this recognition led to signal 2 required for 
lymphocyte activation8. Remarkably, within the next decade Janeway`s theory 
would be confirmed. 
Groundbreaking work initiated by the discovery of Toll by Hoffmann and 
colleagues in 19969, led Janeway and Medzhitov to describe LPS as a potent 
immune trigger to initiate NFκB signalling, leading to upregulation of co-
stimulatory molecule CD80 (signal 2) and release of cytokines IL-1 and IL-6 
in human cell lines10. Several publications followed, from various groups, 
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demonstrating a number of human receptors with Toll homology11-13, which are 
now collectively known as the Toll-like receptor (TLR) family. 
Janeway`s theory, although well articulated and for a large part proven, left some 
inexplicable phenomena, like allograft rejection and anti-tumour immunity, 
which both can occur in the absence of pathogens. His principle was further 
expanded on by Matzinger in 1994 in the article entitled “Tolerance, Danger 
and the Extended family”14. Matzinger reasoned that the immune system does 
not distinguish between self and non-self, but rather uses receptors, expressed on 
APCs, to recognise danger signals not only from pathogens, but also from injured 
or stressed cells.           
Prior to these discoveries, DCs had been described as merely “natural adjuvants”15. 
In less than 10 years, the discovery of innate receptors revolutionised DCs as an 
inextricable link between innate and adaptive immunity. It was already known 
that after antigen uptake, DCs efficiently process antigens for presentation in 
the context of MHC. However, these later findings led to the understanding that 
before DCs can prime the adaptive immune response, they must complete a full 
maturation process induced by alarmins; pathogen associated molecular patterns 
(PAMPs) and danger associated molecular patterns (DAMPs). We now know that 
DCs are equipped with an impressive repertoire of innate PRRs including, TLRs, 
NLRs, RLRs and CTLRs, which together grants them the ability to decipher the 
nature of a given insult. This allows DCs to mediate a fully integrated immune 
response, to provide not only signal 1, but also 2 and 3, which are essential to 
completely direct the specificity,strength and class of T cell responses (Figure 1). 
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1.3 Tolerogenic DCs- paving the way for immunological tolerance. 
Despite the identification of DCs in the early 1970s, research into this cell type, 
compared to T cells for example, was vastly under-represented. This stemmed 
from the difficulty in isolating DCs from whole blood, and the low cell yield 
when one succeeded. It was understood that DCs found in the periphery arose 
Figure 1: Polarisation of naive T cells depends on 3 key signals from DCs. Signal 1 
is the antigen-specific signal mediated via peptide MHC:TCR interaction. Signal 2 DCs 
become activated upon recognition of PAMPs or DAMPs expressed by pathogens or 
local injured tissues/cells. This leads to upregulation of co-stimulatory molecules CD80 
and CD86 which can trigger CD28 (on T cells) and leads to feedback stimulation of the 
DCs e.g. via ligation of CD40 on DCs by CD154. Signal 3 is the crucial polarising signal 
secreted by the activated DCs, and is mediated by various soluble factors such as IL-12 
and IL-4 which promotes the development of Th1 or Th2 cells, respectively. The nature 
of signal 3 depends on the activation of particular PRRs (TLRs, CTLRs) by PAMPs 
or DAMPs and can lead to a diverse secretion of various cytokines. Depending on the 
local environment and cytokines produced, naive Th0 cells can differentiate into helper 
T cell populations ranging from the important inflammatory Th1 subset to the equally 
important Tr1 regulatory subset. 
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from proliferating precursors within the bone marrow compartment, so several 
groups sought to generate DCs ex vivo, with the aim to obtain larger cell 
numbers for experiments. Steinman and colleagues demonstrated the generation 
of “large number” of DCs from murine bone marrow cultured in the presence 
of GM-CSF16 and many laboratories were also trying to generate human DCs 
from similar precursors. As a reward for the efforts of several groups17, often 
utilising HSCs as the starting population18,19, finally in 1994 a landmark paper 
from Sallusto and Lanzavecchia, described the in-vitro generation of human DCs 
from blood derived monocytes, maintained in GM-CSF and IL-420. Although 
not 100% homologous with blood derived myeloid DC (mDCs), monocyte- and 
HSC-derived DCs became a widely used tool to increase our understanding of 
human DC biology. Despite the identification of specific mDCs markers for 
isolation from peripheral blood, (BDCA1-4)21, monocyte derived DCs are still 
extensively used today as a model to study interstitial mDCs. This is distinct from 
the field of skin DC biology where innovative culture systems have facilitated 
the migration of native DCs directly from their environment. This remains the 
ultimate goal for studying interstitial DCs found in other human organs, but due 
to their scarcity and the lack of reliable techniques, this remains elusive.
Nevertheless using these in-vitro systems the concept of tolerogenic DCs (tolDCs) 
first arose when it was observed that treatment of HSC derived DCs with IL-10, 
resulted in a DC population with impaired allostimulatory ability22. In the years 
that followed many groups explored ways of generating tolDCs, from HSCs and 
monocytes in vitro using various anti-inflammatory and immunosuppressive 
agents. These agents included IL-1023,24, TGF-β25, adenosine and the vitamin 
D3 metabolite 1α, 25-dihydroxyvitamin D3 (1α, 25(OH) 2D3)26. Particularly in 
the field of transplantation, clinically approved immunosuppressive drugs such 
as corticosteroids27-29, cyclosporine30, tacrolimus and rapamycin31,32 have been 
used in vitro to target DC differentiation and function, with the latter molecule 
leading the greatest debate. It was found that although rapamycin interfered with 
monocyte-derived DC generation, it did not suppress mDC differentiation in vivo, 
and in fact increased their IL-12 production and T cell stimulatory capacity33. 
This study highlights the important of careful consideration before choosing 
an immunomodulatory strategy. The ability to induce tolerance in an antigen 
specific manner is the ultimate goal clinically, in fields such as transplantation, 
autoimmune disease and allergy34-38. The synthetic glucocorticoid, dexamethasone 
(Dex), amongst others, is already approved as a broad immunosuppressant for 
the treatment of a variety of autoimmune diseases including chronic idiopathic 
thrombocytopenic purpura39, systemic lupus erythematosus, and Graves’ disease. 
In these patients higher levels of regulatory T cells have been identified40, 
indicating that Dex is a promising tool clinically. More recently, exciting 
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studies have been performed using Dex as a tolerogenic adjuvant in a model of 
suppressed immunisation41. The authors showed that administration of Dex in 
combination with peptide antigen resulted in expansion of Ag specific T regs that 
persisted in vivo and prevented the development of autoimmune diabetes. The 
exact mechanism was further elucidated to be dependent on the Dex treatment 
which led to enrichment of tolerogenic APCs in vivo42, indicating that Dex does 
not only target T cells but also APCs. Additionally, extensive in vitro studies, 
performed with human DCs, showed that Dex altered the phenotype and function 
of DCs, rendering them tolerogenic, with absent production of IL-12 and a poor 
allostimulatory capacity27,28,43,44. 
In the field of transplantation there are two major hurdles to overcome 
immunologically, namely direct and indirect allorecognition, which can both 
result in graft injury and rejection. Depending on their origin (donor or recipient), 
tolDCs can be exploited to potentially treat both phenomena and prolong allograft 
survival. For the control of indirect alloreactivity, one could exploit tolDCs (of 
recipient origin) in vitro by loading the cells with antigen of donor origin. Although 
this has proved successful in preliminary murine experiments45, it will be important 
to identify which type of donor material would be most efficiently ingested by 
tolDCs, and to identify what source of dying material would be most effectively 
presented. Kuswah et al. suggested that specifically uptake of apoptotic murine 
DCs by DCs potently promotes immune tolerance46, but unfortunately they did 
not compare their findings to necrotic cells. Considering that immune tolerance 
remains the most promising, yet elusive, strategy for treating autoimmunity and 
preventing transplant rejection, much can be gained from understanding the exact 
mechanism of how apoptotic cells are able to promote immune tolerance. Finally, 
it will be very important to demonstrate that uptake of such material does not alter 
the tolerogenic nature of these cells and that their regulatory cytokine profile is 
maintained.
1.4 Dendritic cells and immune homeostasis.
Historically the maintenance of immunity versus tolerance has been attributed 
to T cells, and loss of tolerance, e.g. during autoimmunity, has been considered 
to be a “T cell problem”. However, there is an increasing body of evidence to 
support the idea that DCs are the master regulators of these processes, and as 
already mentioned, can be exploited therapeutically, for on the one hand boosting 
immunity to tumours or viruses, and on the other, restoring tolerance to innocuous 
antigens1,47. Until recently, immature DCs characterised as having low MHC and 
B7 molecules were believed to induce T-cell anergy or T regs, while mature 
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DCs expressing high levels of MHC and B7 molecules were the immunogenic 
DCs. This paradigm has been challenged by the observation that T regs can be 
induced by fully mature, antigen bearing DCs48,49. Similarly, semi-mature DCs50 
with a distinctive cytokine profile of IL-10+IL-12- have been shown to possess 
tolerogenic functions43, supporting the notion that the maturation status of DCs 
should no longer be the only distinguishing feature of immunogenic, as opposed 
to tolerogenic DCs (tolDCs)51. As such, the only true way to identify a regulatory 
DC compared to an immunogenic DC is to identify functional differences. 
Cytokines and chemokines receptors52,53 have proven to be very useful in 
differentiating helper T cell subsets. Greater understanding into the cytokine 
profile of different DC subsets would significantly enhance our understanding of 
disease pathogenesis and may aid identification of these subsets in vivo.
1.5 Dendritic cells and soluble mediators of immunity. 
A key mechanism of how DCs communicate with other cells, and ultimately 
orchestrate the nature and intensity of a given immune response is through the 
production of soluble mediators. 
1.5.1 Cytokines and Dendritic cells.
The most widely studied mechanism of how immune cells communicate with one 
another focuses on a large group of proteins called cytokines. These cytokines 
are low-molecular-weight proteins that regulate the nature, intensity and duration 
of the immune response. Historically cytokines have been classified into groups 
based on their cellular secretion or activity with regard to a given cell population. 
More recently cytokines have been grouped based on the cytokine receptors 
they utilise, which has led to the establishment of several major cytokine groups 
including:
•	 Haematopoietin family (utilises class I cytokine receptors) which includes; 
IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-11, IL-12, IL-13, IL-15, IL-21, IL-
23, IL-27, IL-35, GM-CSF, G-CSF, OSM, LIF, CNTF and prolactin.
•	 Interferon family (utilises class II cytokine receptors) which includes; 
IFN-α, IFN-β, IFN-γ and cytokines IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, 
IL-28 (IFN-λ 2/3), IL-29 (IFN-λ1). 
•	 TGF-β and Growth Factor family (utilises tyrosine kinase cytokine 
receptors) which includes TGF-α, TGF-β, M-CSF, EGF, FGF, FLT3.
•	 TNF family (utilises family TNF receptors) which includes; TNF-α, LT-
a, LT-b, BAFF, APRIL, FASL, TRAIL, CD40L, OX40L, 4-1BBL, CD70/
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CD27L and CD30L.
•	 Chemokine family (utilises G protein coupled chemokine receptors) which 
includes; CCL5, MIP-1, MCP-1, IL-8, CXCL-12, IP-10.
•	 IL-1/TLR family (utilise TIR domains): which includes IL-1α/β, IL-18, IL-
33, IL-37
The cytokine network is a highly integrated and complex system which is 
generated in response to immune challenge. The overall balance between 
immunogenic and regulatory cytokines is what determines the nature of a 
particular immune response. Cytokines are not generally pre-stored proteins, but 
rather are transiently produced in response to stimuli. As such, their mRNAs 
are typically short lived. The net effect of any cytokine is critically dependent 
on the timing of its release, the local milieu in which it acts, the presence of 
competing or synergistic elements, cytokine receptor density on target cells, and 
tissue responsiveness to each cytokine. 
Many cytokines can exert similar functions, and this redundancy is often attributed 
to the nature of cytokine receptors, whereby one receptor chain can often be used 
by multiple cytokine receptors e.g. gp130. These common structural features 
make it possible to further group cytokines within families. For example the class 
I receptor family listed above can be further subdivided into 3 further groups: 
GM-CSF receptor family (common beta subunit): IL-3, IL-5, GM-CSF  
IL-6 receptor family (common gp130 subunit): IL-6, IL-11, LIF   
IL-2 receptor family (common gamma chain): IL-2, IL-4, IL-7, IL-9, IL-15
Despite the structural similarities between the members, cytokines within a 
particular family can often have surprisingly divergent functions54. One such 
family with a remarkable degree of chain sharing, yet entirely distinct functions 
is that of the IL-12-family. 
1.5.2 The IL-12 family.
The IL-12 family is a further subdivision of the IL-6 superfamily and is composed 
of four heterodimeric complexes each consisting of an alpha chain (IL-12p35, IL-
23p19 and IL-27p28) and a beta chain (IL-12p40 and Ebi3). The IL-12p40 subunit 
can pair with either IL-12p35 or IL-23p19 to yield IL-12 and IL-23 respectively. 
The second beta chain subunit Ebi3, can pair with 2 other alpha chain subunits, 
IL-27p28 and IL-12p35, to yield IL-27 and IL-35 respectively. Chain sharing has 
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become a quintessential feature of this cytokine family and their receptors, yet 
despite this, each member possesses a unique and distinct biological function.
IL-12 is a pro-inflammatory cytokine produced by activated antigen presenting 
cells, including DCs, and its main role is in the initiation and commitment of 
naive CD4+ T cells to IFNγ producing Th1 cells56. This induction of IFNγ, 
results in a feedback loop, whereby additional APCs, in response to the IFNγ, 
are primed to produce IL-12 which further feeds naive CD4+ T cells towards Th1 
commitment57-59. IL-12 signals via IL-12Rβ1 and IL-12Rβ2 and is produced by 
DCs activated with microbial products including poly I:C, zymosan and most 
notably LPS. This production is potently enhanced upon ligation of CD4060 or 
when microbial stimuli are combined e.g. poly I:C + LPS61. IL-12p40 is produced 
vastly in excess to IL-12p70, and p40 subunits can homodimerise to yield IL-
12p8062. This molecule has been proposed to act as a negative regulator for IL-
12p70 due to its ability to bind to IL-12Rβ1. In addition to this, several cytokines 
have been identified as negative regulators of IL-12, namely, the Th2 cytokines 
Figure 2: IL-12 family members. Illustration of the IL-12 family members together 
with their receptors and the predominant STATs used by the individual cytokines. 
Note: IL-35 can also signal via two alternative receptors, a homodimer of gp130 or a 
homodimer of IL-12Rβ2. It has been reported that the heterodimer of gp130 and IL-
12Rβ2 yields the most potent suppressive abilities of IL-3555 and is therefore the receptor 
illustrated in the diagram above.   
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IL-4 and IL-13, IL-10 and type I IFNs, most notably IFN-β63. 
IL-23, like IL-12, utilises the beta chain IL-12p40, and is an immunogenic 
cytokine with an important role in the commitment and maintenance of Th17 
cells. IL-23 signals via IL-12Rβ1 and the IL23R64 and was first identified by 
Kastelein and colleagues in 200065. Its functional importance came to light when 
studies were performed to investigate the role of IL-12 in experimental models 
for encephalomyelitis (EAE) and arthritis. It was found that while IL-12p40-/- 
mice were protected from disease, IFNγ-/- , IFNγR-/- or STAT-1-/- mice were 
still susceptible, thereby suggesting a Th1 independent mechanism of disease 
pathogenesis. Further work identified that both IL-12p40-/- and IL-23p19-/- mice 
were protected from EAE while IL-12p35-/- mice were highly susceptible, and 
had elevated levels of IL-1766-70. These leading studies paved the way for the 
identification of a novel and distinct new lineage of helper T cells, Th1771. 
Although not critical for the initiation of Th17 differentiation from naive T cells, 
IL-23 seems to play a crucial role in the stabilisation of Th17 cells72, and more 
recently has been identified as a playing an important role in the generation of 
highly pathogenic, IL-23R expressing, Th17 cells73,74. In line with IL-12, microbial 
products, are potent induces of IL-23 production by DCs, and interestingly 
stimulation of DCs with IL-12 increases transcription of IL-23p19. 
IL-27, unlike IL-12 and IL-23, plays duals roles possessing both immunogenic 
and immunoregulatory properties and is composed of IL-27p28 and Ebi3. Initially 
identified as an EBV induced gene in EBV infected B cells, EBI3 was found to 
encode a 34kDa protein bearing structural homology to IL-12p4075. In the initial 
paper describing the EBI3 gene, very high levels were found in placental tissue 
which highlights the diverse nature of EBI3 expression compared to other IL-12 
family member subunits. Since then, although Ebi3 protein expression has been 
mostly described in haematopoietic cells75-78, several studies have accumulated 
data describing expression of this protein in placental synctiotrophoblasts79, 
endothelial cells, intestinal mucosa80,81 and aortic smooth muscle cells82. This 
expression of Ebi3, often in the absence of its typical pairing subunits has fuelled 
speculation that Ebi3 may possess biological functions in its own right or may 
dimerise with as yet unidentified partners. 
First identified in 200283 IL-27 signals via gp130 and WSX-1 and was initially 
classified as a proinflammatory cytokine due to its ability to synergise with IL-
12 and enhance IFNγ production by naive T cells83,84. It was also later found 
to up-regulate expression of IL-12Rβ2 on naive T cells. However IL-27 alone 
cannot induce IFNγ production by naive T cells and, in more recent years IL-27 
has been demonstrated to possess many immunoregulatory functions. The first 
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report to highlight the regulatory properties of IL-27 showed that mice infected 
with Leishmania died from excessive immune responses if they were deficient 
in the IL-27R85. Following on from this it was demonstrated that IL-27 could 
convert activated Th1 cells into IL-10 producing Tr1 cells86-88. This was in part 
found to be mediated via c-MAF89,90. IL-27 has been gaining increasing attention 
in the field of autoimmunity due to many reports demonstrating that IL-27 can 
suppress Th17 responses91-94, and it has shown particular promise in the treatment 
of EAE in murine models95,96. IL-27 does not only exert its activity on T cells 
but has also been demonstrated to up-regulate the inhibitory molecule B7H1 on 
DCs97,98 and limit ATP mediated NALP3 activation via upregulation of CD3995. 
Inducers of IL-27 production by APCs include TLR agonists LPS, Poly I:C and 
Loxoribine. Notably, IFNβ, currently in clinical trials to limit the pathogenesis 
of MS has been shown to mediate its effects through the induction of IL-2799. 
An interesting feature of IL-27 is that the alpha chain IL-27p28 is in its own 
right a cytokine, namely IL-30. To date IL-30 had been shown to inhibit Th17 
differentiation induced by IL-6 and TGF-β94 and has also been shown to act as a 
natural antagonist to gp130 signalling100. As such IL-30 can limit IL-27 signalling 
as well as members of the IL-6 family including IL-6 an IL-11. Interestingly, 
over expression of IL-30 has been shown to disrupt germinal centre formation 
in mice100 which is in line with reports that IL-27 can facilitate germinal centre 
formation via induction of IL-21101. 
   
IL-35 is the most recently identified member of the IL-12 family and is a 
potent anti-inflammatory cytokine produced by regulatory T cells in mouse 
and man. It is composed of the alpha chain of IL-12 (IL-12p35) and the beta 
chain of IL27 (Ebi3). In 1997 it was first reported that Ebi3 and IL-12p35 could 
heterodimerise102, however it was almost a decade later before this protein was 
named and its function elucidated103. Remarkably despite the knowledge of the 
dimerisation of IL-12p35 and Ebi3, the identification and characterisation of IL-
27 came first. This perhaps alludes to the challenges in studying the expression 
and function of IL-35.             
To date IL-35 has been shown to induce a regulatory T cell population, iTr35, 
which suppresses via IL-35 secretion but does not express Foxp3, IL-10 or 
TGF-β104. This regulatory T cell subset possesses a profound anti-inflammatory 
phenotype with the ability to reduce inflammation in animal models of IBD 
and EAE, and mediate infectious tolerance105. Interestingly activated B cells 
expressing IL-35 have also been demonstrated as key negative regulators of 
immunity in an animal model of EAE106. Ectopic expression of IL-35 in pancreatic 
beta cells prevents autoimmune diabetes107, and administration of recombinant 
IL-35 protects against collagen-induced arthritis108. In humans, iTr35 cells can be 
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induced by the addition of IL-35 to activated naive CD4+ T cell cultures109 or by 
exposure to virus-infected DCs in a B7H1 and sialoadhesin dependent manner110. 
Conversely to the protective role of IL-35 in inflammatory conditions, transfer 
of in vitro generated iTr35 cells prevents the development of CD8+ anti-tumour 
responses and accelerates B16 melanoma development in mice104. Additionally a 
novel population of CD8+ IL-35-secreting tumour Ag-specific T regs have been 
shown to arise spontaneously in some prostate cancer patients111. 
Only recently the receptor for IL-35 was identified to be gp130 and IL-12Rβ255. 
Intriguingly this means that IL-27 can not only sensitise naive CD4+ T cells to 
IL-12 but also IL-35, highlighting the local cytokine network as being a crucial 
determinant in orchestrating the immune response. In many ways the IL-12 
family could easily be argued as the cytokine family with the greatest influence 
in determining local T cell populations. Our full understanding of the newest 
member of this cytokine family is still in its infancy and unlike the other 3 
Figure 3: IL-12 family mediated generation and cross regulation of Th subsets. 
Illustration representing the most well described helper T cell populations directly 
regulated by IL-12 family members. The green arrows depict induction of a response; 
either inflammatory or regulatory. The dashed blue lines indicate inhibition of a 
response. This diagram does not represent indirect mechanisms of how IL-12 family 
members regulate immune responses e.g. Tr1 cells induced by IL-27 can continue to 
exert their regulatory potential without further requirement for IL-27. 
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members of the IL-12 family, IL-35 has not yet been shown to be produced by 
myeloid cells in mouse or human. Considering its potent regulatory potential 
the possible secretion of IL-35 from tolerogenic or regulatory DCs could be a 
new previously unexplored mechanism into how these cells can tailor immune 
responses. 
1.5.3 Complement: A role in regulating the immunogenicity of DCs?
As mentioned earlier the discovery of innate PRRs transformed our appreciation 
for the innate arm of the immune system as being a key player in the regulation 
of adaptive immune responses. This re-ignited interest in innate immunity has 
sparked a renaissance in an even older innate system: Complement. 
First discovered by its ability to assist or “complement” the bactericidal 
activity of blood, the complement system has established itself as an important 
mediator of apoptotic cell and immune complex clearance, pathogen eradication 
and is involved in lowering the threshold of B cell activation and antibody 
production. However more recently, complement activation has been shown to 
influence local T cell responses. Largely limited to murine data, the alternative 
pathway of complement has been demonstrated to play a role in the DC: T cell 
synapse112-114. Both APC and T cells have been shown to increase C3a and C5a 
receptors on their surface, while a surface regulator, DAF, has been shown to be 
decreased, allowing for further complement activation115,116. The link to the AP 
is particularly interesting. Unlike most other complement components, the key 
positive regulator of the AP, properdin (fP), is mainly produced by white cells. 
Furthermore, the key negative regulator, fH, although largely produced by the 
liver, has also been shown to be produced by extra-hepatic sources117-120. Limited 
data has shown by RT-PCR and western blot that DCs can function as a source for 
several complement components118,121. Despite their unique ability to prime and 
direct T cell responses, little is known about the contribution of local DC derived 
complement factors in regulating the potency of T cell activation. Additionally, 
studies investigating the regulation of complement factor production by DCs are 
even sparser. Interestingly, some complement components have been shown to 
possess GAS and ISRE elements in their promoters122, and fP has been shown to 
be subject to IFNγ regulation in THP-1 cell lines123. IL-27 is a unique member of 
the IL-12 family, in that it has been shown to share some functional properties 
with IFNγ97,124,125. In view of the link between complement activation and 
autoimmunity and the therapeutic potential of IL-27 in such disease settings, it 
would be interesting to evaluate the effect of IL-27 on DC complement production. 
Considering the central role of the AP of complement in many human diseases 
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much can be gained from fully investigating the regulation of AP components in 
DCs and the functional contribution in DC T cell interactions.   
1.6 Dendritic Cells and the role of the local environment. 
Although it is widely acknowledged that regulatory DCs exist in vivo, we know 
surprisingly little about how they develop and how to identify them. Recently 
an interesting idea, pioneered by Matzinger has surfaced, suggesting that the 
organs in which immune cells reside, may not be just passive hosts, but play 
a  crucial role in actively promoting immune regulation at the level of the 
tissue126,127. Evidence to support this notion has been already gathering over the 
last decade. Many groups have identified stromal networks in lymphoid organs 
as being a key source of growth factors, cytokines and chemokines, in addition 
to their traditional role as a support network128. Most notably, stromal cells from 
the bone marrow (MSCs) have recently been under intense investigation due 
their ability to modulate T cell activity and promote induction of regulatory T 
cells129, and a regulatory phenotype in monocyte derived DCs130,131. Concerning 
individual tissues, stromal cells including fibroblasts, and epithelial cells have 
come to light as exerting important biological functions in the control of local 
immune responses, and depending on their origin may exert their modulatory 
effects through different mechanisms132-134. In this regard, DCs residing in 
non-lymphoid organs are particularly intriguing. DCs have been identified in 
virtually all tissues, including the kidney, and definitive experimental proof has 
shown that in mice they form an extensive lattice like network within the renal 
parenchyma135. Also in human, DC subsets can be identified in pre-transplant 
biopsies of normal kidneys136, and their frequency strongly increases during renal 
allograft rejection137.
Kidneys are the most frequently transplanted organ and resident DCs are a very 
important constituent involved in initiating the direct pathway of allo-recognition 
in transplantation, in addition to playing a central role in the innate immune 
response following injurious stimuli to the organ. There are many open questions 
in renal DC (rDC) biology, although in mouse it has been shown that mobilised 
rDCs, in-vivo, are functionally immature with a poor allostimulatory capacity and 
most promisingly, have been shown to prolong allograft survival138. Understanding 
into how the renal stroma influences DC phenotype and function is limited to 
murine data, but has yielded interesting results. Huang et al demonstrated that 
DCs generated in the presence of renal MSC like cells led to the generation of 
a regulatory DC population with diminished allostimulatory capacity139,140. The 
ontogeny of different tissue resident DCs has not yet been fully elucidated, but 
General introduction   •   25
   1
knowledge of how the local environment influences the local APC population, 
and how this changes during stromal cell perturbation, would certainly contribute 
significantly to our understanding of organ specific disease pathogenesis and 
prognosis. It is plausible that individual tissues imprint a particular functional 
signature in their resident DCs, e.g. cytokine profile or upregulation of particular 
chemokine receptors. This is important to fully investigate, for a potential use 
of tolDC therapy would be to navigate them towards the affected target organ, 
where they should exert their regulatory function in a way that preserves organ 
function. Additionally identification of unique functional markers on tissue 
resident rDCs would provide an invaluable method to distinguish between 
resident and infiltrating DCs in transplantation, or potentially discriminate 
between immunogenic versus regulatory DCs. 
1.7 Scope of the thesis.
The current thesis was dedicated to understanding the expression, regulation 
and production of IL-12 family members in DCs and tolDCs and is divided into 
five chapters: Chapter 2 presents data regarding the ability of human tolDCs 
to produce IL-12p35 and Ebi3, the alpha and beta chain of IL-35, respectively. 
In this chapter we demonstrate for the first time that abrogating the production 
of IL12A in tolDCs diminishes the immunosuppressive capability of these cells 
and points to IL-35 as being a novel mediator of immune suppression by tolDCs. 
Chapter 3 details how phagocytosis of apoptotic or necrotic cells by immature 
DCs or tolDCs modulates the release and expression of IL-12 cytokine family 
members, particularly the IL-12/IL-35 axis. Importantly, we also describe that 
tolDCs maintain a stable regulatory cytokine profile upon ingestion of necrotic 
material. Chapter 4 describes the production of two key regulators of the 
alternative pathway of complement by DCs and tolDCs. We show that IL-27 
and members of the Interferon family differentially regulate the expression of 
fH and properdin and we demonstrate how alteration in the balance between 
properdin and fH can alter the allostimulatory capabilities of DCs. Considering 
the abundant expression of Ebi3 in tolDC populations, and the potent regulatory 
properties of IL-35, in Chapter 5 we sought to investigate whether the local renal 
DC network would be positive for Ebi3 expression in normal human kidney. 
While we did observe very prominent Ebi3 expression in normal kidney, this was 
found to be particularly abundant in podocytes and not the renal DC network. We 
further demonstrated in a patient cohort, that EBI3 expression is decreased during 
renal allograft rejection. Chapter 6 describes how the local cellular network can 
influence the cytokine repertoire of DCs. In this chapter we demonstrate the 
ability of human renal fibroblasts to generate a regulatory DC population, in part 
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through the secretion of IL-6. Finally in Chapter 7 we discuss and conclude our 
findings and describe potential areas of interest that warrant further investigation.
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Abstract
IL-35 is a novel cytokine of the IL-12 family, existing as a heterodimer of IL-
12p35 and EBV-induced gene 3 (Ebi3). IL-35 has anti-inflammatory properties 
and has been described to be produced by regulatory T cells in humans and 
mice, where it is required for optimal suppression. Distinct from other IL-12 
family members, expression of IL-35 has not been clearly described in antigen 
presenting cells. In view of its immune-regulatory properties, we investigated the 
expression, regulation and function of IL-12p35 and Ebi3 in human monocyte 
derived dendritic cells (DCs) and tolerogenic DCs (tolDCs), generated in the 
presence of dexamethasone. These tolDCs did not produce detectable levels of 
bioactive IL-12p70 or the homodimer IL-12p40. In line with this, we demonstrate 
by Q-PCR that tolDCs completely lack transcriptional expression of IL-12p40. 
However, tolDCs maintain mRNA expression of IL-12p35 and Ebi3. Using 
intracellular flow cytometry and western blot we show that tolDCs are able to 
produce Ebi3 and IL-12p35, and both can be further enhanced upon stimulation 
with IFNγ, LPS or CD40 ligation. Supernatant of tolDCs has the capacity to 
suppress T cell activation. Using IL-12A silencing we demonstrate that IL-12p35 
is required for tolDCs to reach their full suppressive potential. Taken together, 
our results indicate that tolDCs produce IL-35, providing an additional novel 
mechanism by which these cells elicit their tolerogenic potential.
Introduction
Dendritic cells (DCs) represent a heterogeneous family of professional APCs that 
have many functions in both the initiation and maintenance of immunity and 
immunological tolerance1,2. Several factors, including IL-10, TGF-β, Vitamin D3 
and corticosteroids have been shown to modulate DC function in vitro and in 
vivo, and lead to the generation of tolerogenic DCs (tolDCs)3-6. These tolDCs 
represent an altered status in DC differentiation and are currently considered in 
the design of therapeutic strategies to treat patients suffering from autoimmune 
disease7,8 and those undergoing transplantation9,10. Impaired expression of IL-12 
in tolDCs is thought to be a crucial requirement for these cells to elicit their 
tolerogenic potential, and indeed many tolDC populations have been shown to 
lack IL-123,5. However the IL-12 family is ever expanding and little is known 
about the regulation and expression of other IL-12 family members in tolDCs.
The IL-12 family is composed of four heterodimeric complexes each consisting 
of an alpha chain (IL-12p35, IL-23p19 and IL-27p28) and a beta chain (Ebi3 and 
IL-12p40)11. The IL-12p40 subunit can pair with either IL-12p35 or IL-23p19 to 
yield IL-12 and IL-23 respectively12,13. The second beta chain subunit Ebi3, can 
pair with 2 other alpha chain subunits, IL-27p28 and IL-12p35, to yield IL-27 
and IL-35 respectively. Although there is a large degree of chain sharing within 
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this family, each cytokine possesses a unique and distinct function. IL-12 and 
IL-23 have primarily pro-inflammatory properties and play an important role 
in the development of Th1 and Th17 T helper cell subsets respectively. IL-27 
possess dual roles playing a  protective role in tumour immunity14,15, but as an 
immunoregulatory cytokine can induce Tr1 cells16,17 and lead to the generation 
of a tolerogenic DC expressing elevated levels of CD3918. The most recently 
characterised member of this family is IL-35, a potent anti-inflammatory cytokine, 
which has been shown to be required for the optimal suppressive activity of 
regulatory T cell populations in both mice and man19-22. DCs are known producers 
of three family members, IL-12, IL-23 and IL-27. In tolDCs little is known about 
the expression of these family members aside from the characteristic loss of IL-
12 production and limited transcriptional data on IL-23 and IL-2723. For IL-35, 
production by myeloid cells in human or mouse has not yet been demonstrated.
In this study we addressed the expression profile and regulation of all IL-12 
family members in human DCs and tolDCs with a particular emphasis on the 
subunits which combined make up IL-35. We show that tolDCs did not produce 
detectable levels of bioactive IL-12p70, the homodimer IL-12p40 or express 
IL-12p40 transcripts. However tolDCs maintain mRNA and protein expression 
of IL-12p35 and Ebi3. We show that supernatants of tolDCs are sufficient to 
suppress T cell proliferation, and that supernatants of cells silenced for IL-12p35 
are hampered in their suppressive potential, thereby implying a role for IL-35 in 
tolDC function.
Materials and Methods
Generation of human monocyte derived DCs
Human monocytes were isolated from buffy coats obtained from healthy donors using Ficoll density gradient 
centrifugation followed by positive selection using anti-CD14 MACS microbeads (Miltenyi Biotech GmBH, 
Bergisch Gladbach, Germany). DCs were generated and cultured in RPMI supplemented with 10% heat 
inactivated FCS, 90 U/ml penicillin and 90 U/ml streptomycin (Gibco/ Life Technologies, Bleiswijk, The 
Netherlands), supplemented with 5 ng/ml GM-CSF and 10 ng/ml IL-4 (Invitrogen/ Life Technologies, Bleiswijk, 
The Netherlands) as described before3. TolDCs were generated by the addition of Dexamethasone (10-6M Dex) 
(Pharmacy, LUMC, Leiden, The Netherlands), only at the start of culture (day 0). Cultures were refreshed with 
medium containing cytokines on day 3. For differentiation into mature DCs, cells were harvested, washed and 
stimulated on day 6 with 200 ng/mL LPS (E.Coli 0127:B8 Sigma-Aldrich, Zwijndrecht), 20µg/ml Poly I:C, 
10 µg/ml PGN (InvivoGen) or 100 ng/ml IFNγ (Peprotech, Germany). CD40L-activation was performed with 
CD40L transfected L cells (L-CD40L) in a DC: L cell ratio of 5:1. Non-transfected L cells served as control 
cells (L-Orient).
DC-T cell co culture
Total CD4+ lymphocytes were negatively selected from PBMCs using CD4+ T cell isolation kit II (Miltenyi 
Biotech GmBH, Bergisch Gladbach, Germany), and subsequently labelled with carboxyfluorescein diacetate 
succinamidyl ester (CFSE) (Molecular Probes, Europe BV Leiden, The Netherlands). In short, T cells were 
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suspended in PBS and incubated for 15 minutes at 37°C with 5 μM CFSE. The reaction was quenched by 
washing the cells in medium containing 10% FCS before resuspending at 1×106/ml in total RPMI culture 
medium. Labelled CD4+ T cells were co-cultured with allogeneic DCs at a 10:1 T cell/DC ratio for 5 days. The 
T cells were then harvested and proliferation was assessed by CFSE dilution.
Surface and Intracellular flow cytometry
For cell surface flow cytometric analysis, cells were stimulated overnight, harvested, washed, and stained for 
30 minutes at 4°C in FACS buffer (PBS, 0.5% heat inactivated NHS, 1% BSA, 0.02% NaN3) with anti-CD86, 
anti-CD14 MΦ P9 (BD biosciences, San Diego, CA, USA), anti-B7H1, anti-B7DC, anti-ILT3 (Biolegend), 
anti-HLADR (B8.11.2, ATCC), anti-Mannose Receptor (clone D547, msIgG1 in house) or anti-DC-SIGN 
(R&D Systems, Wiesbaden, Germany). Nonconjugated antibodies were detected with PE-conjugated goat-anti-
mouse Ig (Dako, Glostrup, Denmark). Isotype matched control antibodies were used to determine the level of 
background staining. For intracellular staining cells were stimulated overnight, followed by incubation in the 
presence of Brefeldin-A (Sigma-Aldrich, Zwijndrecht) for a further 5 hours. The cells were then harvested, 
washed and fixed in PBS containing 4% formaldehyde and 1% heat inactivated FCS, washed with PBS containing 
10% heat inactivated FCS and permeabilised with perm buffer (PBS, 0.5% saponin, 1% heat inactivated FCS) 
for 10 minutes. Cells were stained with anti-Ebi3-APC or anti-IL-12p35-APC for 30 minutes at 4°C in perm 
buffer. APC-conjugated isotype matched control antibodies were used to determine the level of background 
staining. The fluorescence was measured on a FACS Calibur flow cytometer, and data were analysed with Cell 
Quest Software (BD Biosciences, San Diego, CA, USA) and FlowJo Software (Tree star, USA).
mRNA isolation, cDNA synthesis, and real-time PCR
Day 6 DCs were plated in a 12-well plate at a density of 1x106/ml and harvested after indicated time 
points. mRNA was isolated using an RNeasy kit (Qiagen, Hilden, Germany) following the manufacturer’s 
instructions. Digestion of genomic DNA was performed by using the on-column RNase-free DNase set. Reverse 
transcriptase system kit (Promega, Leiden, The Netherlands) was used to synthesise cDNA conforming to the 
manufacture’s instruction and was stored at -20ºC for further analysis. Specific primers (Table I) for human 
IL12A, IL12B, IL23A, IL27A, IL27B, IL10 and GAPDH were designed using the computer software Oligo 
explorer and synthesised at Biolegio. Quantitative PCR was performed using SYBR Green qPCR master mix 
(Bio-Rad, Veenendaal, The Netherlands). GAPDH was used as the endogenous reference gene. Data analysis 
was performed using Bio-Rad CFX Manager Software (Bio-Rad). For each sample, the relative abundance 
of target mRNA was calculated from the obtained Ct values for the target gene and expressed relative to the 
endogenous reference gene GAPDH. 
Table I: Real Time PCR Oligonucleotide sequences
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Cytokine production
DCs were plated at 1x106/ml and stimulated accordingly. Cell culture supernatants were harvested after 48 
hours and frozen at −80°C until analysis. Subsequently they were tested for the presence of IL-12p70, IL-12p40, 
(Biolegend) IL-10 (Sanquin, Amsterdam, The Netherlands) and IL-27 (eBioscience) by ELISA according to 
manufacturer’s instructions. IFNγ levels were determined in the cellular supernatants of T cells from indicated 
time points (eBioscience).
Western Blotting
DCs were plated at  1×106 /ml, stimulated for 16 hours, followed by the addition of Brefeldin A for a further 
5 hours. Cells were harvested, washed in ice-cold phosphate-buffered saline and lysed in medium stringency 
lysis buffer for 30 minutes. The lysates were centrifuged at 13,000 rpm, the supernatants harvested and protein 
concentration was determined by a Pierce assay. The samples were diluted in 1x SDS loading buffer, boiled 
for 5 minutes in reducing conditions, followed by separation on 10% SDS-PAGE gel. Gels were transferred to 
nitrocellulose membranes, blocked with TBS plus 0.1% Tween-20 (TBS-T) and 3% BSA or milk and probed 
with indicated primary antibodies;  purified anti-IL-12p40, anti-IL-12p35 (Santa Cruz Heidelberg, Germany) 
or purified anti-Ebi3 (Abnova, Huissen The Netherlands). After incubation with HRP-conjugated secondary 
antibody, proteins were detected with super signal ECL system. Blots were stripped and β-actin was used as a 
loading control using HRP conjugated anti-β actin (Abcam, Cambridge, UK).
Immunofluorescence microscopy 
Cells were cultured on 8 well chamber slides (NUNC) in the presence of stimuli and Brefeldin-A. The cells 
were subsequently washed and fixed in PBS containing 4% formaldehyde, 1% heat inactivated FCS followed 
by washing with PBS containing 10% heat inactivated FCS and permeabilised with perm buffer (PBS, 0.5% 
saponin, 1% heat inactivated FCS) for 10 minutes.  The DCs were then stained using IL-12p35-APC or purified 
anti-Ebi3 (Abnova), followed by goat anti-mouse-Alexa488 (Molecular Probes). Hoechst was used for nuclear 
staining.
RNA interference
DCs were transfected with 50 nM siRNA through the use of the transfection reagent Lipofectamine 2000 (Life 
Technologies) and were used for experiments 24 hours after transfection. The following SMARTpool siRNAs 
were used (Dharmacon, Fisher Scientific, Netherlands): IL-12A and nontargeting siRNA as a control. Silencing 
of expression was verified by real-time PCR in tolDC and IL-12p40/p70 ELISAs in DC.
T cell proliferation assays
Naïve CD4+ T cells were isolated by negative selection using naïve CD4+ T cell isolation kit II (Miltenyi 
Biotech), from cord blood derived PBMCs. Cells were stimulated as described previously20. Briefly cells were 
plated at a density of 25,000/well in 96 well round bottom plates in the presence of αCD3/28 coated beads. 
Supernatants from stimulated tolDCs were harvested and incubated with the T cells at a dilution of 1:2. T cell 
proliferation was assessed by the addition of  3[H]-thymidine (0,5 µCi/well) for the last 8 hours. Percentage 
suppression was calculated by 1-(cpm T cells + tolDC sup / cpm T cells alone) times 100.
Statistical analysis
Statistical analysis was performed with Graph Pad Prism (Graph Pad Software, San Diego, CA) using a one-
tailed t-test. P-values ≤ 0.05 were considered statistically significant.
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Results
DCs generated in the presence of dexamethasone display typical features of 
tolerogenic DCs with low expression of CD86 but high B7H1 and B7DC.
We have previously demonstrated that Dex treated DCs display reduced levels of 
co-stimulatory molecules3. To further investigate the phenotypical characteristics 
of DCs and tolDCs, freshly isolated monocytes were cultured in the presence of 
GM-CSF and IL-4, with the addition of Dexamethasone to generate tolDCs. Both 
cell types expressed characteristic markers of myeloid DCs including DC-SIGN 
(CD209) and Mannose Receptor (CD206), while tolDCs preserved the expression 
of CD14 upon differentiation from monocyte to immature DC (data not shown). 
In an immature state both DCs expressed comparable levels of CD86 and 
immunoregulatory molecules B7H1 (CD274) and ILT3 (CD85k), while HLA-
DR and B7DC (CD273) were more abundantly expressed on tolDCs (Fig.1). 
Stimulation using IFNγ, LPS or PGN resulted in the generation of mature 
DCs as shown by increased expression of co-stimulatory molecules including 
CD86 and HLA-DR (Fig.1A,B). tolDCs were significantly impeded in their 
ability to upregulate CD86 or HLA-DR upon stimulation with any agents used 
(Fig.1A, B). In contrast tolDC upregulated B7H1 (Fig.1C) and to a lesser degree 
B7DC and ILT3 (Fig.1D,E). To fully ascertain the allostimulatory capabilities 
of tolDCs, immature and mature DC/tolDCs were co-cultured with allogenic 
CD4+ T lymphocytes for 5 days, after which the T cells were analysed for CFSE 
dilution (Fig.1F). DCs were potent inducers of T cell proliferation which was 
further enhanced when the DCs were first matured for 24 hours with LPS or PGN. 
Conversely tolDCs were hampered in their ability to stimulate allogenic T cells 
regardless of maturation stimulus used (Fig.1G). In line with the proliferation data 
DCs induced a strong IFNγ production by the T cells, whereas tolDCs induced 
almost negligible amounts of IFNγ production (Fig.1G). In summary the tolDCs 
used in this study display typical characteristics of myeloid tolerogenic DCs.
TolDC maintain expression of IL-12p35 in the absence of IL-12p40.
A key characteristic of tolDCs is their ability to preserve production of 
immunoregulatory cytokines while maintaining low to absent production of 
inflammatory cytokines. Upon activation, DCs showed strong production of 
IL-12p40 and IL-12p70, whereas these cytokines were completely absent in 
supernatants of activated tolDCs (Fig.2A,B). In contrast, tolDCs produced 
significantly higher levels of IL-10 upon stimulation as compared to DC (Fig.2C). 
To further explore the expression of IL-12 in DC and tolDC we assessed by 
RT-PCR the expression of  IL12A (IL-12p35) and IL12B (IL-12p40), together 
making IL-12p70. In line with our ELISA data DCs showed a strong IL12B 
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expression upon stimulation while tolDCs were greatly inhibited in this ability 
(Fig.2D). However, tolDCs maintained their expression of IL12A and expressed 
significantly higher basal levels compared to DC (Fig.2E). Upon stimulation, 
where IL12B remains absent (Fig.2D), IL12A expression is significantly increased 
in tolDCs to comparable and even higher levels than DC (Fig.2E). 
Figure 1: DCs generated in the presence of dexamethasone display a tolerogenic phenotype 
and have a reduced allostimulatory capacity. Monocytes were isolated from PBMCs and cultured 
for 6 days in the presence of IL-4 and GM-CSF to obtain immature DC. tolDC were generated by 
the addition of 10-6M Dexamethasone to the moDC cultures at day 0. Cells were activated overnight 
with IFNγ, LPS or PGN. The expression of (A) CD86, (B) HLA-DR, (C) B7H1, (D) B7DC and (E) 
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Differential kinetics of LPS induced IL-12 family members in DC and tolDC.
The IL-12 family is composed of 4 related yet distinct heterodimeric cytokines 
and chain sharing has become a quintessential feature of this cytokine family24, 
25. We demonstrated that tolDCs lack expression of IL12B (IL-12p40) yet 
maintain expression of IL12A (IL-12p35) (Fig.2). We investigated the expression 
of all family members in immature unstimulated DCs and tolDCs and found 
that although tolDCs expressed lower levels of IL12B compared to DC, they 
maintained expression of all other family members and IL10 (Fig.3A). 
Notably both IL27B (Ebi3) and IL12A expression was even higher in tolDC 
compared to DC. We further investigated the regulation of the IL-12 family in 
DC and tolDC in LPS triggered cells. We found that DCs displayed a pronounced 
upregulation of IL12A and IL27A (IL-27p28) with the expression of both subunits 
peaking at 6 hours (Fig.3C,F). This was distinct from IL10 and IL23A (IL-
23p19) which showed the greatest expression at 2 hours (Fig.3G,E), and IL27B 
which gradually increased over time and reached its highest level at 48 hours 
ILT3 and on DCs and tolDCs was analysed using flow cytometry. Dashed line indicates the mean 
MFI of isotype controls used. (F) DC and tolDC were harvested on day 6 and either unstimulated or 
stimulated with IFNγ, LPS or PGN for 24 hours. The DCs were then harvested and co cultured with 
CFSE labelled allogenic CD4+ T cells at a ratio of 1:10. On day 5 the T cells were harvested and the 
CFSE staining was analysed using flow cytometry. Data shown is representative of 3 independent 
experiments. Data shown in (G) is the mean ± SD of those 3 experiments. Cytokine production was 
measured using ELISA. T cell culture supernatants were harvested on day 5 and analysed for (H) 
IFNγ production. Data shown is the mean ± SD of 3 experiments.  
Figure 2: TolDC maintain expression of IL-12p35 in the absence of IL-12p40. Dendritic cells 
were harvested after 6 days of culture and stimulated with irradiated CD40L cells at a ratio of 1:5 
dendritic cells, or a combination of IFNγ + LPS. After 48 hours the supernatants were harvested 
and (A) IL-12p40, (B) IL-12p70 and (C) IL-10 were measured. Data shown is the mean ±SD 
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(Fig.3D). While IL12B was rapidly induced in DCs, expression remained very 
low in tolDCs (Fig.3B). tolDCs demonstrated only a minor increase in IL12A 
and IL27B despite possessing up to 100 fold higher basal level of expression 
compared to DC (Fig.3C,D). IL23A expression was also higher in tolDC at time 0 
but gradually decreased over time before returning to the initial expression level 
(Fig.3E). IL27A expression was comparable between the two cell types up until 6 
hours, after which a drop off was noted for tolDC (Fig.3F). Finally although IL10 
started off with a higher level of expression in tolDC the pattern of upregulation 
of 6 independent experiments.Cells were stimulated for 6 hours after which mRNA was isolated 
followed by cDNA synthesis. The transcript levels of (D) IL12B (E) IL12A were determined by RT-
PCR. GAPDH mRNA expression from the same samples was used as an endogenous reference gene 
(relative mRNA expression).Data shown is mean ± SD of 4 independent experiments. Untransfected 
L cells were used as a control for CD40L cells and yielded results in line with medium conditions 
(data not shown). 
Figure 3: Kinetic expression of IL-12 family members and IL-10 mRNA in LPS-treated DCs 
and tolDCs. Cells were harvested on day 6, mRNA was isolated followed by cDNA synthesis. The 
transcript levels of (A) IL12B, IL12A, IL27B, IL23A, IL27A and IL10 were determined by RT-PCR 
in unstimulated cells. Cells were stimulated with LPS for indicated time points; mRNA was isolated 
followed by cDNA synthesis. The transcript levels of (B) IL12B, (C) IL12A, (D) IL27B (E) IL23A, 
(F) IL27A and (G) IL10 were determined. GAPDH mRNA expression from the same samples was 
used as an endogenous reference gene (relative mRNA expression). Data shown is mean ± SD of 2 
independent experiments. 
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was comparable between the two cell types with a transient upregulation at 2 
hours followed by a gradual decrease over time (Fig.3G). The relative abundance 
of both IL27B and IL12A transcripts in unstimulated tolDC compared to DC, 
in contrast to other IL-12 family subunits, is intriguing and may indicate some 
inherent regulation of these subunits within tolerogenic DCs. 
Stimulation of tolDCs favours upregulation of the immunoregulatory chains 
IL-12p35, Ebi3 and IL-27p28.
Although tolDCs specifically maintained the expression of subunits involved in 
immunoregulatory processes (Fig.3), they remained relatively refractory to LPS 
stimulation in terms of IL-12 family expression. We investigated if this profile 
was intrinsic for these cells or was activation dependent. 
We observed that although DCs expressed relatively abundant levels of IL12B, 
particularly upon stimulation with LPS, IFNγ + LPS or Poly I:C, transcripts of 
this subunit were significantly reduced in tolDC (Fig.4A). 
We demonstrate that IL12A is maintained in tolDCs and expressed comparably 
to DC across the different stimuli used. Notably treatment with a combination 
of IFNγ + LPS yielded the highest IL12A expression in tolDCs (Fig.4B). IFNγ, 
and a combination of IFNγ +LPS also displayed the greatest increase in IL27B 
expression when comparing DC to tolDCs (Fig.4C), with CD40 ligation showing 
the next highest expression in tolDC. IL27A levels were comparable between 
both DCs but IFNγ yielded the strongest induction of IL27A transcripts in tolDCs 
(Fig.4D). In summary tolDCs do not express IL12B but do maintain expression 
of  IL12A, IL27A and IL27B which can be further induced upon activation with 
IFNγ, IFNγ + LPS and CD40 ligation.
Figure 4: Stimulation of tolDCs favours upregulation of the immunoregulatory chains IL-
12p35, Ebi3 and IL-27p28. Dendritic cells were stimulated for 6 hours with IFNγ, LPS, PGN, 
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chains.
We investigated if our observations regarding transcriptional expression of IL-
27p28, Ebi3 and IL-12p35 were translated into protein by assessing production 
in DC and tolDCs. Using an IL-27 ELISA we found that DCs, but not tolDCs, 
produced IL-27 upon IFNγ + LPS stimulation, although we did find considerable 
variation across the 6 donors analysed (Fig.5A). Notably a combination of 
IFNγ + LPS or CD40L with either IFNγ or LPS, were the best inducers of IL-
27 production in DCs while the individual stimuli alone were poor inducers 
(Fig.5B). Under all conditions tolDCs were significantly hampered in their IL-27 
production (Fig.5B). 
Ebi3 and IL-12p35 can dimerise to form IL-35; however there are no reliable 
methods for the detection of IL-35 in human cellular supernatants. We established 
by intracellular fluorescent microscopy that tolDCs do express the individual 
chains, Ebi3 and IL-12p35, and that production of both can be increased upon 
stimulation with IFNγ or IFNγ + LPS (Fig.5C). To quantify this, we measured 
Ebi3 and IL-12p35 by intracellular flow cytometric staining in both DC and 
tolDC. We found that although tolDCs had lower basal levels of Ebi3 compared 
to DC, they showed a stronger induction upon stimulation (Fig.5D). The relative 
increase in Ebi3 expression upon stimulation with IFNγ or IFNγ + LPS in tolDCs 
was 6 fold or higher (Fig.5D). Although tolDC have a lower basal level of 
IL-12p35 compared to DC, they increase expression comparably to DC upon 
stimulation with IFNγ or IFNγ + LPS (Fig.5E). To further reinstate our findings 
we performed a western blot for IL-12p35 and Ebi3 on whole cell lysates. In line 
with our flow cytometry and microscopy data, tolDCs do express both IL-12p35 
and Ebi3, and both appear to increase upon stimulation. Importantly, in contrast 
to DC, tolDC do not express IL-12p40 using any stimuli assessed (Fig.5F). 
TolDCs require expression of IL-12p35 to elicit their full tolerogenic potential.
To determine the functional significance of IL-12p35 and Ebi3 produced by 
tolDC, we investigated the suppressive activity of tolDC supernatants on αCD3/
CD28 activated T cells. Supernatants from CD40 ligated tolDCs demonstrated a 
pronounced inhibition of T cell proliferation which was not observed with mock 
activated tolDCs (Fig.6A). Using different tolDC and T cell donors, we found 
Poly (I: C) or a combination of both IFN γ + LPS. Irradiated CD40L cells were added at a ratio 
of 1:5. The transcript levels of (A) IL12B, (B) IL12A, (C) IL27B, (D) IL27A were determined 
by RT-PCR. GAPDH expression from the same samples was used as an endogenous reference 
gene (relative mRNA expression). Data shown is mean ± SD of 3-5 independent experiments. 
Untransfected L cells were used as a control for CD40L cells and yielded results in line with 
medium conditions (data not shown). 
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Figure 5: TolDC maintain and can enhance their protein expression of IL-12p35 and Ebi3 in 
the absence of IL-12p40. (A) DCs and tolDCs were harvested on day 6, replated and stimulated 
with IFNγ + LPS; IL-27 levels were assessed by ELISA. (B) Cells were stimulated with IFNγ 
+ LPS, IFNγ+CD40L, LPS+CD40L or CD40L for 48 hours followed by detection of IL-27 by 
ELISA. Data shown is mean ± SD of 3-6 independent experiments. (C) tolDCs were cultured on 
8 well chamber slides and either untreated, or stimulated with IFNγ or IFNγ + LPS followed by 
overnight incubation with Brefeldin A. The cells were then fixed and permeabilised, followed by 
incubation with purified anti-huEbi3 or IL-12p35-APC. Ebi3 was detected using GaM-Alexa488. 
For flow cytometry DCs and tolDCs were either untreated or stimulated for 16 hours with IFNγ 
alone or IFNγ + LPS, followed by culture for a further 5 hours in the presence of 10µg/ml Brefeldin 
A. The cells were then harvested, fixed and permeabilised, followed by incubation with (D) Ebi3-
APC or (E) IL-12p35-APC. Data shown is representative of 3 independent experiments, with 
graphed data showing the mean ± SD of those 3 experiments. (F) DCs were treated similarly for 
the generation of cellular lysates. Samples were loaded on 10% SDS gel followed by transfer to 
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that supernatant from CD40L activated tolDC consistently induced suppression 
ranging from 30-80% (median 60%) (Fig.6B).
To establish the role of IL-35 production by tolDC in T cell suppression, we 
performed RNA interference of IL12A. By mRNA analysis we found at least a 
tenfold inhibition of IL12A expression in activated tolDCs (Fig.6C). Importantly 
IL27B and IL10 remained unaffected by IL12A silencing, and use of a non-specific 
siRNA did not affect IL12A expression (Fig.6C). 
nitrocellulose membranes. Blots were probed with indicated primary antibodies and detected with 
super signal ECL system. (data not shown). 
Figure 6: TolDCs require IL-12p35 in order to elicit their full tolerogenic potential. tolDCs 
were harvested on day 6 and stimulated with irradiated CD40L or mock transfected cells at a ratio 
of 1:5 for 48 hours. Supernatants were harvested and incubated with αCD3/28 stimulated naïve 
CD4+ T cells at a dilution of 1:2 for 72 hours. 3H incorporation was determined during the last 8-12 
hours of culture. Results shown in (A) are from a representative experiment (mean ± SD of CPM 
from triplicate cultures). Data shown in (B) is the mean ± SEM percentage suppression from 14 
independent experiments. (C) IL12A was silenced in tolDCs demonstrating up to 90% interference 
in mRNA transcripts of IL12A. IL-12A silenced or control treated tolDCs were harvested and 
stimulated as described above for 48 hours. The supernatants were then incubation with αCD3/28 
stimulated naïve CD4+ T cells at a dilution of 1:2 for 72 hours. 3H incorporation was determined 
during the last 8-12 hours of culture. CPM shown in (D) are from a representative experiment of 
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Using supernatants from CD40L stimulated tolDCs we found that IL12A silenced 
supernatants were significantly impaired in their suppressive capacity (Fig 6D, 
6E), thereby indicating that IL-12p35 is required by tolDCs to elicit their full 
tolerogenic potential. To confirm that the IL12A siRNA directly targeted IL-
12p35 protein we demonstrated, in activated control DCs, that IL-12p70 was up 
to 60% inhibited while IL-12p40 was unaffected (Fig 6F). As a consequence, the 
capacity of DC supernatant to induce IFNγ production in activated T cells was 
significantly reduced (Fig 6G).
Discussion.
The IL-12 family is gaining increasing attention as being a key regulator of 
immunity and immunological tolerance25,26. A common feature of tolerogenic 
DCs is the lack of IL-12, however little is known about the expression, regulation 
or function of the other family members in human tolDCs. In this study we 
focused on the IL-12/IL-35 axis and found that tolDCs maintain, and can increase 
expression of Ebi3 and IL-12p35, and that IL-12p35 is required for their full 
tolerogenic potential.
Despite the remarkable degree of chain sharing between the four members of the 
IL-12 family, each one has its own unique biological function. IL-12 and IL-23 
are pro-inflammatory cytokines crucial for the development of Th1 and memory 
Th17 cells respectively27,28. On the other hand IL-27 and IL-35 are inhibitory 
and immunoregulatory cytokines20,29-31. IL-35 although a relatively new player 
within this family has already been shown to induce proliferation of iTr35, a 
regulatory T cell subset which possesses a profound anti-inflammatory phenotype 
with the ability to reduce inflammation in animal models of IBD and EAE20. With 
the striking immunoregulatory functions of IL-35 it became evident to us that 
the possible secretion of IL-35 from tolerogenic DCs could be a new previously 
unexplored mechanism into how these cells can suppress T cell responses. To 
study this we used a well characterised human tolDC and first established that 
they displayed typical features associated with regulatory DC populations -low 
CD86, high B7H132 and poor ability to stimulate allogenic T cells8,33. In addition 
we observed that these cells express high levels of the endocytic receptor CD206 
as well as the immunoregulatory molecules B7DC34,35 and ILT336. Our focus was 
3 independent experiments performed. Percentage inhibition shown in (E) is the mean ± SD of 
those 3 experiments. DCs were harvested on day 6 and were either mock (-), IL-12A, or Non-target 
siRNA treated, followed by stimulation with IFNγ + LPS. Cell supernatants were harvested and 
assessed for production of (F) IL-12p70 and IL-12p40 by ELISA, data shown is mean ± SD of 4 
independent experiments. siRNA treated DCs were stimulated with CD40L, supernatants were 
harvested after 48 hours and incubated with αCD3/28 activated total CD4+ T cells for 3 days. (G) 
IFNγ levels were determined in the T cell supernatants by ELISA.
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on the cytokine repertoire of these cells and one of the more intriguing qualities of 
tolDCs is the profound lack of IL-12p40/70 production regardless of stimulation 
used. We have shown that tolDCs completely lack IL-12p40 expression yet 
preserve their transcriptional expression of the other IL-12 family members, in 
particular those who, upon dimerisation are associated with anti-inflammatory 
properties, namely Ebi3, IL-12p35 and IL-27p28. 
Analysing LPS triggered DCs, we observed that IL-12p35/p40 were transient 
and superimposable with both subunits reaching their highest level at 6 hours in 
DCs. A similar peak in expression was noted for IL-27p28, though the increase 
in expression appears to occur more rapidly than for p40/p35. Conversely Ebi3 
does not peak until 24-48 hours post activation in DCs. This differential pattern 
of expression has been likewise noted in previous studies37,38 and has fuelled 
speculation that Ebi3 may have a unique biological function independent of 
its typical pairing subunits. Recent evidence using murine cells showed that 
type 2 anti-inflammatory macrophages express high level of Ebi339. We have 
also observed elevated Ebi3 levels in M-CSF generated human M2 compared 
to GM-CSF generated M1 macrophages (unpublished data). Intriguingly, the 
authors show that intracellular Ebi3 expression can block LPS induced M1 to 
M2 transition and IL-12p70 production39, suggesting that Ebi3 may play a role in 
maintaining the regulatory functions of M2 macrophages. Further work is needed 
to fully extrapolate this data to human macrophage subsets.
In our study with dendritic cells we not only observed consistently higher levels 
of Ebi3 in tolDCs, but also IL-12p35. We observed minimal upregulation when 
the tolDCs were stimulated with LPS so we addressed whether this was an 
intrinsic characteristic of these cells or was activation dependent. Notably IFNγ 
seemed to have the greatest effect on tolDC in terms of Ebi3/p35/p28 expression 
with just a moderate increase noted in DCs. This may be explained by the finding 
that tolDCs express higher levels of IFNγR1/2 and STAT1 compared to DC (data 
not shown). Although IFNγ is well acknowledged as an inflammatory mediator, 
in recent years it has also been appreciated as a key coordinator of immunity 
with many anti-inflammatory molecules also under its control, including B7H140 
and IDO41,42. More recently IFNγ has even been demonstrated to lead to the 
generation of a tolerogenic DC population in vitro43. In fact, Ebi3 and IFNγ 
have been demonstrated to be important to limit allograft rejection in mouse, 
whereby IFNγ upregulation of Ebi3 in autologous tolerogenic DCs was found to 
be a crucial mechanism in graft maintainance44. It is intriguing that in our current 
study, using human cells, Ebi3 was also strongly upregulated by IFNγ in tolDCs.
As described earlier Ebi3 can dimerise with either IL-27p28 or IL-12p35 to yield 
IL-27 or IL-35 respectively. In view of the expression of IL-27p28 in tolDCs we 
investigated IL-27 production in both DC and tolDC. IL-27 has been shown to 
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be produced by DCs stimulated with Poly I:C45 or macrophages stimulated with 
IFNγ + LPS46. We did not find any striking effect with Poly I:C in our study but 
did find that IFNγ + LPS induced a strong IL-27 production in DCs. In addition 
we show that CD40 ligation alone or in particular when combined with IFNγ or 
LPS can also induce IL-27 production. In contrast tolDCs had low levels of IL-27 
in their supernatants with only a combination of IFNγ with either LPS or CD40L 
showing any detectable levels. This may be explained by the rapid loss of IL-
27p28 transcripts in tolDC after 6 hours which we observed using LPS induced 
kinetics. Further work is required to evaluate whether IL-27p28 transcripts are 
less stable in tolDC compared to DC or are possibly targeted for degradation.
Unfortunately there are no reliable methods to determine IL-35 in cellular 
supernatants. However we did show that tolDCs do express the individual 
chains required to form IL-35. We established the functional significance of our 
findings in tolDCs by performing a T cell proliferation assay in the presence 
of supernatants from activated tolDC and IL-12A silenced tolDC. Using the 
supernatants from control silenced tolDCs we demonstrated a robust inhibition 
of T cell proliferation while supernatants from IL-12A silenced tolDCs were 
significantly impaired in this ability, indicating that tolDCs require IL-12p35 
to elicit their full tolerogenic potential. There has been much speculation as to 
whether DCs, particularly tolerogenic DCs could produce IL-3526. It has been 
reported that IL-12p35 needs to be part of a heterodimer in order to be secreted47. 
IL-12p35 can heterodimerise with IL-12p40 or Ebi3 and the tolDCs used in this 
study do not produce IL-12p40. Although we cannot exclude that there may be a 
yet unidentified additional chain which IL-12p35 may pair with it, it seems likely 
considering the abundance of IL-12p35 and Ebi3 in tolDCs, that the partial loss 
of suppressive capacity in IL-12A silenced tolDCs may be a reflection of the 
loss of IL-35. Taken together, our results suggest that human tolDCs produce IL-
35, an exciting new immunoregulatory cytokine, providing an additional novel 
mechanism by which these cells can elicit their tolerogenic potential.
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Abstract
Uptake of apoptotic cells by dendritic cells (DCs) is considered to contribute 
to induction and maintenance of immunological tolerance. Tolerogenic DCs 
(tolDCs) are being sought after as cellular therapy in transplantation and 
autoimmunity, and can be generated in-vitro using glucocorticoids. In this study 
we investigated how uptake of dead cells affects the production and expression of 
different members of the IL-12 family by either immature DC or tolDC.
We show that compared to regular immature DCs, tolDCs display elevated levels 
of PS-recognising bridge molecule-receptors αvβ5 and CD36, have enhanced 
phagocytic abilities with accelerated uptake of apoptotic cells. We confirm that 
apoptotic cell uptake results in diminished production of IL-12p40 and IL-12p70 
by DCs. We now show that this also results in increased expression of IL-12p35 
and Ebi3. TolDCs completely lack expression of IL-12p40, yet have enhanced 
levels of Ebi3 and IL-12p35. Uptake by tolDCs of either apoptotic or necrotic cells 
does not affect the expression of Ebi3/IL-12p35, and does also not increase IL-
12p40. This is distinct from culture of immature DCs with necrotic cells, which is 
sufficient to induce IL-12p40 secretion. Conversely, ingestion of apoptotic cells 
by DCs leads to increased expression of IL-12p35 and Ebi3 without affecting 
IL-12p40. In conclusion we have shown that uptake of apoptotic versus necrotic 
cells by DCs differentially regulates members of the IL-12 family. Apoptotic 
cells favour expression of Ebi3 and IL-12p35, and we propose that differential 
regulation of the IL-12 family is an additional mechanism in determining the 
immune response to dying cells.
Introduction
Dendritic cells (DCs) are highly specialised antigen (Ag)–presenting cells (APCs) 
that are uniquely capable of orchestrating a repertoire of immune responses, 
ranging from the initiation of Ag specific immunity, to the active induction and 
maintenance of specific tolerance to self Ags in the periphery1-3. 
Consequently, cellular immunotherapies have been developed with the aim to 
exploit the immunoregulatory functions of DCs to silence immune responses 
in transplantation and autoimmunity4, 5. Several agents have been explored for 
the induction of tolerogenic DCs (tolDCs), and glucocorticoids (GCs) including 
dexamethasone (dex) have been shown to induce the development of such a 
population with potent anti-inflammatory properties6, 7. 
The concept of tolerogenic DCs (tolDCs) was proposed almost 20 years ago8, 
9, and early on, diminished production of IL-12 was identified to be a hallmark 
feature of these cells10, 11. Since then, IL-12 has become part of an entire 
cytokine family made up of 4 related, yet distinct cytokines, namely IL-12, IL-
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23, IL-27 and IL-3512. IL-12 and IL-23 are primarily immunogenic, playing a 
role in the commitment and maintenance of Th113, 14 and Th1715, 16 populations 
respectively. IL-27 appears to play a dual role, possessing both immunogenic17-19 
and immunoregulatory properties20-22. The most recent member, IL-35, has 
been described as a potent anti-inflammatory cytokine with an important role 
in mediating infectious tolerance23. Unlike the other 3 members, IL-35 has not 
yet been shown to be produced by DCs, but has been described as a product of 
inducible regulatory T cells in mouse and man24, 25. Although there are several 
studies demonstrating that diminished IL-12 production is a critical characteristic 
of tolDCs, little data is available about the more recent members and their 
regulation26. 
Recognition and uptake of apoptotic27 or necrotic cells28 by DCs has been 
recognised as an important regulatory mechanism in immune homeostasis. 
Rather than merely being passively non-inflammatory, these studies imply that 
apoptotic cells can actively infer an immuno-regulatory state within the ingesting 
DCs29, 30. Much of this work has focused on immunogenic DCs and there have 
been few studies looking at the phagocytic potential of tolDC and the subsequent 
functional consequences for these cells31.
In this study we investigated the phagocytic potential of tolDCs compared to DCs 
and analysed the regulation of the IL-12 family member subunits in both cell types 
upon uptake of apoptotic versus necrotic cells. We show that, compared to DCs, 
tolDCs are superior at ingesting specifically apoptotic material. As previously 
described, we confirm that apoptotic cell uptake results in diminished production 
of IL-12p40 and IL-12p70. We now show that this also results in the increased 
expression of IL-12p35 and Ebi3. We conclude that ingestion of apoptotic versus 
necrotic cells by DCs differentially regulates the IL-12 family members thereby 
playing a role in determining the immune response in such events.
 
Materials and Methods
Cell culture and Reagents
Human monocytes were isolated from buffy coats (ethical approval number: BTL 10.090), obtained from 
healthy donors using Ficoll density gradient centrifugation followed by positive selection using anti-CD14 
MACS microbeads (Miltenyi Biotech). DCs were generated and cultured in RPMI 1640 supplemented with 
10% FCS, 90 U/mL penicillin, and 90 μg/mL streptomycin (Life technologies), 5 ng/mL GM-CSF and 10 ng/
mL IL-4 (Biosource Europe, Belgium), as described before32. TolDCs were generated by addition of Dex (10−6M 
Dex) (Pharmacy, L.U.M.C., Leiden, the Netherlands) only at the start of culture (day 0). Cultures were refreshed 
with medium containing cytokines on day 3. For stimulation experiments immature DCs were harvested on day 
6, washed and seeded accordingly, followed by addition of 200 ng/ml LPS (E.Coli 0127:B8 Sigma-Aldrich) and 
100 ng/ml IFNγ (Peprotech). To quantify cellular debris in culture, images (n=15) of a number of cell culture 
plates were captured at day 6 and the amount of cellular fragments was counted and expressed as a percentage 
of viable cells for both DC and tolDC.
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Flow Cytometry
Cells were harvested, washed, and stained for 30 min at 4°C in FACS buffer (PBS, 0.5% heat inactivated 
NHS, 1% BSA, 0.02% NaN3) with appropriate antibodies including anti-αvβ5 (RnD systems), anti-CD93, 
anti-CD36 , anti-Tim-1, anti-Tim-4 (Biolegend), anti-CD91 (BD Biosciences) and anti-CD206 (clone D547). 
Nonconjugated antibodies were detected with PE-conjugated goat-anti-mouse Ig. Isotype matched control 
antibodies were used to determine the level of background staining.
Induction of apoptosis and necrosis
Jurkat T cells were cultured in complete RPMI medium. Cells were washed with PBS and exposed to ultraviolet 
(UV)–C light (TUV lamp, 254 nm; Philips Electronic Instruments, Eindhoven, The Netherlands) at a dose of 50 
J/m2. After UV irradiation, cells were cultured for 3 hours in serum-free RPMI for the generation of apoptotic 
cells. Necrosis was induced by incubating Jurkat cells at 56°C in a water bath for 1 hour. Both apoptosis and 
necrosis were confirmed by double-staining with fluorescein isothiocyanate (FITC)–labeled annexin V and 
Propidium Iodide (PI)(VPS Diagnostics, Hoeven, The Netherlands) according to established methods33. Cells 
were only used if a purity of >70% was achieved i.e. apoptotic (>70% AnnV+, PI-), necrotic cells (>70% 
AnnV+, PI+). Neutrophils were isolated as previously described34 and cultured overnight in serum free RPMI 
supplemented with 5ng/ml GM-CSF, to facilitate the generation of early apoptotic neutrophils by spontaneous 
apoptosis. For DC apoptosis, cells were plated at 2.5 x 106/ml in a 6 well plate and irradiated with a UV 
transilluminator with a peak intensity of 9000 mW/cm2 at the filter surface and a peak emission of 312 nm for 
4 mins, followed by culture at 37oC for 2 hours. Necrosis was induced by incubation at 56oC for 1hr. For some 
experiments, prior to the induction of apoptosis, Jurkat cells or neutrophils were fluorescently labeled with 
carboxyfluorescein diacetate succinamidyl ester (CFSE; Molecular Probes). In short, cells were suspended in 
PBS at 20 × 106 cells/mL and incubated for 15 minutes at 37°C with 5 μM CFSE. The reaction was quenched by 
washing the cells in medium containing 10% FCS before resuspending at 5 × 106 cells/mL in serum-free RPMI. 
The cells were subsequently used for apoptosis or necrosis induction as decribed above.
Phagocytosis assay
CFSE labeled apoptotic/necrotic cells (1 × 105) were cocultured with DCs, at a 1:1 ratio for 1 hour at 37°C or 
4°C in 100 μL RPMI. DCs were stained with an APC-conjugated mAb against HLA-DR. Uptake was analysed 
by flow cytometry. The percentage of HLA-DR-positive cells that stained positive for CFSE was used as a 
measure for the percentage of DCs, that ingested (37°C) and/or bound (4°C) apoptotic cells. Cells were analysed 
using FACSCalibur and CellQuest software  or FlowJo.Phagocytosis was further investigated by fluorescent 
microscopy using appropriate filter settings. Images were captured at indicated time points, and were analysed 
using ImageJ software version 1.33 (NIH Image, Bethesda, MD). For this purpose, CFSE-labelled apoptotic 
cells (1 × 105) and PKH-26 (4μM, Sigma-Aldrich) labelled DCs were cocultured at a 1:1 ratio in 24 well culture 
plate for 24 hours at 37°C. 
Viable and apoptotic/necrotic DC cultures
Immature DCs were harvested at day 6 and plated in a 12 well plate at a density of 0.5 x 106/well. Apoptotic/
necrotic DCs were harvested and added to viable DCs at a density of 2.5 x 106/well for 24 hours. Where 
indicated cells were then stimulated with IFNγ and LPS and left in culture for a further 24 hours.
mRNA isolation, cDNA synthesis, and RT-PCR
mRNA was isolated from DCs using an Rneasy kit according to the manufacturer’s instructions (Qiagen). DNA 
was digested using the on-column RNase-free DNase set. cDNA was synthesised using a reverse transcription 
system kit (Promega) following the manufacturer’s guidelines. Specific primers for human IL27B, IL27A, IL12A, 
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IL12B, IL10, IDO1, TGFβ and GAPDH (Table I) were designed using the computer software Oligo explorer 
and synthesised at Biolegio. Primer specificity was tested by homology search with the human genome (basic 
local alignment search tool or BLAST; National Center for Biotechnology Information) and later confirmed 
by electrophoresis through 2% agarose gels containing ethidium bromide followed by visualisation under UV 
light. GAPDH was used as an endogenous reference gene. For each sample, the relative abundance of target 
mRNA was calculated from the obtained Ct values for the target gene and expressed relative to the endogenous 
reference gene GAPDH. 
Table I: Real Time PCR Oligonucleotide sequences
Cytokine production
DCs were plated at 1x106/ml and treated accordingly. Cell culture supernatants were harvested after 48hr and 
frozen at −80°C until analysis. Subsequently they were tested for the presence of IL-12p70 and IL-12p40 
(Biolegend) and IL-10 (Sanquin, Amsterdam, the Netherlands) by ELISA according to manufacturer’s 
instructions.
Statistical analysis
Statistical analysis was performed by sample t test using GraphPad Prism (GraphPad Software, San Diego, CA). 
Differences were considered statistically significant when P values were less than 0.05.
Results
TolDCs display reduced levels of cellular debris in culture and express 
elevated levels of αvβ5 and CD36.
We have previously shown that the generation of DCs in the presence of 
glucocorticoids led to the induction of a potent tolDC population with the ability to 
suppress allogenic T cell proliferation and cytokine secretion6, 32. When generating 
these tolDC, we observed significantly reduced yields (Fig.1A). Despite this, we 
noted that the cultures were notably cleaner compared to untreated DCs (Fig.1B). 
Quantification showed that, compared to control DC, tolDC had significantly less 
cellular debris after 6 days in culture (Fig.1C). 
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Cell surface FACS analysis demonstrated that both immature DC and immature 
tolDC expressed several molecules implicated directly or as an accessory bridging 
molecule, in the uptake of apoptotic cells, including αvβ5, CD93, CD36, CD91, 
CD206 and the PS receptor Tim-3, but not Tim-1 (Fig.1D). Several receptors 
had a tendency to be elevated, and expression of the integrin αvβ5 and the 
thrombospondin 1 receptor CD36 was consistently and significantly higher in 
tolDC compared to DC across a number of different donors (Fig.1E), together 
suggesting that tolDCs may have an enhanced phagocytic capacity compared to 
DCs.
Figure 1:tolDC cultures display signs of enhanced phagocytosis. Monocytes were isolated from 
PBMCs and DCs were generated by culturing in RPMI/ 10% FCS supplemented with GM-CSF 
and IL-4. TolDCs were generated by addition of Dex (10−6M Dex) at the start of culture (day 0). 
(A) Indicates lower harvest yield of immature tolDCs after 6 days of culture, data shown is mean 
± SEM (n=7; **p= 0,0066).(B) Viable immature DC or tolDC were imaged on day 6 of culture. 
Arrows in DC indicate the presence of dying cell debris which is not presence in the cultures of 
tolDCs. (C) Indicates quantification of cell debris in culture as a percentage of viable cells, data 
shown is mean ± SEM (n=3; ***p=0.0003). (D) Representative histograms of cell surface FACS 
analysis on DC and tolDC at day 6 of culture, stained for a number of different known receptors 
involved in apoptotic cell clearance. Histograms shown were gated on PI negative cells, dashed 
lines represent isotype control mAb staining. Results shown are from a representative experiment 
of 3 independent experiments performed (E) Demonstrates mean ± SEM (n=3 ; * p ≤  0,03) of those 
3 experiments.
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TolDC display enhanced and accelerated phagocytosis of apoptotic cells.
To compare the phagocytic ability of immature DCs and immature tolDCs we used 
a phagocytosis assay where DCs were incubated with viable, early apoptotic or 
necrotic CFSE labelled Jurkat cells33. Incubation of DCs with apoptotic or necrotic 
cells was followed by a temperature-dependent uptake (Fig.2A). Although DCs 
were already efficient at taking up both apoptotic and necrotic material, tolDC 
displayed a significantly enhanced ability to phagocytose apoptotic cells (Fig.2B). 
Interestingly no difference was observed in necrotic cell uptake between DC and 
tolDC. Additional experiments demonstrated that, compared to DCs, tolDCs 
were also more efficient at ingesting apoptotic primary neutrophils (Fig.2C).
To confirm our findings that tolDC possess enhanced phagocytic abilities we 
performed microscopic imaging over time. Representative pictures (Fig.2D) at 2 
and 24 hours show a time-dependent clearance of apoptotic cells by viable DCs 
and tolDCs. Quantification demonstrated that tolDCs were more efficient in 
clearance of apoptotic cells (50% in 8 hours) compared to DC (50% in 15 hours) 
(Fig.2E). This accelerated uptake was not evident for the clearance of necrotic 
cells, whereby both DC and tolDC had a similar clearance (50% in 13-15 hours 
respectively) (Fig.2E).  
Figure 2: Increased and accelerated uptake of apoptotic cells by tolDC compared to DC. 
Viable immature DC or tolDCs were incubated with CFSE labelled viable, apoptotic and necrotic 
Jurkats at a ratio of 1:1 for 1hr at (A) 37oC or  4oC. DCs were detected using APC labelled HLA-
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Apoptotic cells profoundly inhibit IL-12p40 and IL-12p70 production by 
activated DCs.
To further explore the immune regulatory effects of apoptotic cell uptake by viable 
DCs, we focused on the regulation of IL-12 production. In order to mimic the 
experimental conditions during tolDC generation and removal of cellular debris 
(Fig.1C), we generated apoptotic and necrotic DCs/tolDCs by UV irradiation and 
heating respectively. Apoptotic cells were characterised as Annexin V positive 
and PI negative (AnnV+, PI-), while necrotic cells were double positive (AnnV+, 
PI+) (Fig.3A).Viable immature DCs alone produced low amounts of IL-12p40 
and this production was significantly inhibited when these cells were exposed 
to apoptotic cells. In contrast, addition of necrotic cells induced a significant 
increase in IL-12p40 production (Fig.3B). Under these experimental conditions, 
production of IL-12p70 could not be detected (data not shown). As a control, no 
IL-12p40 was released from apoptotic or necrotic DCs alone, in the absence of 
viable immature DCs. None of the conditions described resulted in a detectable 
production of IL-12p40 by immature tolDCs (Fig.3B).
Activation of DCs using a combination of LPS and IFNγ induced a strong IL-
12p40 (Fig.3C) and IL-12p70 (Fig.3D) production. Activation in the presence 
of apoptotic cells led to a significant inhibition of both IL-12p40 and IL-12p70 
production, while this inhibition was not observed for necrotic cells. Also under 
these activation conditions, mature tolDCs were completely hampered in their 
capacity to produce either IL-12p40 or IL-12p70. IL-10 has previously been 
shown to be upregulated in APCs upon uptake of apoptotic material. We measured 
production of IL-10, but did not see any significant differences upon uptake of 
apoptotic or necrotic cells (Fig.3E) Activation of DCs with a combination of 
IFNγ+LPS resulted in increased production of IL-10 in both viable DC and tolDC. 
DR antibody and percentage phagocytosis was determined by dividing the number of double 
positive (HLA-DR APC+, CFSE+) DCs by the sum of single (APC+) and double positive (APC+, 
CFSE+) DCs. Data shown in (A) is representative of 4 independent experiments. Data shown in 
(B) is the mean ± SEM (n=4; **p=0.0019 using paired t test). (C) Viable immature DC or tolDCs 
were incubated with CFSE labelled neutrophils, which had undergone spontaneous apoptosis, at 
a ratio of 1:1 for 1hr at 37oC or 4oC. DCs were detected using APC labelled HLA-DR antibody 
and percentage phagocytosis was determined by dividing the number of double positive (HLA-
DR APC+, CFSE+) DCs by the sum of single (APC+) and double positive (APC+, CFSE+) DCs. 
Data shown in (C) is the mean ± SD (n=3; *p≤ 0.05 using paired t test). (D) Viable PKH labelled 
DC or tolDC were incubated with CFSE labelled apoptotic Jurkat cells at 37ºC in a ratio of 1:1 
and followed in time for 24 hours using Cell IQ® live cell imaging. Representative pictures were 
taken of both DC and tolDC at 2 and 24 hours. Images captured were analysed (E) by counting the 
number of remaining unbound and uningested apoptotic or necrotic Jurkat cells at indicated time 
points and expressed relative to dying cells counted at t=0. Dashed lines in (E) indicate t1/2(the point 
at which 50% of the dying cells were cleared by DC and tolDC respectively). 
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Activation in the presence of apoptotic or necrotic cells did not significantly alter 
IL-10 production by mature DCs or mature tolDCs under any conditions analysed 
(Fig.3F). In summary uptake of apoptotic cells by mature DCs significantly 
inhibits production of IL-12, while IL-10 remains unaffected.
Apoptotic cell uptake does not alter transcriptional expression of IDO, 
TGF-β or IL-10.
Three key soluble mediators that have been shown to be upregulated upon uptake 
of apoptotic cells are IDO, TGF-β and IL-10. We observed by ELISA that IL-10 
remained unaffected by uptake of either apoptotic or necrotic cells even upon 
Figure 3: Stimulation of DCs with IFNγ and LPS in the presence of apoptotic DCs profoundly 
inhibits IL-12 production. (A) Viable, (UV-irradiated) Apoptotic or (heat-treated) Necrotic DCs 
were generated and defined by Annexin V/PI positivity. Viable immature DCs and tolDCs were 
harvested at day 6 and cultured for 48hr alone, with apoptotic DC, or with necrotic DC. As a control 
apoptotic and necrotic DCs were additionally cultured in the absence of viable cells to account for 
production of cytokines by dying cells alone. After culture the supernatants were harvested and an 
ELISA was performed for (B) IL-12p40 and (E) IL-10. Alternatively viable DC and tolDC were 
cultured alone, with apoptotic DC, or with necrotic DC for 24 hours and then stimulated with a 
combination of IFNγ and LPS for a further 24 hours. After that the supernatants were harvested and 
analysed for (C) IL-12p40, (D) IL-12p70, (F) IL-10. Data shown is mean ± SEM (n=4) *p=<0.03, 
DC alone versus DC with apoptotic/necrotic DC using paired t-test.
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subsequent activation with IFNγ+LPS (Fig.3). 
We further challenged immature DC and immature tolDCs with apoptotic or 
necrotic autologous cells and found that the ingestion of dying cells did also not 
alter the expression of either IDO or TGFβ (Fig.4A, B). We questioned whether 
stimulation of DCs and tolDCs upon ingestion of apoptotic or necrotic material 
may alter the expression of IDO or TGFβ but stimulation in the presence of dying 
cells did not significantly alter the expression of any molecule assessed in mature 
DCs or mature tolDCs (Fig. 4A, B).
TolDCs have decreased transcriptional expression of IL-12p40, yet have 
enhanced levels of both Ebi3 and IL-12p35.
We have shown that tolDCs are completely impeded in their ability to produce 
IL-12p40 and IL-12p70. Considering that IL-12p70 is a heterodimer of IL-12p40 
and IL-12p35, and belongs to the larger IL-12 family, we sought to investigate 
the expression levels of the different subunits of the IL-12 family in DCs and 
tolDCs. We demonstrate, in line with our protein data on IL-12p40 and IL-12p70, 
that immature tolDCs have strongly diminished transcriptional expression of 
IL12B (Fig.5A). Strikingly however, these cells have an increased expression of 
IL12A, along with its alternate pairing subunit, IL27B (Fig.5A). IL27B can also 
heterodimerise with IL27A to form IL-27, however no significant difference was 
Figure 4: Apoptotic cell uptake does not alter transcriptional expression of IDO, TGF-β or 
IL-10. Viable, (UV-irradiated) Apoptotic or (heat-treated) Necrotic DC and tolDCs were generated 
as described. Viable immature DC and tolDC were harvested at day 6 and cultured alone, with 
autologous apoptotic, or with autologous necrotic DC/tolDC for 48 hours after which mRNA 
was isolated followed by cDNA synthesis. Alternatively cells were additionally stimulated for 6 
hours with IFNγ+LPS after the initial 48 hour incubation. The transcript levels were determined 
by RT-PCR in (A) DC (B) tolDC for IDO, TGFβ and IL10. Data shown is mean ± SD (n=2-3). 
Relative mRNA expression indicates expression of the mRNA of interest relative to the expression 
of GAPDH.
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noted between immature DCs and immature tolDCs in terms of IL27A expression.
In view of the enhanced phagocytic abilities of tolDCs (Fig.2C), we questioned 
whether uptake of dying cells could affect the elevated IL27B and IL12A levels. 
To investigate this, we further challenged viable immature tolDCs with apoptotic 
or necrotic tolDCs or apoptotic or necrotic immunogenic DCs and analysed 
expression of IL12B, IL12A, IL27B and IL27A. However addition of apoptotic 
or necrotic cells to immature tolDCs did not alter the expression of the different 
IL-12 family subunits (Fig.5B). 
Figure 5: tolDCs maintain expression of IL-12p35 and Ebi3 in the absence of IL-12p40. 
Immature DCs and tolDCs were harvested on day 6, mRNA was isolated and cDNA was generated 
for (A) RT-PCR analysis for expression of IL12B, IL12A, IL27B, and IL27A. Relative mRNA 
expression indicates expression of the mRNA of interest relative to the expression of GAPDH. 
Viable, (UV-irradiated) Apoptotic or (heat-treated) Necrotic DCs or tolDCs were generated and 
defined by Annexin V/PI positivity (data not shown). Viable immature tolDC were harvested at 
day 6 and cultured alone, with apoptotic DC/tolDC, or with necrotic DC/tolDC for 48 hours after 
which mRNA was isolated followed by cDNA synthesis. Alternatively cells were additionally 
stimulated for 6 hours with IFNγ+LPS after the initial 48 hour incubation. The transcript levels 
were determined by RT-PCR in (B) Medium and (C) IFNγ+LPS stimulated tolDCs for IL12B, 
IL12A, IL27B and IL27A. Data shown is mean ± SEM (n=4-7) **p ≤ 0.002, *p ≤ 0.03 DC versus 
tolDC using Mann-Whitney test.
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We questioned whether stimulation of tolDCs upon ingestion of apoptotic or 
necrotic material may alter the stable cytokine profile of these cells. Stimulation 
with IFNγ +LPS led to increased expression of all IL-12 members with IL27A 
demonstrating the greatest increase. Stimulation in the presence of dying cells 
did not significantly alter the expression of any IL-12 family members assessed, 
indicating that tolDCs maintain a stable cytokine profile upon stimulation, 
irrespective of challenge with either apoptotic or necrotic cells (Fig.5C).
Culture of immature DC with apoptotic DCs leads to increased expression of 
both IL-12p35 and Ebi3.
To investigate whether the robust stability of transcriptional expression of the 
IL-12 family was a general characteristic of DCs, or was intrinsic for tolDCs 
upon ingestion of apoptotic and necrotic cells, we cultured immature DCs with 
apoptotic or necrotic DCs. We first established that culture of apoptotic or necrotic 
DCs with viable DCs more broadly altered the function of DCs, by assessing their 
allostimulatory capacity following uptake of apoptotic or necrotic material. We 
observed that ingestion of apoptotic DCs by viable cells resulted in an impaired 
allostimulatory ability, as assessed by CD4+ T cell proliferation and IFNγ 
production. Conversely, ingestion of necrotic DCs by viable DCs significantly 
enhanced both allogenic T cell proliferation and IFNγ production (Fig.6A). In 
contrast to IFNγ, IL-17A production remained unaffected. Focusing on DCs, we 
observed microscopically that culture of DCs with apoptotic cells resulted in 
the formation of small clusters, whereas culture of immature DCs with necrotic 
cells induced a more distinct morphological change, with some of the viable cells 
becoming more stretched and adherent; typical features suggestive of activated 
DCs (Fig.6B). When analysing mRNA expression we observed that IL12B was 
not affected by co-culture with apoptotic cells, but was significantly enhanced by 
necrotic cells (Fig.6C). This was in line with our initial ELISA data (Fig.3B). In 
contrast, although still relatively low, there was an increased expression of both 
IL12A and IL27B when DCs were cultured in the presence of apoptotic DCs 
(Fig.6C). Importantly, this stimulatory effect was not observed in the presence of 
necrotic cells. The expression of IL27A was not significantly altered upon uptake 
of apoptotic or necrotic cells (Fig.6C). 
Discussion
In the last decade a shift in rationale has been seen in the field of apoptosis where it 
is becoming increasingly evident that apoptotic cells are not just immunologically 
inert, but actively shape the immune capacity of the ingesting cell35. In this 
study we found that apoptotic and necrotic cell uptake profoundly affects the 
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cytokine profile of the ingesting dendritic cell and that uptake of apoptotic cells 
by immature DCs led to increased expression of Ebi3 and IL-12p35.We observed 
previously that DCs generated in the presence of dexamethasone became a potent 
immunoregulatory population with complete absence of IL-12 and the ability 
to suppress allogenic T cell proliferation6, 32. In this study we demonstrate that 
these same tolDCs have enhanced expression of several receptors involved 
in the clearance of dying cells, including αvβ536, CD3637 and CD9130, and 
Figure 6: Culture of immature DC with apoptotic or necrotic DCs has differential effects 
on the transcriptional regulation of IL-12 family members. Viable (A) immature DCs were 
harvested at day 6 and cultured for 48hr alone, with apoptotic DC, or with necrotic DC. The cells 
were then harvested washed and cultured at a ratio of 1:40 with allogeneic CD4+  T cells for 5 days. 
Proliferation was determined by the addition of 3H for the last 18 hours and supernatants were 
assessed for IFNγ and IL-17A production. (B) Clusters of cells present in apoptotic conditions 
suggest enhanced activation in immature DCs cultured with apoptotic material. Arrows in necrotic 
conditions indicate the activated and adherent viable DCs observed when cultured in the presence 
of necrotic DCs. Cells were harvested after the 48 hour culture and mRNA was isolated followed 
by cDNA synthesis. Alternatively cells were additionally stimulated for 6 hours with IFNγ+LPS 
after the initial 48 hour incubation. RT-PCR was performed in (C) Medium and (D) IFNγ + 
LPS stimulated DCs for IL12B, IL12A, IL27B and IL27A. Relative mRNA expression indicates 
expression of the mRNA of interest relative to the expression of GAPDH. Data shown is mean ± 
SEM (n=3-7) *p≤0.05 DC alone versus DC with apoptotic/necrotic DC using Mann-Whitney test.
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have enhanced phagocytic abilities compared to non tolerogenic DCs. As a 
consequence, although tolDCs have reduced cell yields after culture there is a 
complete absence of cellular debris, indicating that tolDCs continuously ingest 
dying bystander cells. 
An intriguing observation in our study was that the accelerated clearance of 
apoptotic cells by tolDC was not observed for necrotic cells. This resembles 
our previous observation that anti-inflammatory type-2 macrophages displayed 
a preference for recognition of early apoptotic cells33. Some molecules, most 
notably phosphatidylserine (PS)33, 38, have been implicated as triggers for 
phagocyte recognition and subsequent removal of apoptotic cells. We showed that 
tolDCs do express elevated levels of PS-recognising bridge molecule-receptors, 
however blockade of these molecules during phagocytosis assays did not alter the 
% uptake of apoptotic material by tolDCs (data not shown).
Several studies have looked at the effect of phagocytosis on DC function, 
including IL-12 production29, 39. However limited data is available with regard to 
the other members of the IL-12 family, particularly the most recently identified, 
IL-35. Although IL-12 and IL-35 share IL-12p35, the common α-chain, both 
cytokines possess a unique spectrum of functional activities. Where IL-12 is 
widely acknowledged as a critical mediator in the induction and maintenance of 
Th1 responses13, 14, data regarding IL-35 is more finite. Studies have shown that 
IL-35 is a potent immunoregulatory cytokine responsible for the induction of 
iTr35 a specific subset of regulatory T cells23, 40. Considering that DCs possess 
all the chains of the IL-12 family, a complex relationship exists between the 
opposing roles of IL-12 and IL-35 in the induction of specific T cell responses, 
although the definitive role of IL-35 has yet to be fully ascertained41-43. 
We questioned whether regulation of the IL-12 family more broadly could be 
an additional response to apoptotic versus necrotic cell uptake. We show that 
addition of necrotic cells induced a significant increase in IL-12p40 production. 
Activation of DCs with LPS and IFNγ induced a strong IL-12p40 and IL-12p70 
production which was profoundly inhibited in the presence of apoptotic cells. 
This inhibition was not observed for necrotic cells, which not only reaffirms the 
consensus that apoptotic cells generally do not provoke inflammation, but also 
that they actively downregulate immunity30, 44-47. Still, there are some conflicting 
reports regarding this calming effect of apoptotic cells on DC activation, since 
some studies have shown that apoptotic cells can induce IL-12 production in 
DCs48, 49. Often the apoptotic cells used in these studies had been stimulated prior 
to apoptosis induction which may explain some discrepancies, or in addition the 
method of inducing apoptosis may also lead to the considerable variation between 
different studies. Many studies have been performed to elucidate the mechanisms 
of how necrotic cells lead to immune activation. The most extensively studied 
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danger signals released from necrotic cells, include heat shock proteins50, 
HMGB151, nucleic acids and degradation products such as urate. In contrast, 
molecular mechanisms into how apoptotic cells may promote tolerance are far 
less defined. Interest in this particular aspect has been growing in the past years 
and a recent publication by Sekar et al, demonstrated that uptake of apoptotic 
tumour cells by DCs lead to Ebi3 upregulation in an SP1 dependent fashion52.  It 
would be of interest to explore the role of SP1 and S1PR4 in our model using DCs 
as a source of apoptotic material.
In our study, transcriptional analysis confirmed a reduced expression of IL-12p40 
in tolDCs. Strikingly, the expression of the other 3 members was maintained 
in tolDCs and specifically for IL-12p35 and Ebi3 the expression was even 
elevated compared to DCs. Challenge of tolDCs with apoptotic material from 
autologous tolDC or non-tolerogenic DCs, did not further enhance expression of 
IL-12p35 or Ebi3, however ingestion of necrotic cells did also not enhance the 
immunogenic chain IL-12p40. We have shown that tolDCs generated with dex 
are phenotypically very stable and retain their anti-inflammatory profile despite 
repeated challenge with immunogenic stimuli, including TLR agonists and CD40 
ligation32. We show that in addition, ingestion of necrotic cells also does not break 
this anti-inflammatory state. We hypothesised that non tolerogenic DCs may be 
not be so steadfast in their cytokine expression upon encountering apoptotic 
versus necrotic cells. We chose DCs as a source of dying material to avoid 
contaminating mRNA from other cellular sources, as many cells constitutively 
express IL-12p35 to varying degrees. In addition the ratio (1:5) of viable to dying 
cells we used is in line with ratios used in other studies27, 30, 31, 53. We first observed 
that uptake of apoptotic or necrotic material by DCs altered their allostimulatory 
capacity, with apoptotic cell uptake decreasing both T cell proliferation and 
IFNγ production while necrotic cell uptake increased proliferation and IFNγ 
production. In line with these findings, we observed that uptake of necrotic DCs 
led to the upregulation of IL-12p40, which was not observed with apoptotic 
cell uptake. Interestingly while IL-12p40 remained unaffected, ingestion of 
apoptotic DCs led to the upregulation of both IL-12p35 and Ebi3 in the viable 
cells. Previous studies have demonstrated that DCs which had engulfed apoptotic 
cells had a diminished T cell stimulatory capacity which they found was not 
dependent on either IL-10 or TGF-β29. Although several factors including IDO54 
have been shown to mediate T cell inhibition by DCs post apoptotic cell uptake, 
we also did not observe any effect on IL-10, TGF-β or IDO in our study.  It is 
interesting to consider the role which IL-35 may play in such circumstances. In 
fact, although regulatory T cell derived IL-35 has been shown to be important in 
immune regulation, speculation is rife as to whether DCs, particularly tolerogenic 
DC subsets may also contribute to IL-35 production55. Unfortunately reagents to 
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accurately determine IL-35 production are currently lacking and have somewhat 
hampered further understanding into this exciting cytokine. Our data, although 
speculative, does show a robust regulation of both IL-12p35 and Ebi3 by 
apoptotic cell uptake and may imply a role for IL-35 as an additional molecule in 
the control of the immune response to dying cells. 
Although we have shown that ingestion of dying cells alone can alter the 
transcriptional cytokine profile within the DC, this is even more profound when 
the DCs are subsequently activated. In line with previous work we found that 
IL-12p35 is significantly inhibited in activated DCs upon uptake of apoptotic 
cells56. Surprisingly this was also true for Ebi3. Further work is needed to dissect 
the answer as to why apoptotic cells induce Ebi3 expression in immature DCs yet 
can also suppress its upregulation in mature DCs, and furthermore the full role of 
IL-35. Although speculative, several groups have supported the idea that uptake 
of apoptotic DCs by DCs is particularly proficient at promoting tolerance within 
the ingesting DCs44, 57. Although an exact mechanism remains elusive, some 
interesting findings have suggested that cells undergoing apoptosis are capable 
of producing cytokines and chemokines which can influence the response of the 
ingesting phagocyte58. One could imagine that DCs would be particularly adept at 
secreting potent immune mediators that may conflict, or alternatively synergise, 
with non-sterile or sterile signals depending on the concentration and duration of 
stimulus. 
Many groups in the area of transplantation are striving to identify the best way 
to induce tolerance in allograft recipients2, 59, 60. A promising strategy may be 
to culture tolDCs of recipient origin and feed them with donor apoptotic cells. 
Indeed it has been shown in a murine model that targeting of DCs with donor 
apoptotic material can restrain indirect allorecognition61, a major hurdle in the 
quest for transplant tolerance. If future therapeutic interventions will be based 
on this principal it is imperative to understand the full effects of apoptotic and 
necrotic cell uptake on DC and tolDC functions including the effect on their 
cytokine repertoire. It is promising that in this study tolDCs maintained a stable 
immunoregulatory cytokine profile irrespective of ingestion of apoptotic or 
necrotic cells even upon subsequent stimulation.
Taken together our results demonstrate that compared to DCs, tolDCs are 
superior at ingesting apoptotic material, and maintain a stable cytokine profile 
irrespective of apoptotic or necrotic cell uptake. Uptake of apoptotic cells by DCs 
results in diminished production of IL-12p40 and IL-12p70. We demonstrate that 
this also results in the increased expression of IL-12p35 and Ebi3. We conclude 
that ingestion of apoptotic versus necrotic cells by DCs results in differential 
regulation of the IL-12 family members thereby playing a role in determining 
the immune response in such events. Further understanding into the processes 
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governing DC phagocytosis and the effect it exerts over DC cytokines may open 
up many avenues towards the goal of limiting allograft rejection in transplantation 
and dampening down immune responses in autoimmune diseases.
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Abstract
Dendritic cells (DCs) and complement are both key members of the innate 
immune system, and are critical for immunogenic as well as regulatory functions 
of adaptive immunity. Recent experimental mouse models have shown that 
production of alternative pathway (AP) components by DCs strongly affects their 
functional capacity to activate and regulate T cell responses. In this study we 
investigated the production and regulation of properdin (fP) and factor H (fH) 
both integral regulators of the AP, by both human monocyte-derived DCs and 
tolerogenic DCs (tolDCs). Both fP and fH were expressed and produced by DCs, 
as shown by Q-PCR, intracellular staining, Western blotting and ELISA, with 
significantly higher levels of both AP components produced by tolDCs. Upon 
activation with IFNγ both cells increased fH production, while simultaneously 
decreasing production of fP. This was unique for IFNγ as LPS and IFNα or IFNβ 
did not demonstrate this dual regulation. IL-27, a member of the IL-12 family 
which elicits features of IFNγ stimulation, did increase fH, but production of fP 
remained unaffected. The functional capacity of fP and fH produced by DCs and 
tolDCs was confirmed by their ability to bind C3b and the capacity of fP to bind 
to necrotic cells. Inhibition of fH production by DCs through siRNA, resulted in a 
greater ability to induce allogenic CD4+ T cell proliferation. In contrast, inhibition 
of fP production by DCs led to a significantly reduced allostimulatory capacity. 
In summary this study shows that production of fP and fH by DCs, differentially 
regulates the T cell stimulatory capacity of these cells, and that the local cytokine 
environment can profoundly affect the production of fP and fH by DCs.
Introduction 
Dendritic cells (DCs) and the complement system are both integral members 
of the innate immune system1,2. The complement system is composed of three 
distinct pathways-classical, lectin and alternative. Together these pathways 
serve as key mediators of the innate immune response, involved in defending 
the host from pathogens, removing immune complexes and facilitating efficient 
phagocytosis of apoptotic cells2,3. A key role of complement in the humoral arm 
of the adaptive immune response has been demonstrated through experimental 
depletion of complement resulting in poorer antibody responses, and opsonisation 
with complement fragments which profoundly lowers the amount of antigen 
needed to induce antibody production4,5. Recently, there has been an increasing 
body of evidence demonstrating that complement may function more broadly as 
a link between innate and adaptive immunity. This includes murine studies which 
have demonstrated a role for the AP in the DC: T cell synapse6-8. Both APC and 
T cells have been shown to increase C3a and C5a receptor on their surface, while 
a surface regulator, decay accelerating factor, has been shown to be decreased, 
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allowing for further complement activation9.10. 
The AP is unique in that it can become auto activated via C3 hydrolysis generating 
a C3b like molecule which can bind covalently to an activating surface recruiting 
factor B, which is then cleaved by factor D generating a C3 convertase (C3bBb). 
This C3 convertase can convert further C3 to C3b, with stabilisation of the enzyme 
by properdin (fP) allowing for propagation of the AP activation11. Regulation of 
the AP is key, with fP promoting AP activation and negative regulators such as 
factor H (fH), limiting the availability of C3b, or acting as a co-factor for factor 
I, which degrades C3b. This delicate balance between activators and inhibitors 
of the AP is crucial for controlling complement activation12. The majority 
of complement proteins are produced by the liver, although white blood cells 
including DCs can also act as a local source of certain complement proteins13. 
The source of fP is largely restricted to white cells, including neutrophils14,15. 
Factor H is most abundantly expressed in the liver, but also here extra hepatic 
production has been described, which includes mesangial cells, endothelial cells 
and fibroblasts16-19. This suggests that local cell populations, either resident or 
infiltrating, can significantly contribute to the overall complement activation at a 
particular site of inflammation.
DCs are distinct among other cells in the immune system as they are uniquely 
equipped to respond to a host of innate stimuli while also adapting and tailoring 
their functions in response to the local cytokine environment. This had led to 
the understanding that DCs are not just immunogenic but that tolerogenic DCs 
also exist. These tolDCs are characterised by differences in cytokine production 
and expression of co-stimulatory molecules, which has a direct impact on the 
strength and quality of their T cell stimulatory capacities20. Previous studies 
have demonstrated by RT-PCR that DCs can express many components of the 
complement system21,22, however protein data to support this has been limited. 
Furthermore there is only limited data available on the regulation of AP component 
production by DCs or particularly tolDC populations. Local production of 
complement components such as C3 by APCs at the site of inflammation or 
immunological synapse can be instrumental in the immune response8. With the 
demonstration that local AP activation at the interface of APC and T cells plays 
a key role in the regulation of T cell responses23, regulation of the AP in the 
local environment will be key in controlling the strength of the T cell response. 
Therefore, we investigated the regulation of two integral modulating factors of 
the AP, fP and fH. Combined both molecules have the ability to influence the 
balance of the AP towards activation or regulation.
In this study, we demonstrate that DCs are a source of fP and fH and that tolDCs 
are superior producers of both components. We observed a differential regulation 
of fP and fH, whereby IFNγ profoundly inhibited fP in both cell types, while 
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simultaneously increasing production of fH. This distinct dual effect was found 
to be unique for type II IFN. IL-27 did significantly enhance fH levels in DC 
supernatants but not fP. Importantly, RNA interference of fH in DCs increased 
their allostimulatory capacity, while siRNA targeting of fP decreased T cell 
proliferation. Taken together, our data suggests that the local cellular and cytokine 
microenvironment are crucial for overall complement regulation and thereby T 
cell immunity.
Materials and Methods
Cell culture and Reagents 
Human monocytes were isolated from buffy coats obtained from healthy donors using Ficoll density gradient 
centrifugation followed by positive selection using anti-CD14 MACS microbeads (Miltenyi Biotech GmBH, 
Bergisch Gladbach, Germany). DCs were generated and cultured in RPMI 1640 supplemented with 10% heat 
inactivated foetal calf serum (FCS), 90 U/mL penicillin, and 90 μg/mL streptomycin (Gibco/Life technologies, 
Breda, The Netherlands), 5 ng/mL GM-CSF and 10 ng/mL IL-4 (Biosource Europe, Belgium), as described 
before. Tolerogenic DC (tolDCs) were generated by addition of Dexamethasone (10-6M Dex) (Pharmacy, 
L.U.M.C., Leiden, the Netherlands) only at the start of culture (day 0)24. Cultures were refreshed with medium 
containing cytokines on day 3. For stimulation experiments, immature DCs were harvested on day 6, washed 
and seeded accordingly, followed by addition of 200 ng/ml LPS (E.Coli EH100 Enzo, Belgium), 100 ng/ml 
each of IFNγ, IFNα, IFNβ (Peprotech) or 100 ng/ml IL-27 (R&D). Neutrophils were isolated as previously 
described25, briefly blood from healthy donors was collected using ACD tubes (BD Vacutainer). Neutrophils 
were isolated by Ficoll-Paque and Dextran T-500 gradients (Sigma Aldrich). The preparation contained greater 
than 90% neutrophils as confirmed by flow cytometry using CD16 (R&D Systems), CD11b (BD Biosciences), 
and CD66b (AbD Serotec) antibodies. 
Flow Cytometry
For intracellular staining, cells were stimulated overnight, with the addition of Brefeldin-A (10µg/ml) for the 
last 5 hrs of culture. The cells were then harvested, washed and fixed in PBS containing 4% formaldehyde and 
1% heat inactivated FCS, washed with PBS containing 1% BSA and permeabilised with perm buffer (PBS, 
0.5 % saponin, 0.1% BSA) for 10 mins. Cells were stained with primary antibodies including anti-fP (Quidel) 
and anti-fH (Hycult Biotech, Uden, The Netherlands) for 30 mins at 4°C in perm buffer followed by goat anti 
mouse Ig APC conjugated secondary antibody. Isotype matched control antibodies were used to determine the 
level of background staining. The fluorescence was measured on a FACS Calibur flow cytometer, and data were 
analyzed with Flow Jo and Cell Quest Software. 
mRNA isolation, cDNA synthesis, and RT-PCR
Cells were harvested and mRNA was isolated from DCs using an Rneasy kit according to the manufacturer’s 
instructions (Qiagen, Hilden, Germany). DNA was digested using the on-column RNase-free DNase set. cDNA 
was synthesised using a reverse transcription system kit (Promega) following the manufacturer’s guidelines 
and stored at −20°C until analysis. Specific primers for human Properdin, Factor H, IFNγR1, IFNγR2, gp130 
and WSX-1 (Table I) were designed using the computer software Oligo explorer and synthesised at Biolegio. 
Primer specificity was tested by homology search with the human genome (basic local alignment search tool or 
BLAST; National Center for Biotechnology Information) and later confirmed by electrophoresis through 2% 
agarose gels containing ethidium bromide followed by visualisation under UV light. GAPDH was used as an 
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endogenous reference gene. For each sample, the relative abundance of target mRNA was calculated from the 
obtained Ct values for the target gene and expressed relative to the endogenous reference gene GAPDH. 
Table I: Real Time PCR Oligonucleotide sequences
DC-T cell co culture
Allogeneic CD4+ T cells were isolated from buffy coats by negative selection using the MACS CD4+ T Cell 
Isolation Kit II (Miltenyi Biotec). DCs from all conditions were harvested after 24hrs, washed, and plated in 
96-well round bottom plates at a starting ratio of 1:40 with 100,000 T cells/well. Cells were cultured for 5 days 
and supernatant was harvested to measure IFNγ production by means of ELISA. Proliferation was assessed by 
the addition of 3[H]-thymidine (0, 5 µCi/well)24.
Western Blot DCs were plated at 1 × 106 cells/ml, and stimulated at indicated time points with either IFNγ or 
IL-27. Cells were harvested, washed in ice-cold phosphate-buffered saline and lysed in medium stringency 
lysis buffer for 30 minutes. The lysates were centrifuged at 13,000 rpm and the supernatants were harvested. 
Protein concentration was determined by a Pierce assay and 30ug was loaded per lane. The samples were boiled 
for 5 min in 1x loading buffer under reducing conditions, and SDS-PAGE analysis was performed. Blots were 
probed for p-STAT1, total STAT 1 (both Cell signaling technologies), Properdin (Quidel) and factor H (Santa 
Cruz biotech). Anti β-actin (Abcam, Cambridge, UK) was used as a loading control. Blots were stripped using 
western blot stripping buffer (Thermo Scientific, Illinois, USA).
Confocal microscopy
Cells were cultured on 8 well chamber slides (Nunc) and stimulated overnight with IFNγ followed by 
Brefeldin-A for the last 5 hours of culture. The slides were subsequently washed and fixed in PBS containing 4% 
formaldehyde, 1% heat inactivated FCS followed by washing with PBS containing 1% BSA and permeabilised 
with perm buffer (PBS, 0.5 % saponin, 0.1% BSA) for 10 mins. The DCs were then stained using purified 
anti-fP or anti-fH followed by goat anti-mouse-Alexa 488. Hoechst was used for nuclear staining. Stains were 
visualised using Leica TCS SP5 or Zeiss LSM710 NLO.
Complement binding assays
For determination of properdin function, necrotic cells were exposed to supernatant of DC or tolDC for 1 hour 
at 4°C, followed by detection of properdin binding by flow cytometry and microscopy. Purified human C3b 
was coated overnight on a 96 well Nunc plate followed by exposure to DC or tolDC supernatants and detection 
of properdin binding with rabbit anti human fP. To determine specificity of the assay tolDC sups were fP 
depleted by incubating with anti-properdin pre-coupled A/G beads overnight at 4°C. Both depleted and control 
non-depleted tolDC supernatant was assessed for ability to bind C3b as above. For determination of Factor H 
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binding, DCs were either unstimulated or stimulated with IFNγ prior to supernatant exposure to coated human 
C3b, followed by detection by mouse anti factor H (Abcam).
Cytokine and Complement production
DCs or neutrophils were plated at 1x106/ml in RPMI and treated as per mentioned earlier. Cell culture 
supernatants were harvested after indicated time points and frozen at −20°C until analysis. Subsequently they 
were tested for the presence of IL-12p40 and IL-10 by ELISA (Biolegend, Sanquin respectively) according 
to manufacturer’s instructions, or properdin and fH using in-house specific sandwich ELISAs26,27 Cell culture 
medium with 10% FCS unexposed to cells was negative in all complement assays used. 
RNA interference
DCs were transfected with 50 nM siRNA through the use of the transfection reagent Lipofectamine 2000 (Life 
Technologies) and were used for experiments 24hr after transfection. The following SMARTpool siRNAs were 
used (Dharmacon): CFP, CFH and nontargeting siRNA as a control. Silencing of expression was verified by fP 
and fH ELISA.
Statistical analysis
Statistical analysis was performed with Graph Pad Prism (Graph Pad Software, San Diego, CA) using a one-
tailed t-test. P-values ≤ 0.05 were considered statistically significant.
Results
TolDCs display elevated levels of properdin and fH. 
To investigate the ability of DCs to produce properdin (fP) and factor H (fH), 
we first assessed by RT-PCR if fP and fH were expressed in both DC and tolDC 
populations. We demonstrate that DCs and tolDCs expressed both factors, and that 
tolDCs showed more than 10 fold higher transcription of both fP and fH compared 
to DCs (Fig.1A,B).Western blotting was performed to analyse protein expression. 
Under reducing conditions for fP an expected band of approx. 55kDa was found, 
with no discernible changes noted with IFNγ stimulation over time (Fig.1C). The 
same cell lysates were assessed for the presence of fH, showing a band of approx. 
155kDa in lysates of tolDCs (Fig.1D). In this case, expression of fH clearly 
increased over time with IFNγ stimulation (Fig.1D). We further assessed fP and 
fH production within DCs and tolDCs using intracellular microscopy. Using this 
method we could demonstrate expression of fP and fH protein in both DCs and 
tolDCs (Fig.1E). Incubation with IFNγ reduced the presence of fP, whereas at the 
same time it appeared to increase the expression of fH. To further quantify these 
observations, we performed intracellular flow cytometry, and confirmed these 
opposing effects of IFNγ on fP and fH expression (Fig.1F). 
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Figure 1: Expression and production of properdin and fH by human DC and tolDC. Dendritic 
cells were harvested after 6 days of culture after which mRNA was isolated followed by cDNA 
synthesis. The transcript levels of (A) Properdin (B) Factor H were determined by RT-PCR. GAPDH 
mRNA expression from the same samples was used as an endogenous reference gene (relative 
mRNA expression). Data shown is mean ± SD of 8 independent experiments. DCs and tolDCs 
were either untreated or stimulated for indicated time points with IFNγ. Cells were harvested, lysed 
and samples were loaded on 10% SDS gel followed by transfer to nitrocellulose membranes. Blots 
were probed with antibodies directed against either (C) properdin or (D) Factor H. Blots shown are 
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IFNγ, but not LPS, exerts opposing effects on the production of fP and fH by 
DC and tolDC.
To further assess the differential regulation of fP and fH protein, we performed 
ELISAs on cell culture supernatants. In line with Q-PCR data (Fig.1A,B), we 
found that tolDCs produced significantly more fP and fH compared to DCs 
(Fig.2A,B). For comparison, supernatants from neutrophils, a widely accepted 
source of fP, were shown to produce levels of fP similar to DCs, but with only 
minimal production of fH. 
To investigate whether the differential regulation of fP and fH was a general 
feature of mature DCs or was activation dependent, we compared stimulation 
with either IFNγ or LPS. Both stimuli induced the typical cytokine profile, with 
DCs producing high IL-12 and low IL-10, and tolDCs producing no IL-12 but 
high levels of IL-10 (Fig.2C,D). In view of the large differences in fP and fH 
production (Fig.2A,B), we calculated the relative change upon stimulation for 
each donor measured, with the immature/medium state set at 100%. In both 
DC and tolDC we observed that fP production was significantly reduced in the 
presence of IFNγ (Fig.2E,F). This effect was not observed with LPS stimulation 
where no clear regulation was noted. Regulation of fH demonstrated the opposite 
effect, where both cell types showed a significant increase in fH production 
upon treatment with IFNγ (Fig.2G,H). Also here, despite the strong induction of 
cytokine production (Fig.2C,D), LPS did not show any effect on the production 
of fH. 
TolDCs express elevated levels of IFNγ R, IL-27R and STAT-1.
We observed that IFNγ displayed its most striking differences regarding fP and 
fH when incubated with tolDCs (Fig.1E). IL-27 is a member of the IL-12 family 
of cytokines, but possesses some effector properties in line with IFNγ stimulation 
28, 29. We investigated the level of expression of both IFNγR and IL-27R on DC 
and tolDCs, and found that tolDCs express higher levels of both IFNγR1 and R2, 
together making the IFNγ receptor (Fig.3A). In addition, both DC and tolDCs 
expressed the IL-27R, with tolDCs expressing significantly higher levels of both 
gp130 and WSX-1, together generating the IL-27R (Fig.3B). 
representative of 2 independent experiments. (E) DCs were cultured on 8 well chamber slides and 
either untreated or stimulated with IFNγ for 16 hours followed by incubation with Brefeldin A for 
the last 5 hours of culture. The cells were then fixed and permeabilised, followed by incubation 
with anti-fP or anti-fH followed by detection with GaM-Alexa488. (F) DCs were either untreated or 
stimulated with IFNγ for 16 hours followed by incubation with Brefeldin A for the last 5 hours of 
culture. The cells were then fixed and permeabilised, followed by incubation with purified anti-fP 
or anti-fH followed by detection by flow cytometry with GaM-APC. Data shown is mean ± SD of 
3 independent experiments. 
DC derived fP and fH modulate T cell responses   •   81
   4
Both IFNγ and IL-27 are known to mediate their downstream functions largely 
through phosphorylation of STAT-1. We observed a strong and prolonged 
phosphorylation of STAT-1 in tolDCs upon stimulation with both IFNγ and IL-
Figure 2: IFNγ exerts opposing effects on the production of fP and fH by DC and tolDC. DCs 
were harvested on day 6 and re-plated for another 24 hours. (A) fP and (B) fH production was 
measured using ELISA. Data shown is mean ± SD of 8-24 independent experiments. Dendritic 
cells were harvested after 6 days of culture and stimulated with IFNγ or LPS. After 24 hours the 
supernatants were harvested and (C) IL-12p40 and (D) IL-10 was measured. Data shown is the mean 
±SD of 4 independent experiments. Cells were stimulated for 24 hours after which (E, F) fP and (G, 
H) fH was determined by ELISA. Levels upon stimulation were expressed as a percentage relative 
to medium values (relative change). Data shown is mean ± SD of 12-28 independent experiments. 
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27, while in comparison, DCs had a much lower and transient level of p-STAT-1. 
Interestingly, total STAT-1 levels were elevated in tolDCs compared to DCs 
despite the loading control being similar amongst all conditions analysed (Fig.3C). 
Type I IFNs do not possess the same opposing properties as IFNγ, while IL-
27 specifically increases fH. 
We addressed whether IL-27 could, like IFN-γ, also possess dual roles in regulating 
alternative pathway components in DCs. In addition to IL-27 stimulation we used 
type I IFNs (IFN α and β) to discern whether fP and fH regulation was unique 
for type II IFN (IFNγ) or was more widely regulated across the IFN family. We 
observed that both DCs and tolDCs demonstrated reduced levels of fP upon IFNγ 
stimulation. IFN-α but not IFN-β did significantly reduce fP levels in tolDC 
supernatants, while no regulation of fP was observed in DC with type I IFN 
(Fig.4A,C). In contrast, IL-27 did not demonstrate any clear ability to regulate 
fP production. The levels of fH remained unchanged in both DC and tolDCs 
stimulated with either IFNα or IFNβ but were significantly upregulated upon IL-
27 and IFNγ stimulation respectively (Fig.4 B,D). 
Figure 3: TolDCs express elevated levels of IFNγR, IL-27R and STAT-1. Dendritic cells were 
harvested after 6 days of culture after which mRNA was isolated followed by cDNA synthesis. 
The transcript levels of (A) IFNγR (B) IL-27R were determined by RT-PCR. GAPDH mRNA 
expression from the same samples was used as an endogenous reference gene (relative mRNA 
expression). Data shown is mean ± SD of 9 independent experiments. DCs and tolDCs were either 
untreated or stimulated for indicated time points with IFNγ or IL-27. Samples were loaded on 
10% SDS gel followed by transfer to nitrocellulose membranes. Blots were probed with antibodies 
directed against either (C) total or phosphorylated STAT-1.
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DC derived fP and fH exhibit traditional functional characteristics. 
A key characteristic of serum derived fH is its ability to bind C3b, so we assessed 
whether fH found in DC supernatants can also demonstrate functional activity by 
binding C3b. Although we found minimal binding in immature DC supernatants 
the binding was enhanced in the supernatants from IFNγ stimulated DCs. This 
binding was more pronounced in supernatants of IFNγ-stimulated tolDCs 
(Fig.5A). We assessed the ability of fP derived from DCs and tolDCs to bind 
its traditional ligand C3b and found that while the amount produced by DCs 
might be too little for detection, fP derived from tolDCs showed a strong and 
dose-dependent binding to C3b (Fig.5B). To confirm the specificity of this assay 
we show that binding is inhibited upon depletion of fP using pre-coupled anti-
properdin beads (Fig.5C).Recent evidence suggests that fP possesses additional 
functions aside from C3b binding, and may act as an independent recognition 
molecule for necrotic and apoptotic cells. Necrotic cells were generated as 
previously described 30, and incubated with DC or tolDC conditioned supernatant 
followed by detection of fP binding. Using fluorescent microscopy, fP binding 
was detected on necrotic cells exposed to DC supernatant and this binding was 
Figure 4: Type I IFNs decrease fP production but do not increase fH, while IL-27 specifically 
increases fH. Dendritic cells were harvested after 6 days of culture and stimulated with IFNγ, 
IFNβ, IFNα or IL-27. After 48 hours the supernatants were harvested and (A, C) fP and (B, D) fH 
was measured by sandwich ELISA. Data shown is the mean ±SD of 8-13 independent experiments. 
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even more evident on necrotic cells exposed to tolDC supernatants (Fig.5D). This 
binding to necrotic cells was confirmed by flow cytometric analysis (Fig.5E), 
and quantification across a number of donors showed that tolDC supernatants 
demonstrated significantly higher levels of fP binding to necrotic cells compared 
to supernatant of DCs (Fig.5F). 
Inhibition of fP in DCs decreases allogenic T cell proliferation, while 
inhibition of fH enhances the allostimulatory capacity of DCs. 
In light of the recent evidence that AP components may play a role in the 
allostimulatory capacity of DCs, we investigated whether silencing of fP or fH in 
human DCs could alter T cell activation in an allogenic setting. We successfully 
and specifically silenced fP and fH in both immature and IFNγ-stimulated DCs 
Figure 5: DC derived fP and fH exhibit traditional functional characteristics. Dendritic cells 
were harvested after 6 days of culture and either untreated or stimulated with IFNγ. After 48 hours 
the supernatants were harvested and incubated on a 96-well ELISA plate coated with C3b, followed 
by detection of (A) fH and (B) fP. (C) To determine the specificity of fP binding the same C3b 
binding assay was performed with tolDCs supernatants either untreated or depleted of fP using 
pre-coupled anti-properdin beads. Data shown is representative of 3 independent experiments. 
(D) Necrotic cells were generated and incubated with 48 hour supernatants from immature DC/
tolDC, followed by detection of fP binding by fluorescent microscopy. (F) The same experiment 
was performed followed by detection of fP binding by flow cytometry and calculated by MFI DC 
supernatant / MFI Medium alone. 
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by up to 60% on average (Fig.6A,F). Cells treated with siRNA were harvested 
and co cultured with allogenic total CD4+ T cells at indicated ratios for 5 days. 
Figure 6: Inhibition of fP in DCs decreases the allostimulatory capacity of DCs while inhibition 
of fH enhances allogenic T cell proliferation. DCs were either non treated, or treated with siRNA 
targeting fP or non-specific (non) target. After 24 hours of culture, with or without IFNγ activation, 
supernatants were harvested and fP was measured by ELISA (A). DCs with either fP or control 
silencing, without (B) or with IFNγ (C) stimulation were co-cultured with allogenic CD4+ T cells 
at indicated ratios. T cell proliferation was determined at day 5 of culture by 3[H] incorporation. 
Data shown are the mean ±SD of triplicate cultures. The mean ±SD of proliferation (D) and IFNγ 
production (E) at the 1:40 ratio of 3 independent experiments of cells silenced for fP is shown. DCs 
were either non treated, or treated with siRNA targeting fH or non-specific (non) target. After 24 
hours of culture, with or without IFNγ activation, supernatants were harvested and fH was measured 
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Proliferation was determined by 3[H]-thymidine incorporation. We observed that 
silencing of fP in DCs significantly hampered their ability to induce allogenic 
T cell proliferation compared with DCs with non-targeted siRNA (Fig.6B). 
This inhibition of proliferation was even more pronounced when fP silencing 
was combined with IFNγ stimulation (Fig.6C). The silencing procedure by itself 
did not affect the T cell stimulatory capacity. The reduced proliferation upon fP 
silencing was significant for different individual experiments (Fig.6D). In these 
co-cultures, IFNγ production was relatively low, but showed a trend for reduced 
production in IFNγ-activated, fP-silenced DC (Fig.6E).  
Similar experiments were performed using DCs treated with siRNA targeting 
fH. These cells induced significantly more T cell proliferation compared to non-
target (non) treated DCs (Fig.6G). This was also observed, but to a lesser degree, 
with DCs activated with IFNγ (Fig.6H). Both immature and IFNγ-stimulated 
DCs silenced for fH exhibited more T cell proliferation, in particular at a ratio 
of 1:40 (Fig.6I). We assessed the production of IFNγ in T cell supernatants and 
found that immature DCs silenced for fH induced more IFNγ production. In line 
with our proliferation data the stimulatory effect of silencing fH was less potent 
when the DCs were first activated with IFNγ (Fig.6J). Taken together loss of fH 
induced more T cell proliferation while loss of fP decreased T cell proliferation, 
suggesting that the local complement activation is important in regulating DC: T 
cell responses.
Discussion
Dendritic cells are a heterogeneous population of professional antigen presenting 
cells responsible for both the initiation of immunity and immunological 
tolerance. Recent murine studies have suggested that complement activation 
is a key determinant in the ability of APCs to direct T cell responses. In this 
study we show that production of fP and fH by DCs is subject to regulation by 
IFNγ and IL-27 and that modulation of these regulators of the AP determines the 
potency of the T cell response. This implicates the local cellular and cytokine 
microenvironment as crucial mediators of overall complement regulation and 
subsequent T cell activation.
Several exciting studies over the last decade have introduced complement as a 
system that actively plays a role in regulating T cell immunity. By generating 
bone marrow APCs from C3-/-31,32, factor B-/-, factor D-/-, C3aR-/-33 and C5aR-/-34 
by ELISA (F). DCs with either fH or control silencing, without (G) or with IFNγ (H) stimulation 
were co-cultured with allogenic CD4+ T cells at indicated ratios. T cell proliferation was determined 
at day 5 of culture by 3[H] incorporation. Data shown are the mean ±SD of triplicate cultures. 
The mean ±SD of proliferation (I) and IFNγ production (J) at the 1:40 ratio of 3 independent 
experiments of cells silenced for fH is shown.
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mice, various groups demonstrated that DCs require local complement activation 
in order to become fully competent APCs. To date these studies have mainly 
focused on rodent models, however DCs from C3 deficient individuals35 were 
also shown to have impaired DC differentiation. More recently, a role of C3a 
and C5a derived from human DC in T cell proliferation has been demonstrated 
in vitro and in a humanised mouse model8. Further work on human DCs and 
the contribution of other complement factors has remained finite with mostly 
transcriptional analysis and limited protein data. 
We focused on monocyte-derived DCs and tolerogenic DCs and showed that both 
cells produced fP and fH in an immature state with tolDCs expressing much higher 
levels of both components. Some studies have demonstrated gene expression of 
fP and fH in plasmacytoid DCs21. Although we did not perform PCR analysis on 
pDCs, we did test cellular supernatants and did not find any detectable levels of 
both components analysed in this study (data not shown). 
Several complement components have been shown to possess GAS and ISRE 
elements in their promoters36,37, so we assessed the ability of IFNγ to regulate fP 
and fH. Interestingly, IFNγ possessed opposing roles by decreasing fP production, 
while increasing fH. Decrease of fP upon IFNγ stimulation has been observed in 
primary monocytes and THP-1 cell lines38, but to our knowledge this is the first 
report of this dual effect on fH and fP in human DCs. IFNγ is the only member of 
the type II IFNs so we questioned whether the regulation of fP and fH was unique 
for this specific member, or was a broader feature of the IFN family, including 
type I IFNs. IFNα and IFNβ behaved comparably in terms of fP and fH regulation 
and did not possess the same regulatory properties of IFNγ. 
The IL-12 family has been gaining attention as a key regulator of immunity and 
immunological tolerance39,40, and one family member, IL-27 has been shown to 
exert some functions typically seen with IFNγ stimulation28,29,41,42. Interestingly 
IL-27 stimulation of DCs did increase production of fH but did not influence fP 
production again stressing the uniqueness of IFNγ in its differential regulation of 
these two opposing molecules of the complement system. 
We observed in our study considerable variation using LPS stimulation, with 
no clear regulation of fP or fH evident across a number of donors, despite its 
ability to induce IL-12p40 and IL-10 production. This fluctuating effect of LPS 
on fP production was not observed for fH. There are some conflicting reports 
regarding the ability of LPS to regulate fP. While it has been shown that LPS can 
up-regulate fP in monocytic cells lines38, decreased transcriptional expression has 
been observed in murine BMDCs33. Conversely again upregulation of fP mRNA 
has been seen in human DCs21. This may be explained by different strains of LPS 
used in set of experiments. 
We performed western blot analysis to confirm that fP and fH possessed the 
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expected molecular structure. fP demonstrated an expected band at approx. 
55kDa under reducing conditions. While we did observe a band of approx. 
155kDa for fH in tolDC lysates no clear band was evident in DC lysates. Other 
studies demonstrating fH in DCs have focussed on DC supernatants21 and it may 
be that our detection method was not sensitive enough to detect fH in DC cell 
lysates. Notably we did observe two smaller bands of approx. 30-35kDa (data 
not shown). Further work is needed to determine if these molecules are fH like 
or related proteins and what role they might play in DC biology, although a role 
in phagocytosis has been demonstrated previously43. Functionally both fP and 
fH were active in the traditional complement assessment by binding to C3b. In 
recent years fP has been shown to act as a recognition molecule11,44,45 with the 
ability to bind to, amongst others, apoptotic46 and necrotic cells30. We found that 
fP from DCs could bind necrotic cells though we did not test whether this was 
independent of complement activation. 
We have shown that cytokines can profoundly and differentially regulate the 
opposing regulators of the AP, fP and fH. IFNγ stimulation of DCs also changes 
many phenotypical features of DCs including up regulating co-stimulatory 
molecules such as CD80 and CD86. In order to establish whether simply shifting 
the balance of production of fP and fH could alter the allostimulatory capabilities 
of DCs we silenced fP or fH in DCs and co-cultured these cells with allogenic 
CD4+ T cells. We found that inhibition of fH led to a significant increase in T 
cell proliferation while inhibition of fP led to decreased proliferation. DCs 
silenced for fP and pre-matured with IFNγ were even further hampered in their 
allostimulatory capacity, likely because of the combined silencing by siRNA 
and decreased fP production by IFNγ. Further work is needed to fully establish 
whether the diverging T cell proliferation is a direct effect of fP and fH on the T 
cells or a consequence of altered local complement activation. 
Taken together our results demonstrate a novel role for fP and fH production by 
DCs in the regulation of T cell activation. Both molecules can be influenced by 
IFNγ whereas only fH is increased by IL-27, indicating that the local cellular and 
cytokine environment can potentially influence the local complement activation 
and in turn local T cell responses.
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Abstract
Epstein-Barr virus-induced gene 3 (Ebi3) is a member of the interleukin (IL)-
12 heterodimeric cytokine family, which has important immune-regulatory 
functions. To date, little is known about the role of Ebi3 in human kidney and 
in particular its expression in renal DC populations. Considering the abundant 
expression of Ebi3 in tolDC populations, and the potent regulatory properties 
of IL-35 we investigated the expression of IL-12 family members within 
normal human kidney. We examined the expression of Ebi3 in renal tissue by 
RT-PCR and immune-histochemistry, and found abundant staining for Ebi3 in 
the glomerulus of normal human kidney. In addition we found markedly high 
levels of IL27B in isolated glomeruli compared to whole kidney. Furthermore, 
we observed expression of potential chain sharing partners for Ebi3, namely IL-
27p28 and IL-12p35 in the glomerular region of normal human kidney. Double 
staining suggested that podocytes may be the source of Ebi3 in the glomeruli, and 
further analysis with cultured renal cells demonstrated that podocytes expressed 
high levels of Ebi3 compared to glomerular endothelial cells and mesangial cells. 
Stimulation with inflammatory cytokines IFNγ and TNFα, led to a reduction 
in Ebi3 protein levels in cultured podocytes. We investigated the expression of 
Ebi3 in an in-vivo inflammatory setting, in 38 paired pre transplant and rejection 
biopsies, and found reduced transcriptional expression of Ebi3 in the rejection 
biopsies compared to the pre-transplant samples. Together this data demonstrates 
the novel expression of Ebi3 by podocytes and suggests a possible unidentified 
role for Ebi3 in immune homeostasis of the kidney.
 
Introduction
Since the identification and experimental proof that Dendritic cells (DCs) form an 
extensive lattice like network within the renal parenchyma1, 2 the kidney has come 
to light as expressing surprisingly diverse immune mediators3. Tissue resident 
DCs are thought to be immature sentinels, preserving the immune homeostasis 
of their environment. During periods of inflammation or stress they protect the 
host tissue by shaping a local immune response to avoid destructive excessive 
inflammatory responses and to promote peripheral tolerance4, 5. Aside from DCs, 
resident cells in the kidney, including tubular epithelial cells, have been shown 
to express several immune molecules including CD406, B7H1, ICOS-L7 and 
complement factor C38. Additionally renal endothelial cells have been shown to 
express high levels of MHC class II suggesting that they have the ability to serve 
as local antigen presenting cells during times of inflammation. Together these 
findings warrant further investigation into the full immunological contribution of 
renal cells.  
Many cytokines produced locally have been implicated in renal pathologies, 
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however little is known about local anti-inflammatory mediators that may regulate 
immune responses. The IL-12 family is composed of 4 cytokines, each related, 
but possessing distinct functions 9. Ebi3 can pair with IL-27p28 or IL-12p35 to 
yield IL-27 or IL-35 respectively. These cytokines represent the regulatory arm 
of the IL-12 family and both have been shown to exert potent immune-regulatory 
functions10, 11. Expression of the individual chains of the IL-12 family is largely 
restricted to professional immune cells, particularly DCs and macrophages. Ebi3 
however appears to be more broadly expressed in various tissues with its presence 
demonstrated in placental tissue12, colonic epithelial cells13, smooth muscle cells14 
and endothelial cells. Expression of some members of the IL-12 family and their 
receptors on inflammatory infiltrate have been implicated in the pathogenesis of 
renal diseases, but to date nothing is known about the expression of the IL-12 
family members by the resident cells of the kidney. Considering the abundant 
expression of Ebi3 in tolDC populations, and the potent regulatory properties of 
IL-35 we investigated their expression within normal human kidney. 
In this study we initially analysed the expression of Ebi3 and related partners, 
IL-12p35 and IL-27p28, within human kidney with a particular focus on the 
interstitial areas where renal DCs reside. Instead we found abundant expression 
of Ebi3 and IL-12p35 within the glomerular region. In-vitro experiments strongly 
suggested that podocytes were the source of this abundant Ebi3 expression, and 
that stimulation with inflammatory stimuli can down-regulate Ebi3 expression 
within this cell population. Analysis of an acute rejection patient cohort 
demonstrated that compared to the pre-transplant biopsies, Ebi3 transcripts 
were significantly down-regulated during acute rejection. Together this study 
demonstrates for the first time, the expression of Ebi3 within normal human 
kidney and the observation that Ebi3 expression is reduced during renal allograft 
rejection. These data suggest a possible role for Ebi3 and Ebi3-related cytokines 
in allograft rejection that requires further investigation.
Materials and Methods
Cell Culture
Conditionally immortalised podocytes (a kind gift of prof P Mathieson)16 were grown in DMEM medium 
supplemented 100 U/ml penicillin, 100 μg/ml streptomycin (Invitrogen, Breda, The Netherlands), insulin (5 μg/
ml), transferrin (5 μg/ml), selenium (5 ng/ml) (all Sigma, Zwijndrecht, The Netherlands) and 10% foetal calf 
serum (FCS). Conditionally immortalised glomerular endothelial cells (GEnC) (a kind gift of prof P Mathieson)17 
were cultured in endothelial growth medium 2 (EGM2 Bulletkit, Lonza) containing 10% FCS and growth 
factors as supplied. For podocytes and GEnCs, cells were grown at the permissive temperature of 33°C until 
confluent at which point they were trypsinised and reseeded in fresh flasks at a dilution of between 1:3 and 1:5. 
The cells were grown to 70 to 80% confluence before thermo switching to 37°C to inactivate the SV40 T antigen 
and facilitate differentiation. At both temperatures, cells were refreshed with medium 3-4 times per week. Adult 
mesangial cells (AMC)18 were cultured in DMEM supplemented with 5% FCS at 37°C. Immortalised human 
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renal PTEC (HK-2)19 were grown in serum-free DMEM-F12 (Bio-Whittaker, Walkersville, MD) supplemented 
with 100 U/ml penicillin, 100 μg/ml streptomycin, insulin (5 μg/ml), transferrin (5 μg/ml), selenium (5 ng/ml), 
triiodothyronine (40 ng/ml), epidermal growth factor (10 ng/ml), and hydrocortisone (36 ng/ml, all purchased 
from Sigma, Zwijndrecht, The Netherlands). Immortalised human renal fibroblasts (TK173)20 , characterised by 
the expression of CD73 and PDGRFβ, were cultured in RPMI 1640 with 10% FCS. Human monocytes were 
isolated from buffy coats obtained from healthy donors using Ficoll density gradient centrifugation followed 
by positive selection using anti-CD14 MACS microbeads (Miltenyi Biotech GmBH, Bergisch Gladbach, 
Germany). DCs were generated and cultured in RPMI supplemented with 10% heat inactivated FCS, 90 U/ml 
penicillin and 90 U/ml streptomycin (Gibco/ Life Technologies, Bleiswijk, The Netherlands), supplemented 
with 5 ng/ml GM-CSF and 10 ng/ml IL-4 (Invitrogen/ Life Technologies, Bleiswijk, The Netherlands) as 
described before 21.
mRNA isolation, cDNA synthesis and RT-PCR
Cells were plated at a density of 0.5x106/ml in 6 well plates and stimulated with IFNγ(100ng/ml) (Peprotech, 
Germany) or TNF-a (20ng/ml) (R&D systems) for indicated time points.  Cells were washed after indicated time 
points and mRNA was isolated using an RNeasy kit (Qiagen, Hilden, Germany) following the manufacturer’s 
instructions. Digestion of genomic DNA was performed by using the on-column RNA-free DNase set. Reverse 
transcriptase system kit (Promega, Leiden, The Netherlands) was used to synthesise cDNA according to the 
manufacture’s instruction and was stored at -20ºC for further analysis. cDNA was amplified by RT-PCR 
using primers for IL12A, IL12B, IL23A, IL27A and IL27B (Table I). SYBR Green qPCR master mix (Bio-
Rad, Veenendaal, The Netherlands). GAPDH was used as the endogenous reference gene. Data analysis was 
performed using Bio-Rad CFX Manager Software (Bio-Rad). For each sample, the relative abundance of target 
mRNA was calculated from the obtained Ct values for the target gene and expressed relative to the endogenous 
reference gene GAPDH. 
Table I: Real Time PCR Oligonucleotide sequences
Western Blotting
Cells were plated at 0.5×106 per well in a 6 well plate and stimulated as indicated for 16 hours. Cells were 
harvested, washed in ice-cold phosphate-buffered saline and lysed in medium stringency lysis buffer for 30 
minutes. The lysates were centrifuged at 13,000 rpm, the supernatants harvested, and protein concentration 
was determined by a Pierce assay. The samples were diluted in 1x SDS loading buffer, boiled for 5 minutes in 
reducing conditions, followed by separation on 10% SDS-PAGE gel. Gels were transferred to nitrocellulose 
membranes, blocked with TBS plus 0.1% Tween-20 (TBS-T) and 3% milk and probed with purified anti-Ebi3 
(Abnova, Huissen the Netherlands). After incubation with HRP-conjugated secondary antibody, proteins were 
detected with super signal ECL system. Blots were stripped and β-actin was used as a loading control using HRP 
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conjugated anti-β actin (Abcam, Cambridge, UK).
Microscopy
For Light-microscopy paraffin-embedded tissue sections were deparaffinised and rehydrated followed by heat 
antigen retrieval using proteinase K. Slides were then washed in PBS and endogenous peroxidases were directly 
blocked with 0,4% H2O2 followed by 1% BSA/ 1% NHS in PBS for 30 minutes at RT. Slides were incubated 
with primary antibodies in 1 % BSA/ 1% NHS in PBS for 1 hour, using mouse anti-human Ebi3 (Abnova) 
or mouse anti-human Ebi3 (DV.25). Both antibodies were detected using the mouse EnVision+ System-HRP 
(DAKO, Glostrup, Denmark) for 30 minutes. Slides were counter stained using Mayer’s hemalum solution. 
Cover slips were mounted with Entellan (Merck, Darmstadt, Germany).
For Immunofluorescence staining frozen 4 µm Tissue sections were fixed in cold acetone and endogenous 
peroxidases were blocked with 0,4% H2O2 for 30 minutes at room temperature (RT). Subsequently slides 
were washed and blocked with non-specific serum (1% heat-inactivated normal human serum (NHS)/ 1% 
bovine serum albumin (BSA) in PBS) for 30 minutes at RT. Slides were then incubated with indicated primary 
antibodies in 1% NHS/ 1% BSA in PBS overnight at RT, washed and incubated on the next day with secondary 
Alexa568  for 1 hour at RT. Nuclei were counterstained with Hoechst. Non-conjugated mouse isotype antibodies 
were used to determine the level of non-specific background staining. Sections were mounted with DABCO 
glycerol (Sigma, Uithoorn, The Netherlands).
Statistical analysis
Statistical analysis was performed with GraphPad Prism (GraphPad Software, San Diego, CA) using a one-
tailed or two-tailed t-test as described. P-values ≤ 0.05 were considered statistically significant.
Results
Ebi3 is highly expressed in the glomeruli and distal tubules of normal human 
kidney.
Considering the potent immuno-modulatory functions of Ebi3 related cytokines 
we assessed the expression of the Ebi3 in normal human kidney. We performed 
immunohistochemical staining in both frozen and paraffin sections of the cortex 
of normal human kidney and observed an abundant expression of Ebi3 staining 
in the glomeruli and Bowman’s capsule. We found little expression of Ebi3 
present within the interstitial spaces, however we did observe a strong Ebi3 
staining within a proportion of tubuli (Fig.1A). We confirmed this staining using 
two different antibodies, and found a comparable pattern of expression between 
both antibodies (Fig.1A). Staining for Ebi3 on frozen tissue demonstrated similar 
staining to that observed in paraffin tissue, with a strong Ebi3 signature observed 
in the glomerular region (Fig.1B).  Incubation of sections with isotype-matched 
control antibodies showed no reactivity, thus confirming the specificity of the 
detected signals. mRNA was isolated from the glomeruli of normal kidney or 
whole kidney (paired samples) and analysed for the expression of IL27B. Although 
IL27B was expressed in whole kidney, in line with the immunohistochemistry 
findings, the glomerular mRNA fraction showed significantly higher levels of 
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IL27B expression (Fig.1B). These data suggest that Ebi3 is produced in normal 
human kidney and may exist as a homodimer, or as a heterodimer to form IL-27 
or IL-35.
 
IL-12p35 and IL-27p28, potential pairing partners for Ebi3, are both 
expressed in normal human kidney. 
Considering the abundant expression of Ebi3, particularly within the glomerular 
regions of NHK (Fig.1), we sought to investigate if the potential pairing partners 
for Ebi3 were also present. We observed by IHC that in addition to Ebi3, normal 
human kidney expressed high levels of IL-12p35 and to a lesser degree, IL-27p28 
(Fig.2A). Notably IL-12p35 expression demonstrated a comparable staining 
to Ebi3 within the glomerular region, but expression in tubuli appeared to be 
in a distinct population than that of the Ebi3 staining in distal tubuli (Fig.2A). 
Figure 1: Ebi3 is highly expressed in the glomeruli and distal tubules of normal human 
kidney. Sections of normal human kidney were stained for Ebi3 in (A) Paraffin embedded tissue. 
(B) Immunofluorescent staining was performed on cryosections (4µm) of normal human kidneys 
for Ebi3 (green). Nuclei were stained with Hoechst (blue). Non-conjugated mouse and rabbit 
isotype antibodies were used to determine the level of non-specific background staining. Pictures 
are representative for at least five different donors. (C) mRNA was isolated from glomeruli or 
whole kidney from different donors followed by cDNA synthesis. The transcript levels of IL27B 
were determined by RT-PCR. GAPDH mRNA expression from the same samples was used as an 
endogenous reference gene (relative mRNA expression). Data shown is mean ± SD (* p≤0.05). 
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We performed double staining for Ebi3 (red) and IL-27p28 (green) on frozen 
tissue and found little or no overlap between Ebi3 staining and IL-27p28 within 
glomeruli (Fig.2B). In contrast when we performed the same staining for Ebi3 
(red) and IL-12p35 (green) we observed large areas of overlapping staining 
within the glomeruli (Fig.2B). Notably we did not see any double staining in 
the tubular interstitial areas (not shown). To determine the cell type expressing 
Ebi3 within the glomerular region, we performed double staining for Ebi3 (red) 
with the C type lectin receptor and podocyte marker, DEC-205 (green), or Ebi3 
(red) with a marker for endothelial cells (CD31). We found that staining for both 
Ebi3 and DEC-205 were often found in close contact within glomeruli suggesting 
that podocytes are most likely the source of Ebi3 within glomeruli (Fig.2C). In 
contrast it was evident that Ebi3 and CD31 staining had no overlapping regions 
within the glomeruli or interstitial areas. The only evidence of Ebi3 and CD31 co-
staining was within small capillaries or the inner layer of large vessels, which is in 
line with previous studies demonstrating Ebi3 expression in vascular endothelial 
cells (Fig.2C).
Figure 2: IL-12p35 and IL-27p28, potential pairing partners for Ebi3, are both expressed 
in normal human kidney. Paraffin and frozen sections of normal human kidney were stained for 
(A) Ebi3, IL-12p35 or IL-27p28. (B) Immunofluorescent staining was performed on cryosections 
(4µm) of normal human kidney for Ebi3 (red) and IL-27p28 (green) or Ebi3 (red) and IL-12p35 
(green). (C) Immunofluorescent staining was performed on cryosections (4µm) of normal human 
kidney for Ebi3 (red) and DEC-205 (green) or Ebi3 (red) and CD31 (green). Nuclei were stained 
with Hoechst (blue). Non-conjugated mouse and rabbit isotype antibodies were used to determine 
the level of non-specific background staining. Pictures are representative for at least five different 
donors. 
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Analysis of IL-12 family expression in cultured glomerular and interstitial 
cells.
Given the abundant expression of Ebi3 and IL-12p35 in normal kidney, and the 
co-staining of Ebi3 with the podocytic marker DEC-205, we sought to further 
confirm the source of Ebi3 in the kidney by assessing the mRNA transcripts 
of IL-12 family members in cultured renal cell lines. We cultured glomerular 
endothelial cells, podocytes and mesangial cells in addition to fibroblasts and 
tubular epithelial cells. In addition we assessed transcript levels in immature DCs 
as a representative of professional APCs. We found that transcripts of IL12A, 
IL27B and IL23A demonstrated the most abundant levels in renal cell cultures 
with up to 100 fold higher levels of expression compared to IL27A and IL12B 
(Fig 3A). While IL27B transcripts were detected in all cell populations we 
observed between 10 and 100 fold higher expression in tubular epithelial cells 
and podocytes respectively (Fig.3A), which is in line with our IHC observations 
in (Fig.2).  In contrast, expression of IL12A was only modestly elevated in 
cultured podocytes and did not demonstrate the clear expression profile observed 
with IL27B. Notably, expression of IL12A, IL23A and IL27B in podocytes was 
Figure 3: Analysis of IL-12 family member expression in cultured glomerular and interstitial 
cells. Conditionally immortalised GEnCs, podocytes, mesangial cells, fibroblasts, tubular epithelial 
cells and immature monocyte dervied DCs were assessed for transcriptional expression of IL27B. 
GEnCs and podocytes were grown at the permissive temperature of 33°C until confluent at 
which point they were trypsinised and reseeded in 6 well plates at 0.5×106 cells per well before 
thermoswitching to 37°C for 5 days. All other cell lines were plated in 6 wells plated and together 
mRNA from the five cell lines and imDCs was isolated followed by cDNA synthesis. The transcript 
levels of (A) IL12A, IL12B, IL23A, IL27A and IL27B was determined by RT-PCR. GAPDH mRNA 
expression from the same samples was used as an endogenous reference gene (relative mRNA 
expression). Data shown is mean ± SD of 2 independent experiments. 
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relatively comparable with the levels observed in immature DCs, indicating that 
podocytes may be an important novel source of local IL-12 family members with 
the kidney.
Podocytes express abundant levels of Ebi3 which is down-regulated upon 
stimulation with inflammatory cytokines.
It was previously demonstrated that IFNγ + TNFα stimulation led to a synergistic 
up-regulation of Ebi3 in aortic smooth muscles so we adopted a similar approach 
by stimulating cells with IFNγ, TNFα or the two combined, for 24 hours (Fig.3A), 
and found that the stimuli used, exerted differential affects depending on the 
cell in question. IFNγ alone did not alter the expression of IL27B by glomerular 
endothelial cells whereas TNFα alone or combined with IFNγ led to up-regulation 
of IL27B (Fig.4A). Podocytes demonstrated transcript levels of IL27B in line 
with that found in immature DCs.  Podocytes did not demonstrate significant 
alterations upon stimulation but it did appear that IFNγ down-regulated IL27B 
expression in these cells (Fig.4A). This is contrary to IL12A expression whereby 
Figure 4: Podocytes express abundant levels of Ebi3, which is down-regulated upon stimulation 
with inflammatory cytokines. Conditionally immortalised GEnCs, podocytes, mesangial cells, 
fibroblasts and tubular epithelial cells were assessed for expression of IL27B upon stimulation. 
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IFNγ stimulation led to upregulation of expression in all cells except fibroblasts 
(data not shown). Mesangial cells expressed very low transcripts of IL27B, and 
no clear regulation was observed. Similar to podocytes, IFNγ down-regulated 
IL27B expression in fibroblasts, while no clear regulation was observed in 
tubular epithelial cells (Fig.4A). To determine whether our findings regarding 
transcriptional expression of IL27B corresponded to protein levels, we focussed 
our studies on the glomerular cells, which demonstrated the most abundant 
staining in-vivo (Fig.1). We investigated the expression of Ebi3 by western 
blot upon stimulation with IFNγ, TNFα or a combination of the two (Fig.4B). 
We found in the unstimulated conditions that, in line with our RT-PCR data, 
podocytes expressed higher levels of Ebi3 compared to glomerular endothelial 
cells or mesangial cells. Notably, while both mesangial cells and endothelial 
cells maintained Ebi3 expression upon stimulation, podocytes demonstrated 
a reduction.  All together these data suggests that podocytes may be the main 
source of glomerular Ebi3 expression within normal human kidney.
Expression of IL27B is significantly down regulated during acute renal 
allograft rejection.
In view of the abundant expression of Ebi3 expression in normal human kidney 
and isolated glomeruli (Fig.1), and the modest regulation upon stimulation in 
immortalised cultured podocytes (Fig.4), we investigated the expression of 
Ebi3 during an in vivo inflammatory setting namely, renal allograft rejection. 
From a limited number of available normal human kidney and acute rejection 
samples we observed that compared to healthy tissue, Ebi3 in the rejection 
biopsies appeared reduced within the glomerular region (Fig.5A). This was 
observed across a number of donors. In the normal tissue in (Fig.1) we noted that 
a proportion of the tubuli also expressed high levels of Ebi3. Additionally Ebi3 
GEnCs and podocytes  were grown at the permissive temperature of 33°C until confluent at which 
point they were trypsinised and reseeded in 6 well plates before thermoswitching to 37°C for 5 
days. All cells were plated at 0.5×106 per well in a 6 well plate and stimulated for 24hrs with IFNγ, 
TNFα or a combination of both. Additionally imDCs were generated and either unstimulated or 
stimulated with IFNγ. The transcript levels of (A) IL27B was determined in all cell lines and DCs by 
RT-PCR. GAPDH mRNA expression from the same samples was used as an endogenous reference 
gene (relative mRNA expression). Data shown is mean ± SD of 2 independent experiments. (B) 
Conditionally immortalised GEnCs, podocytes and mesangial cells were assessed for expression 
of Ebi3 by western blot. Cells were cultured as described for (A). Cells were harvested, washed 
in ice-cold phosphate-buffered saline and lysed for 30 minutes. The samples were seperated under 
reducing conditions on 10% SDS-PAGE gel. (B) Gels were transferred to nitrocellulose membranes, 
blocked with TBS plus 0.1% Tween-20 (TBS-T) and 3% milk and probed with purified anti-Ebi3. 
Blots were stripped and β-actin was used as a loading control using HRP conjugated anti-β actin. 
Data shown is representative of 2 independent experiments. 
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has been shown to be expressed by macrophages, DCs and T cells therefore we 
carefully examined the interstitium and areas of infiltrate for Ebi3 expression. 
Despite areas of dense infiltrate in rejection biopsies no staining for Ebi3 was 
evident in these areas (Fig.5A). We further evaluated by RT-PCR the expression 
of IL27B in renal biopsies from 38 patients with a first acute rejection episode. 
For comparison, the available pre-transplant biopsies (n=38) of these patients 
were used.  Overall, the most striking observation was the wide heterogeneous 
expression of IL27B in pre-transplant biopsies compared to the paired rejection 
biopsies. In light of the abundant expression of Ebi3 within glomeruli, one should 
consider that we cannot correct for the number of glomeruli in each sample which 
may lead to the variability in the pre-tx population.  Despite this wide spread 
in the normal pre-transplant samples, IL27B expression was significantly down-
regulated in the rejection biopsies (Fig.5B). Out of the 38 patients analysed, 26 
Figure 5: Expression of IL27B is down regulated during acute renal allograft rejection. 
Sections from normal human kidney and acute rejection kidney were stained for (A) Ebi3 in paraffin 
embedded tissue. Non-conjugated mouse and rabbit isotype antibodies were used to determine the 
level of non-specific background staining (not shown). (B) mRNA was isolated from paired pre-
transplant and acute rejection tissue from 38 patients followed by cDNA synthesis. The transcript 
levels of IL27B were determined by RT-PCR. GAPDH mRNA expression from the same samples 
was used as an endogenous reference gene (relative mRNA expression). Data shown is the median 
level of expression (* p≤0.05).
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demonstrated significant decreases in IL27B expression while 12 showed the 
converse, with increased IL27B expression compared to the paired pre-transplant 
biopsy (Fig.5B). 
Discussion
This study describes the first evidence for expression of Ebi3 in human kidney 
suggesting a role for Ebi3 and related cytokines in the immune-homeostasis of 
the kidney. 
The Epstein-Barr virus-induced gene 3 (Ebi3) is a member of the IL-12 family 
of cytokines which together are becoming increasingly acknowledged as playing 
a key decisive role in the maintenance of immunity versus tolerance21, 22. The 
Ebi3 gene was first identified in EBV infected B cells and was found to encode a 
soluble protein, IL-27β, with structural similarities to IL-12p4023. Both IL-12p40 
and Ebi3 represent the beta chain subunits of the IL-12 family, and both subunits 
can pair with two alpha chain subunits within the family. Ebi3 has been shown 
to form heterodimers with IL-27p28 to yield IL-27, or most recently IL-12p35 
to yield IL-35. Both cytokines possess unique immune-modulatory functions, 
although IL-27 appears to possess dual roles with an ability to also promote 
Th1 and anti-tumour CTL responses24-26. However, a large body of literature has 
also described the potent regulatory features of IL-27, which amongst others are 
to promote induction of IL-10 producing Tr1 cells from activated Th1 cells27, 
28, down-regulate Th17 responses29, 30 and to induce a regulatory phenotype in 
APCs31, 32. IL-35 has been shown to possess profound regulatory abilities and is 
produced by regulatory T cells in mouse and man and appears to be an important 
inducible anti-inflammatory cytokine with a significant role in inhibiting Th17 
responses11, 33, 34. 
Expression of Ebi3 has been mostly described in haematopoietic cells23, 35-37 
including DCs and we initially sought to investigate the expression of Ebi3 within 
renal DC populations. However several studies have accumulated data describing 
expression of this protein in extra-haematopoietic sources including placental 
synctiotrophoblasts12, endothelial cells, intestinal mucosa13, 38 and aortic smooth 
muscle cells14. This expression of Ebi3, often in the absence of its typical pairing 
subunits has fuelled speculation that Ebi3 may possess biological functions in its 
own right or may dimerise with as yet unidentified partners.  
Despite the extensive DC network that resides within the renal interstitium we 
did not detect any significant staining that would be indicative of the local DC 
network. In contrast to TGF-β which has been described as a house keeping 
anti-inflammatory cytokine39, IL-35 and IL-27, like IL-10, are most likely not 
constitutively produced, but rather are inducible upon a particular stimulus. This 
may be why we did not observe any expression of Ebi3 in the area of resident 
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DCs. Additionally the cytokine profile of renal DCs is largely unknown, so it is 
difficult to determine whether these cells would actually be a source of IL-27/IL-
35 in vivo. Despite the absence of staining in the interstitial area, we did observe 
an abundant expression of Ebi3 protein in the glomerulus and Bowman’s capsule, 
and in a proportion of tubuli. We assessed the mRNA isolated from glomeruli 
from whole kidney of different donors and found a high level of IL27B expression 
within the glomeruli, which was in line with the immunohistochemical staining. 
Tubular epithelial cells however, are known for their impressive endocytic 
capacities, so it is difficult to say whether Ebi3 is actively produced by tubular 
epithelial cells or is endocytosed from the lumen. Further in-situ hybridisation 
experiments would be necessary to address this specific question. We performed 
double staining to investigate whether other IL-12 members were also expressed 
within human kidney and found relatively abundant expression of IL-12p35 and 
to a lesser degree IL-27p28. In contrast, staining for IL-23p19 was not observed 
(not shown). Both IL-27p28 and IL-12p35 are known partners for Ebi3 but 
only IL-12p35 demonstrated an overlapping staining profile with Ebi3 in the 
glomerular region of human kidney. Investigation into the expression of IL-35 in 
human kidney has been completely unexplored and further confocal imaging and 
in-situ hybridisation would be useful in fully confirming the expression of this 
regulatory cytokine. This would open up further lines of research to understand 
the role this cytokine may play in renal immune homeostasis and its expression 
during renal pathology. We also performed double staining of Ebi3 with podocytic 
and endothelial markers. While we did not observe co-staining with CD31, 
Ebi3 did appear to stain in regions where podocytes were present. To expand 
on the findings observed in renal tissue, we cultured cells that are found within 
the glomerulus and interstitium to investigation the production and regulation 
of Ebi3 within renal cells. Interestingly podocytes showed the most abundant 
mRNA and protein expression of Ebi3 indicating that these cells are likely to 
be the source of Ebi3 staining within the glomeruli of human kidney. Podocytes 
are highly specialised cells which support the glomerular capillaries and regulate 
glomerular permeability. Considering podocytes are in close contact with the 
circulation it is likely that these cells encounter antigen from foreign or noxious 
sources. More recently studies have shown that podocytes can acquire functions 
typically attributed to macrophages and Dendritic cells, including expression of 
CD80 upon LPS stimulation40, up-regulation and activation of TLR4 leading to 
the local release of chemokines41 and even presentation of exogenous antigen in 
the context of MHC class II42. Additionally studies have shown that podocytes 
are proficient cells at clearing Ig complexes from the glomerular basement 
membrane43 and have the ability to ingest and process antigen for presentation42, 
together indicating that podocytes are important immunologically active cells 
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within the kidney. These exciting new revelations warrant further immunological 
investigation into these novel antigen presenting cells.
Notably the expression of IL27B was lower in cultured podocytes compared 
to isolated glomeruli. Despite the presence of “contaminating” endothelial 
and mesangial cells in the glomerular isolate, it strongly suggests that primary 
podocytes may express even higher levels of IL27B than we observed with 
immortalised cells. We had also observed staining for Ebi3 in the bowman’s 
capsule of the glomeruli, where parietal epithelial cells (PECs) reside. It is thought 
that considering podocytes do not have the ability to self renew, that PECs may 
migrate and differentiate into podocytes in vivo44, so it is intriguing to observe 
the expression of Ebi3 within both cell populations. Upon stimulation with 
inflammatory cytokines, we found that the podocytes in culture demonstrated 
a reduction in Ebi3 expression. This in contrast to findings using epithelial and 
endothelial cell lines from other sources, where it was found that IFNγ, IL-1 and 
TNFα could significantly enhance Ebi3 expression13, 14.  It would be informative 
to investigate the regulation of Ebi3 in primary podocytes to determine if a 
similar observation occurs. Nevertheless, in light of the abundant expression of 
Ebi3 in both human kidney and cultured podocytes, we sought to investigate the 
expression of Ebi3 in an inflammatory renal state. Considering the most important 
threat to the loss of a functioning renal allograft is rejection we analysed the 
changes in Ebi3 expression in paired pre transplant and rejection biopsies from 
38 patients. We first observed by immunohistochemical staining that glomerular 
Ebi3 expression appeared to be decreased during rejection. Interestingly, staining 
for the podocytes marker DEC-205 was also reduced in the glomeruar region 
of rejection biopsies45 (data not shown), which further supports the hypothesis 
that podocytes are the source for Ebi3 within the kidney. This was confirmed by 
RT-PCR and overall we found that Ebi3 expression was significantly reduced in 
almost 70% of the patients. In summary this study demonstrates the production of 
the novel IL-12 family member, Ebi3, in human kidney. We provide evidence that 
podocytes are the likely source of Ebi3 and that inflammatory mediators reduce 
expression. In addition we describe a reduction of IL27B expression in renal 
allograft rejection samples compared to the pre-transplant specimen. Together 
these findings warrant further investigation to fully understand the role of Ebi3 
in the immune homeostasis of the kidney and the functional significance of its 
reduction during rejection.
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Abstract
Fibroblasts reside within the renal interstitium in close proximity to neighbouring 
Dendritic cells (DCs). It is likely that these cells play a central role in the 
maintenance and function of resident and infiltrating renal DCs, though studies 
to confirm this have been lacking. We investigated whether renal fibroblasts 
influence human DC generation and function. We found that co-culture with 
renal fibroblasts led to the generation of monocyte derived dendritic cells (Fibro-
DCs) with significantly reduced CD80, CD83 and CD86, but elevated B7H1 and 
B7DC expression. In addition these Fibro-DCs displayed a reduced capacity 
to produce IL-12p40 and IL-12p70 but maintained normal levels of IL-23 and 
IL-27. Furthermore IL-10 production was elevated, which together resulted in 
a regulatory DC population with a profoundly reduced capacity to stimulate 
allogenic T cell proliferation and IFNγ production, while preserving IL-17A. 
Supernatant transfer experiments suggested that a soluble mediator from the 
fibroblasts was sufficient to inhibit the immunogenic capability of DCs. Further 
experiments demonstrated that IL-6 was at least partially responsible for the 
modulating effect of renal fibroblasts on DC generation and subsequent function. 
In summary, renal fibroblasts may play a crucial decisive role in regulating local 
DC immune responses in vivo. Better understanding into this cell population and 




Dendritic cells (DC) represent a heterogeneous family of professional antigen 
presenting cells (APCs) that have many functions in both the initiation and 
maintenance of immunity and immunological tolerance1. Renal dendritic cells 
(rDCs) are a major constituent of the mononuclear phagocytic system within 
normal kidneys2-4 , but the generation and function of the rDC network is not yet 
fully understood5,6.
Tissue resident DCs are thought to be immature resting sentinels, preserving the 
immune homeostasis of their environment. During inflammation they defend the 
host tissue by shaping a local immune response to avoid destructive excessive 
inflammatory responses and to in turn promote peripheral tolerance7,8. Some 
of the strongest evidence in supporting the hypothesis that individual tissues 
have the ability to educate their own APCs9 , are several studies focusing on 
stromal or mesenchymal stem cells10-12. DC differentiation in the presence of 
tissue-dependent microenvironment leads to a more regulatory cell population 
with lower expression of co-stimulatory molecules and poor induction of T cell 
proliferation. This process is described for several organs8,13 including the bone 
marrow niche, spleen, lung14, thymus and intestine15. More recently the presence 
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of kidney derived MSC like cells has been identified in mouse16 although their 
exact location in vivo has yet to be fully discerned. It has been suggested that 
renal fibroblasts may be a stromal lineage of kidney MSCs, thereby warranting 
further investigation into their immunological contribution.  
Renal fibroblasts have been shown to be in close proximity to rDCs in mouse 
kidneys17. Due to their prime location it is conceivable that interstitial renal 
fibroblasts are key in orchestrating a fully integrated immune response and may 
play a crucial role in educating local and infiltrating DCs. The immunomodulatory 
properties of human fibroblasts are still unclear however gingival fibroblasts have 
been shown to suppress proliferation of T cells18, and inhibit monocyte derived 
DC generation19. Additionally fibroblasts have been demonstrated to play a direct 
role in guiding the development of regulatory DCs in spleen20, while dermal 
fibroblasts have been shown to switch monocyte differentiation to macrophages 
rather than DCs11. Several factors have been implicated in the modulatory effect 
of stromal and fibroblasts on DCs including VEGF19, IL-611, PGE221 and C322 
however full investigation into the phenotype and function of these subsequent 
regulatory DCs has been limited.
Cytokines are key mediators involved in directing and maintaining a specific 
immune response as well as controlling inflammatory responses. One cytokine 
family which is gaining increasing attention, with the ability to modulate T cell 
activity in both a pro and anti-inflammatory way, is the IL-12 family23. The 
members, including IL-12, IL-23, IL-27 and IL-35, are heterodimeric cytokines, 
composed of an alpha and beta chain, which they share among each other. The 
subunit IL-12p40 can pair with IL-12p35 or IL-23p19 to form IL-12 or IL-23 
respectively and Ebi3 can match with either IL-27p28 or IL-12p35 to form IL-
27 or IL-35 respectively. IL-12 and IL-23 are mainly immunogenic cytokines, 
whereas IL-27 and IL-35 are more regulatory. 
In this study we demonstrated that renal fibroblasts, partially via IL-6 secretion, 
led to the generation of a DC with decreased expression of immunogenic 
markers, reduced allostimulatory capabilities, and a distinct cytokine profile, with 
decreased levels of IL-12 but not IL-23, IL-27 or IL-10. Further investigation 
into the mechanisms involved may be important in fully understanding immune 
mediated renal diseases.
Material and Methods
Cell Culture and Reagents
DCs were generated as previously described24. On day 6, DCs were stimulated with 100ng/ml recombinant 
human IFN-γ (Peprotech, Germany) and 200ng/ml LPS (E.Coli EH100 Enzo, Belgium), CD40L or a 
combination of LPS+CD40L. CD40L activation was performed with irradiated (70Gy) CD40L-transfected L 
cells at an L cell: DC ratio of 1:5. Non-transfected L cells served as a control. DCs were plated at 1.0x106/well 
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for 24 or 48hrs. Afterwards cells and supernatants were analysed as described.
Fibro-DC generation
The established human renal fibroblast cell line TK173, which has many characteristics in common with 
primary renal fibroblasts25,26, characterised by the expression of CD73 and PDGRFβ, was cultured in RPMI 
1640 with 10% FCS. The cells were harvested, irradiated (70Gy) and allowed to adhere overnight. The cultures 
were then washed to ensure only viable adherent cells remained, prior to co-culture with monocytes at a ratio 
of 1:7.5 at day 0. Day 6 DCs, co-cultured with fibroblasts, were carefully flushed from adherent fibroblasts and 
used similarly to Ctrl-DCs.
Flow Cytometry 
Cells were harvested, washed in buffer (1% BSA, 0.5% heat-inactivated NHS and 0.02% NaN3 in PBS) and 
stained for 30 minutes at 4ºC. Antibodies included DC-SIGN (R&D Systems, UK), Mannose-Receptor (clone 
D547), CD80, B7H1, B7DC (BioLegend, the Netherlands), CD14, CD86, CD1a-FITC, CD83-APC and HLA-
DR-APC (BD biosciences, the Netherlands). Non-conjugated antibodies were visualised by PE-conjugated 
GaM-IgG1 (DAKO, Belgium). Cells were assessed for fluorescence intensity by flow cytometry (FACS 
caliber). Data was analysed by FlowJo Software (Treestar, USA).
mRNA isolation, cDNA synthesis and RT-PCR
DCs were harvested after 6hrs stimulation and mRNA was isolated using an RNeasy kit (Qiagen, Germany). 
Reverse transcriptase system kit (Promega, The Netherlands) was used to synthesise cDNA according to the 
manufacture’s instruction. cDNA was amplified by RT-PCR using primers for the following genes: IL12B, 
IL12A, IL23A, IL27B, IL27A and IL10 (Table I) and SYBR Green qPCR master mix (Bio-Rad, the Netherlands). 
GAPDH was used as the endogenous reference gene. Data analysis was performed using Bio-Rad CFX Manager 
Software. 
Table I: Real Time PCR Oligonucleotide sequences
Cytokine production
Cell culture supernatants were harvested and stored until analysis. Levels of IL-12p40, IL-12p70 (BioLegend), 
IL-23, IL-27, IL-6 (eBioscience, Austria) and IL-10 (Sanquin, the Netherlands) were determined by ELISA 
according to the manufacturer’s instructions. Supernatant of the DC:T cell co-culture was tested for the presence 
of IFNγ and IL-17A (eBioscience).
DC:T cell co culture
Allogeneic CD4+ T cells were isolated from buffy coats by negative selection using the MACS CD4+ T Cell 
Isolation Kit II (Miltenyi Biotec). DCs from all conditions were harvested after 24hrs, washed, and plated in 
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96-well round bottom plates at a starting ratio of at 1:20 with 0.1x106 T cells. Cells were cultured for 5 days 
and supernatant was harvested to measure IFNγ and IL-17A production by means of ELISA. Proliferation was 
assessed by the addition of  3[H]-thymidine (0,5 uCi/well) for the last 18hrs. 
Microscopy
For light-microscopy, paraffin-embedded tissue sections were deparaffinised and rehydrated followed by heat-
antigen retrieval using TRIS-EDTA-buffer. Slides were then washed in PBS and endogenous peroxidases 
were blocked with 0,4% H2O2 followed by 1% BSA/1% NHS in PBS for 30 minutes. Slides were incubated 
with primary antibodies in 1% BSA/1% NHS in PBS for 30 minutes, using mouse anti human MR (R&D) 
or rabbit anti human PDGF-Receptor β (Abcam, UK), followed by detection using the respective mouse/
rabbit EnVision+ System-HRP (DAKO) for 30 minutes. Slides were counter-stained using Mayer’s hemalum 
solution. Cover slips were mounted with Entellan (Merck, Germany).
For immunofluorescence staining, frozen 4 µm sections were fixed in cold acetone and blocked as described for 
paraffin sections. Slides were then incubated with anti-MR (D547 IgG1) and anti-PDGFRβ, overnight at RT, 
and incubated on the next day with GaM-IgG1-Alexa568 (Molecular Probes, Europe BV, the Netherlands) and 
GaR-HRP (DAKO) for 1hr at RT. HRP conjugated antibodies were visualized by incubation with Tyramide-
fluorescein isothiocyanate in tyramide buffer (NEN™ Life Science Products, Boston, USA). Nuclei were 
counterstained with Hoechst. Sections were mounted with DABCO glycerol.
Statistical analysis
Statistical analysis was performed with Graph Pad Prism (Graph Pad, CA) using a one-tailed t-test. P-values ≤ 
0.05 were considered statistically significant.
Results
Renal DCs and fibroblasts are in close proximity to one another in the renal 
interstitial network.
We have previously demonstrated that myeloid DCs form an extensive network 
throughout the renal interstitium in human kidneys3. We assessed the expression 
of the Mannose Receptor (MR) as a marker of resident rDCs and observed an 
abundant expression of MR staining in the cortical interstitial region of normal 
human kidney. In contrast to murine kidney27, we found little expression of MR 
present within glomeruli (Fig.1A). Fibroblasts, visualised by the expression of 
PDGFRβ, were also largely abundant in the interstitial network surrounding 
the tubuli. Distinct from MR staining, PDGFRβ was also highly expressed in 
glomeruli (Fig.1B). When performing double staining, we observed no double 
positive cells but did observe, in the tubulointerstitial area, that fibroblasts and 
rDCs appeared to be in close contact, implying that fibroblasts might locally 
affect the function of rDCs (Fig.1C).
Fibro-DCs have enhanced expression of the immunoregulatory markers 
B7H1 and B7DC compared to DCs.
To investigate the effect of renal fibroblasts on DC development and function we 
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generated DCs in the absence or presence of the well-established human renal 
fibroblast cell line, TK17325. Both Ctrl-DC and Fibro-DCs were morphologically 
similar on day 6 with the exception that the Fibro-DCs were often seen tethered to 
the co-cultured fibroblasts (Fig. 2A). Flow cytometric analysis of immature cells 
revealed that Ctrl-DC and Fibro-DCs expressed characteristic markers of DCs 
including low CD14 with high DC-SIGN and MR. However, CD1a expression 
was significantly reduced on Fibro-DCs compared to Ctrl-DC (Fig.2B,C). 
Further analysis showed that Fibro-DCs tended to express higher levels of CD80 
and CD86 but this was not found to be significant. In contrast both B7H1 and 
B7DC were significantly upregulated on Fibro-DCs (Fig.2D,E). Next to a direct 
co-culture, we generated DCs in the presence of cell free fibroblast supernatant 
(DC+Fibro sup). On these cells, the reduced CD1a expression and elevated B7H1 
and B7DC could not be demonstrated (Fig.2C,E), indicating that cell contact with 
renal fibroblasts is required for these particular phenotypical changes.
Figure 1: Dendritic cells and fibroblasts are both highly abundant within the renal 
interstitium and are often in close contact with one another. Paraffin sections of normal human 
kidney were stained for (A) Mannose Receptor or (B) PDGFRβ. (C) Immunofluorescent double 
stainings were performed on cryosections (4µm) of normal human kidneys for Mannose receptor 
(red), representing the DC network and PDGFRβ (green), representing the renal fibroblast network. 
Nuclei were stained with Hoechst (blue). Non-conjugated mouse and rabbit isotype antibodies were 
used to determine the level of non-specific background staining. Pictures are representative for at 
least five different donors. 
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Upon activation, Fibro-DCs display diminished levels of CD80 and CD86, 
yet enhanced levels of B7H1 and B7DC.
To further explore the phenotype of Fibro-DCs, cells were harvested and 
stimulated with IFNγ+LPS or CD40L. Both Ctrl-DCs and Fibro-DCs developed 
characteristic clusters of activated DCs with many cells also becoming more 
Figure 2: Fibro-DCs display reduced levels of CD1a but express typical markers of Ctrl-DC 
including DC-SIGN and Mannose Receptor. (A) DCs were generated as previously described 
and cultured for 6 days in the presence of IL-4 and GM-CSF to obtain Ctrl-DC. Fibro-DCs 
were generated by the addition of irradiated renal fibroblasts to the moDC cultures at day 0. The 
expression of monocytic and dendritic cell markers (B) were analysed on unstimulated cells; Ctrl-
DC (filled histograms) and Fibro-DC (solid black line). Dashed lines represent isotype control mAb 
staining. Results are representative of 5-10 independent experiments. The expression of (C) CD14, 
CD1a, DC-SIGN and Mannose Receptor (MR) was analysed using flow cytometry. DC+Fibro sup 
cells were generated by addition of cell free fibroblast supernatant at day 0.  Dashed line indicates 
the mean MFI of isotype controls used. Results shown are the mean ± SD of 5-10 independent 
experiments performed. The expression of co-stimulatory and inhibitory molecules (D) were 
analysed on unstimulated cells; Ctrl-DC (filled histograms) and Fibro-DC (solid black line). 
APC- and FITC-conjugated isotype antibodies were used to determine the level of background 
staining for directly labelled antibodies. Dashed lines represent isotype control mAb staining. 
The expression of (E) CD80, CD86, CD83, B7H1 and B7DC was analysed using flow cytometry. 
Dashed line indicates the mean MFI of isotype controls used. Results shown are the mean ± SD of 
5-10 independent experiments performed.
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adherent to plastic (Fig.3A). This was particularly evident for Fibro-DCs 
stimulated with IFNγ+LPS.
Upon activation with IFNγ+LPS both cell types increased expression of CD80, 
CD83, CD86, B7H1 and B7DC (Fig.3B), compared to non-activated cells 
(Fig.2D). Ctrl-DCs expressed high levels of CD80, CD86 and CD83, whereas 
mature Fibro-DCs expressed significantly lower levels (Fig.3C). This was in 
contrast to B7H1 and B7DC, where expression was higher on Fibro-DCs (Fig.3C). 
DCs generated in the presence of fibroblast supernatant showed reduced levels of 
CD80 and CD86, but did not demonstrate increased levels of B7H1 and B7DC 
(Fig.3C). This suggests that cell contact with renal fibroblasts is necessary to 
actively upregulate immunoregulatory markers. 
The differential regulation of CD86 and B7H1 became more evident when 
calculating the stimulation index of individual experiments, where the more 
than 10 fold induction of CD86 expression on DCs, was significantly reduced on 
Fibro-DC (Fig.3D). As a consequence, the ratio of B7H1:CD86 showed a more 
than 2 fold increase on Fibro-DCs (Fig.3E).
Figure 3: Fibro-DCs display typical phenotypical characteristics of regulatory DCs with 
reduced CD80, CD83 and CD86 but increased levels of B7DC and B7H1 upon stimulation. 
(A) Cells were harvested on day 6, replated and activated overnight with IFNγ+LPS or CD40L. 
The expression of (B) CD80, CD86, CD83, B7H1 and B7DC on Ctrl-DC (filled histograms) and 
Fibro-DC (solid black line) was analysed using flow cytometry. APC- and FITC-conjugated isotype 
antibodies were used to determine the level of background staining for directly labelled antibodies. 
Renal fibroblasts induce regulatory DCs   •   119
   6
Fibro-DCs display a reduced allostimulatory capacity. 
A key hallmark of DCs is their unique capacity to induce T cell proliferation and 
cytokine production, so we assessed whether the reduced expression of CD80 
and CD86 had an affect on T cell proliferation. Ctrl-DC, Fibro-DC or DC+Fibro 
Sup cells were co-cultured with allogenic CD4+ T lymphocytes for 5 days, after 
which the T cells were analysed for proliferation and cytokine production (Fig.4). 
Ctrl-DCs were potent inducers of T cell proliferation while both Fibro-DCs and 
DC+Fibro sup conditions had a significantly reduced allostimulatory capacity 
(Fig.4A). Ligation of CD40 on Ctrl-DC prior to co-culture with T cells led to 
greater proliferation which was again reduced in Fibro-DC and DC+Fibro sup 
conditions (Fig.4B). A similarly reduced T cell stimulatory capacity was also 
observed with other stimuli including IFNγ+LPS (Fig.4C) and LPS+CD40L (not 
shown). Supporting the proliferation results we assessed the levels of  IFNγ in the 
Dashed lines represent isotype control mAb staining. Results shown are from a representative 
experiment of 5-10 independent experiments performed. Data shown in (C) is the mean ± SD of 
those 5-10 experiments. The stimulation index was obtained by comparing expression levels of (D) 
CD86 and B7H1 upon stimulation with IFNγ+LPS compared to unstimulated cells. (E) The ratio 
of B7H1:CD86 was determined in IFNγ+LPS stimulated cells.  Data shown in is the mean ± SD of 
5-10 experiments.
Figure 4: Impaired T cell stimulatory capacity of DCs generated in the presence of renal 
fibroblasts. Cells were harvested on day 6 and either (A) unstimulated or stimulated with (B) 
CD40L for 24hrs. The DCs were then harvested and co cultured with allogenic CD4+ T cells at a 
starting ratio of 1:20. On day 5 the T cell proliferation  was determined by 3H incorporation during 
the last 12-16hrs of culture. Data shown in (A, B) is representative of 3 independent experiments, 
with (C) showing the mean ± SD of those 3 experiments. Cytokine production was measured using 
ELISA. T cell culture supernatants were harvested on day 5 and analysed for IFNγ production 
induced by (D) unstimulated or (E) CD40L stimulated DCs. Data shown in (D, E) is representative 
of 3 independent experiments, with (F) showing the mean ± SD of those 3 experiments at the 1:20 
ratio. T cell culture supernatants were also assessed for IL-17A production production. Data shown 
in (G) is the mean ± SD of 3 experiments at 1:20 ratio.
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T cell supernatant and found that Fibro-DC and DC+Fibro sup conditions were 
significantly hampered in their ability to induce IFNγ production (Fig.4D,E,F). 
Despite the significantly reduced T cell proliferation in Fibro-DC and DC+ 
Fibro sup conditions (Fig.4C) we found that IL-17A levels remained comparable 
between all conditions (Fig.4G), suggesting that Fibro-DCs specifically diminish 
Th1 responses while preserving other T helper responses including Th17. 
Fibro-DCs produce significantly less IL-12 compared to Ctrl-DC, yet 
maintain IL-23.
The IL-12/IL-23 axis is integrally involved in the maintenance of Th1 and Th17 
responses respectively. Therefore we investigated the production of IL-12 and IL-
23 in both Ctrl-DC and Fibro-DC populations. In all cell types the relatively low 
mRNA expression of IL12B (Fig.5A), IL12A (Fig.5B) and IL23A (Fig.5C) was 
strongly increased upon activation with IFNγ+LPS or CD40L. In these activated 
conditions the mRNA expression between Ctrl-DC, Fibro-DC and DC+Fibro 
sup was comparable. However, remarkable differences were observed when 
analysing protein expression. Particularly, activation with IFNγ+LPS induced 
a strong production of IL-12p40 which was significantly reduced in activated 
Figure 5: Fibro-DCs have profoundly reduced levels of IL-12p40 and IL-12p70 in cellular 
supernatants while IL-23 production is maintained. Dendritic cells were harvested after 6 days 
of culture and stimulated with a combination of IFNγ+LPS or irradiated CD40L cells at a ratio of 
1:5 dendritic cells. Cells were stimulated for 6hrs after which mRNA was isolated followed by 
cDNA synthesis. The transcript levels of (A) IL12B, (B) IL12A and (C) IL23A were determined by 
RT-PCR. GAPDH mRNA expression from the same samples was used as an endogenous reference 
gene (relative mRNA expression). Data shown is mean ± SD of 3 independent experiments. Cells 
were stimulated for 24hrs after which the cellular supernatants were collected and assessed for 
levels of (D) IL-12p40, (E) IL-12p70 and (F) IL-23. Data shown is mean ± SD of 3-8 independent 
experiments. Untransfected L cells were used as a control for CD40L cells and yielded results in 
line with medium conditions (data not shown).
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Fibro-DCs or DC+Fibro sup (Fig.5D). IL-12p40 can dimerise with either IL-
12p35 or IL-23p19 to yield IL-12p70 and IL-23 respectively. We found that 
IL-12p70 production was profoundly inhibited in Fibro-DC and DC+Fibro sup 
compared to Ctrl-DC (Fig.5E). However, this stark inhibition was not evident for 
IL-23 production (Fig.5F). Although IL-23 was diminished in CD40L stimulated 
DC+Fibro sup conditions, this was not found to be significant. 
Fibro-DCs maintain expression of IL-27 and have enhanced levels of IL-10. 
IL-27 is another member of the IL-12 family and has been reported to possess 
some anti-inflammatory properties28-30. We assessed by RT-PCR, the subunits 
Ebi3 and IL-27p28, together making IL-27, in each DC type. Both IL27B and 
IL27A expression was comparable between Ctrl-DC, Fibro-DCs and DC +Fibro 
sup conditions (Fig.6A,B). This was also observed in the cellular supernatants 
where all cell types had comparable levels of IL-27 (Fig.6C). 
As an additional cytokine with regulatory properties, we determined the levels of 
IL-10 in all three cell populations. IL10 expression was elevated only in Fibro-DC 
conditions, and not in cells cultured with fibroblast supernatant alone (Fig.6D,E). 
A similar profile was found for mRNA and protein analysis. 
Figure 6: Fibro-DCs maintain expression of IL-27 and have express enhanced levels of IL-
10. Dendritic cells were harvested after 6 days of culture and stimulated with a combination of 
IFNγ+LPS or irradiated CD40L cells. Cells were stimulated for 6hrs after which mRNA was 
isolated followed by cDNA synthesis. The transcript levels of (A) IL27B, (B) IL27A and (D) IL10 
were determined by RT-PCR. GAPDH mRNA expression from the same samples was used as an 
endogenous reference gene (relative mRNA expression). Data shown is mean ± SD of 3 independent 
experiments. Cells were stimulated for 24hrs after which the cellular supernatants were collected 
and assessed for levels of (C) IL-27 and (E) IL-10. Data shown is mean ± SD of 3-8 independent 
experiments. Untransfected L cells were used as a control for CD40L cells and yielded results in 
line with medium conditions (data not shown).
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Generation of DCs in the presence of IL-6 can partially mimic the effect of 
renal fibroblasts.
It became evident to us that fibroblast supernatant alone was sufficient to 
partially induce the regulatory DC phenotype induced by renal fibroblasts. IL-6 
is a pleiotropic cytokine possessing not only inflammatory but also regulatory 
properties and has been implicated as playing a role in the generation of tolerogenic 
DCs in vitro31. We found that IL-6 was produced under steady state conditions 
by fibroblasts in culture (not shown), and demonstrated that IL-6 levels were 
significantly higher in Fibro-DC cultures compared to Ctrl-DC cultures on day 6 
(Fig. 7A). Using recombinant huIL-6, we found that DCs generated in the presence 
of increasing doses of IL-6 were hampered in their ability to produce IL-12, when 
stimulated with IFNγ+LPS (Fig.7B). This reduced IL-12 was evident when DCs 
were generated in the presence of just 100pg/ml IL-6 and reached maximum 
inhibition at 1.0ng/ml (Fig.7B). IL-6 showed a dose dependent increase of IL-
10 production, which was minimal at 100pg/ml and continued to increase, with 
stimulation, until 100ng/ml (Fig.7C). Therefore, it appeared that more IL-6 was 
required to drive IL-10 production, than was necessary to inhibit IL-12 (Fig.7C). 
Flow cytometric analysis revealed that CD86 levels were reduced with increasing 
IL-6 concentrations (Fig.7D). In contrast B7DC and CD1a levels remained 
Figure 7: Generation of DCs in the presence of IL-6 can partially mimic the effect of renal 
fibroblasts. Ctrl-DC and Fibro-DCs were generated as described. Day 6 supernatants were assessed 
for the presence of (A) IL-6 by ELISA. Monocytes were isolated and cultured with increasing 
concentrations of rec human IL-6, in addition to GM-CSF and IL-4. Cytokines were refreshed on 
day 3. On day 6 cells were harvested washed and replated followed by stimulation with IFNγ+LPS 
or CD40L. After 24hrs the levels of (B) IL-12p70 and (C) IL-10 were assessed. The cells were 
tested by flow cytometry for the expression of (D) CD86, (E) B7DC and (F) CD1a. Data shown is 
representative of 2 independent experiments.
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unaffected by the increasing doses of IL-6 (Fig.7E,F). These results suggest that 
like renal fibroblast supernatant, IL-6 is sufficient to reduce the immunogenic 
phenotype of DCs but is not fully adept at inducing the immunoregulatory 
properties, including B7DC expression.
Neutralisation of IL-6 in Fibro-DC cultures can partly restore IL-12 
production. 
The results from the recombinant IL-6 experiments strongly suggested that IL-6 
may be a key determinant in how renal fibroblasts induce some of the functional 
changes we observed in Fibro-DCs (Fig.7). To investigate this, we generated 
Fibro-DCs in the presence of blocking antibodies against IL-6 or IL-6RA. In 
line with this we found that IFNγ+LPS stimulated Fibro-DCs demonstrated a 
strong inhibition of IL-12p40 which was partially reverted when these cells were 
generated in the presence of either αIL-6 or αIL-6RA (Fig.8A). A similar reversal 
of inhibition was also observed for the production of IL-12p70 (Fig.8B). 
Conversely the increased levels of IL-10 production could be partially reduced 
when the Fibro-DCs were generated in the presence of either αIL-6 or αIL-6RA 
(Fig.8C). Flow cytometric analysis showed that reduction of CD86 and CD1a 
on Fibro-DC was not reversed by αIL-6 or αIL-6RA (Fig.8D,F). However, both 
αIL-6 and αIL-6RA prevented the increased expression of B7DC on Fibro-DC 
Figure 8: Neutralisation of IL-6 in Fibro-DC cultures can partly restore IL-12 production. 
Ctrl-DC and Fibro-DCs were generated as described. Antibodies (2.5µg/ml) directed against IL-6, 
IL-6RA or isotype matched controls, were added to Fibro-DC cultures on day 0 and refreshed daily. 
Cells were harvested on day 6, washed and replated followed by stimulation with IFNγ+LPS or 
CD40L. After 24hrs the levels of (A) IL-12p40 and (B) IL-12p70 and (C) IL-10 were assessed by 
ELISA. Data shown is the mean ± SD of 3 independent experiments. The cells were tested by flow 
cytometry for the expression of (D) CD86, (E) B7DC and (F) CD1a. Data shown is representative 
is the mean ± SD of 2 independent experiments.
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(Fig.8E).
Discussion
Dendritic cells represent a heterogeneous population of APCs that are found in 
virtually all tissues of the body, in close contact with the local stromal network 
9,32. In this study we demonstrate that co-culture of DCs with renal fibroblasts, 
partially through the production of IL-6, leads to the generation of DCs expressing 
increased immunoregulatory molecules and with diminished allostimulatory 
capabilities. 
In recent years questions have arisen as to whether DCs present in peripheral 
organs are intrinsically similar because ontogenetically they may be comparable, 
or are they different because the various local microenvironments dictate the 
development of tissue specific DCs32. Renal DCs (rDCs) form an extensive 
surveillance network in the human and mouse kidney and are thought to possess 
immune homeostatic roles involved in inducing and preserving immune tolerance 
against self and innocuous antigens33. Although not fully elucidated, it is believed 
that local rDCs may exacerbate renal pathology during acute injury, such as 
ischemia reperfusion injury (IRI)4.
In the human kidney, fibroblasts and the mononuclear phagocytic system represent 
a significant proportion of the interstitium2,17,34. DCs belong to the latter and we 
demonstrated that both cells are in close contact in human kidney.
The exact precursor for tissue resident DCs is not known, however we investigated 
how renal fibroblasts influence the generation of what is typically considered to 
be the DC precursor during times of stress and inflammation. We found that DCs 
generated in the presence of renal fibroblasts displayed typical markers including 
DC-SIGN and MR. Others have investigated the phenotypical changes in DCs 
cultured with MSCs and noted significantly elevated CD14 expression35,36. In 
some studies it has also been shown that MSCs led to the generation of type 2 
anti-inflammatory macrophages12,37,38. We assessed the expression of CD163, a 
typical M2 marker39,40, and found low expression on both Ctrl-DC and Fibro-DCs 
(data not shown), indicating that Fibro-DCs are a distinct population compared to 
that induced by MSCs. Data regarding kidney derived MSCs is more finite, but 
murine kidney MSCs have been shown to generate a regulatory DC population 
with decreased MHC II and IL-12 production41. Neutralising experiments with 
IL-6 showed a modest recovery of MHC II while IL-12 restoration was not 
investigated41. In addition, others have investigated the modulation of DCs by 
human  tubular epithelial cells (TEC)42. The authors found elevated CD14 and 
B7H1 with decreased HLA-DR and CD86. Although there appears to be some 
degree of redundancy in how renal cells influence DCs, TECs are typically not in 
direct cell contact with renal DCs in vivo, whereas fibroblasts are, suggesting that 
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these cells may be more directly involved in modulating DC responses.
Comparing immature Ctrl-DCs and Fibro-DCs, we observed that both CD80 
and CD86 had a tendency to be higher on Fibro-DCs. This phenomenon, though 
paradoxical, has also been observed on human tolerogenic DCs24 and murine 
BMDCs generated in the presence of kidney MSCs43. Upon maturation Ctrl-
DCs offered characteristic upregulation of CD80 and CD86 but this increase 
was significantly reduced on Fibro-DC. In addition, we show for the first time 
an elevation in B7H1 and B7DC on DCs generated in the presence of renal 
fibroblasts. Both molecules are accepted markers of regulatory DCs and play an 
important role in controlling immune responses44,45.
In line with the stark phenotypical changes, Fibro-DCs were strongly hampered 
in their ability to induce allogenic T cell proliferation. Notably, although IFNγ 
levels were reduced in T cells allostimulated with Fibro-DC, IL-17A levels 
were maintained. It has been previously suggested that the default helper T cell 
skewing by lung and mucosal tissues is Th1746,47. This might explain the observed 
preservation of IL-17A but not IFNγ, by T cells co-cultured with Fibro-DC. We 
found that Fibro-DCs profoundly inhibited the production of both IL-12p40 and 
IL-12p70 when stimulated with IFNγ+LPS. Notably, in line with the IL-17A data, 
IL-23 production was maintained, despite a reduction in IL-12p40 production. 
This raises important questions on the regulation of expression, translation 
and assembly of the IL-12 family of cytokines. It has been suggested that IL-
12p35 is more often the rate limiting factor for IL-12p70 production48,49. We 
assessed the transcriptional expression of the entire IL-12 family. Interestingly, 
although we observed significant inhibition of IL-12p40 at the protein level this 
was not reflected at the mRNA level, thereby implying there may be some post 
transcriptional regulation in Fibro-DCs to limit IL-12p40 translation. This has not 
been seen in other studies as transcriptional regulation has been largely unstudied. 
Further experiments with fibroblast supernatant and recombinant IL-6 suggested 
that renal fibroblasts limited the immunogenic properties of DCs via IL-6 
secretion. IL-6 has been investigated in studies showing DC modulation by MSCs 
and stromal cells11,36,50 and has in recent years been explored for the generation 
of tolerogenic DCs in vitro31,51. However some regulatory phenotypical changes, 
including B7DC and IL-10 upregulation required cell contact with renal 
fibroblasts. Neutralisation of IL-6 in Fibro-DC cultures could partly restore IL-12 
production, but not CD86 expression, indicating that there may be redundancy 
and several other mechanisms could potentially be involved in the regulation of 
DC function by renal fibroblasts. Hepatic stromal cells have been demonstrated 
to induce regulatory DCs through the action of C322. Additionally, PGE2 has 
been implicated in MSC mediated DC modulation52. We did not investigate 
PGE2 but did assess the levels of C3 in Ctrl-DC and Fibro-DC cultures, but 
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did not observe significant differences (data not shown). Nevertheless, local C3 
production has been shown in human53 and mouse54 kidney, so it may be that 
even within the organ itself, there are competing or complementary mechanisms 
of immune homeostasis. 
Considering the importance of DCs in immune regulation, surprisingly little is 
known about the function and regulation of human rDCs, mainly stemming from 
the caveat that the ontogeny of rDCs is not fully understood. However it is widely 
thought that monocytes do represent the local DC population during times of 
tissue stress or inflammation. The majority of the literature on DCs focuses on the 
contribution of the infiltrating DCs to inflammation in murine pathological disease 
models. The influence of the local renal stromal cell network within an organ, and 
its influence on the inflammatory response has been largely unexplored. DCs 
possess an impressive repertoire of innate PRRs, which is key in helping them 
decipher the nature of a given insult. Little is known about the expression of such 
receptors on renal stromal cells, and the function this may play in granting renal 
fibroblasts a more decisive role in regulating local immune responses.
Summarising, we have shown that DCs cultured in the presence of renal fibroblasts, 
have a regulatory phenotype, with lower expression of co-stimulatory molecules, 
and impaired allostimulatory capacity. Production of IL-12 was decreased while 
IL-23 and IL-10 was maintained or even enhanced in Fibro-DC cultures. These 
changes are in part mediated through IL-6 secretion from the renal fibroblasts. 
This study indicates the importance of understanding that the kidney is not only 
a passive host to DCs and that the local micro-environment plays a major role in 
maintaining tissue immune homeostasis in health and disease. 
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7.0 Discussion and Summary.
Most immunologists would probably agree that a lot of the remaining unsolved 
problems in immunology relate, in one way or another, to the question of tolerance 
and the regulation of immune responses. Although much progress had been made 
in understanding the initiation of an immune response, our insight into how this 
is subsequently turned off or regulated is still emerging.  Traditionally, tolerance 
has been defined as a state of unresponsiveness to a particular antigen or insult. 
However in recent years this paradigm has been shifting to the appreciation that 
tolerance is an active process, and many mechanisms are in place to induce, and 
also maintain tolerance to self or innocuous antigens.  
7.1 DCs take centre stage in the maintenance of immune regulation.
DCs arise from the CD34+ cell compartment within the bone marrow. Myeloid 
progenitor cells can differentiate to immature DCs circulating in the blood 
or can migrate into the other tissues e.g. kidney to become interstitial DCs. 
Collectively these cells are broadly referred to as mDCs1,2. In addition, CD14+ 
monocytes have been shown to be an important source of DC precursors during 
periods of physiological stress or injury3,4. Several studies have demonstrated 
that mDCs, under certain conditions, can promote tolerance and regulatory T 
cell induction5,6. The problem lies in identifying when and how to differentiate 
between immunogenic and tolerogenic populations. Extensive evidence from 
both mouse and human DC studies is that the lineage or origin of a DC is 
unlikely to determine whether an immunogenic or regulatory T cell response 
occurs. Furthermore, DCs are highly plastic and have been evolutionarily 
tailored to be responsive to their surroundings. It is more likely therefore, that 
the activation state and the site or tissue of action plays a more important role in 
determining immunity versus tolerance7,8. This becomes particularly important 
when one considers organ transplantation. DCs are found in virtually all organs 
and are therefore an important “passenger” cell population. Kidneys are the most 
frequently transplanted organ and resident DCs are a very important constituent 
involved in initiating the direct pathway of allo-recognition in transplantation, 
in addition to playing a central role in the innate immune response following 
injurious stimuli to the organ. Our knowledge into the local regulation of this 
DC population is remarkably finite, but promising data has suggested that in-
vivo mobilised renal DCs have the potential to prolong allograft survival9 thereby 
warranting further investigation into understanding renal DCs biology and how 
the local renal network could generate and maintain such a potent regulatory 
population.
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A major caveat in DC biology is that we currently do not have sufficient tools 
to discriminate between regulatory and immunogenic DCs in vivo. The only 
apparent success to date has been with the discrimination between mDCs and 
plasmacytoid DCs (pDCs). This is due to the clear expression of BDCA-210 and 
the IL-3R11,12 by pDCs and their strong IFNα signature upon activation. In this 
respect understanding the full cytokine repertoire of mDCs may prove to be very 
beneficial in establishing such a regime for discriminating between immunogenic 
and tolerogenic myeloid DC populations in vivo. In previous years one may have 
suggested the comparison between immature DCs with mature DCs as a model of 
tolerogenic and immunogenic DCs respectively. However more recent data has 
accrued showing that the maturation status alone, as currently defined at least, 
is inadequate for differentiating between an immunogenic versus a regulatory 
DC5,6,13. In light of the avid interest of many groups pursuing in-vitro generated 
tolerogenic DCs for therapeutic use in autoimmunity14,15 and transplantation16,17, 
these cells can provide a useful tool to investigate unexplored diverging functional 
characteristics between immunogenic and tolerogenic DCs. Furthermore, current 
clinical approaches for the treatment of inflammation mostly focus on the 
inhibition of pro-inflammatory responses. Cell-mediated therapy has significant 
potential to provide nontoxic and highly specific treatments for autoimmunity 
and transplantation. Deeper understanding into the mechanisms of how immune 
regulation is maintained may provide new targets in the treatment of chronic 
inflammation. 
To address these issues we focussed on investigating the production and regulation 
of soluble factors secreted by DCs and tolerogenic DCs. In this thesis (chapter 
2, 3) we explored the regulation and expression of IL-12 family members in DCs 
and describe the production of a potent regulatory cytokine, IL-35 by tolerogenic 
DCs. We demonstrated that uptake of apoptotic DCs by DCs profoundly affected 
the transcription regulation of the IL-12/IL-35 axis. We addressed an important 
question; which is that tolerogenic DCs are efficient at ingesting apoptotic material 
and that their regulatory cytokine prolife is maintained even when challenged 
with necrotic material. We identified a unique role for IFN family members and 
IL-27 in the regulation of the balance between fP and fH production (chapter 4), 
which provides new targets for investigation in DC biology. In (chapter 5), we 
described the expression of a regulatory protein, Ebi3 within non-haematopoietic 
cells of the kidney. Finally, the effects of culturing DCs in the presence of renal 
fibroblasts are demonstrated (chapter 6) which provides new insights into how 
the local stromal network within the kidney may dictate the development of DCs 
with a distinct regulatory phenotype.
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7.2 The IL-12 family in immune-regulation.
The IL-12 family has been the subject of intense investigation in recent years 
and together its members are increasingly viewed as being key players in the 
regulation of immunity and immunological tolerance. In many aspects the IL-
12 family perfectly illustrates the grander balance on-going within the entire 
immune system, with IL-12 and IL-23 representing the immunogenic arm, and 
IL-27 and IL-35 representing immune regulation. Whereas IL-12 and IL-23 can 
induce and maintain the generation of inflammatory Th1 and Th17 cells, IL-27 
and IL-35 can induce Tr1 and iTr35 subsets of regulatory T cells18,19. Of the two 
regulatory cytokines, unquestionably more data has been generated with regard 
to IL-27 compared to IL-35. Several studies have demonstrated a direct role for 
IL-27 in the inhibition of Th17 commitment20,21. Additionally IL-27 can suppress 
immune responses indirectly. For example, IL-27 promotes the generation of 
CD39 expressing regulatory DCs which in turn can down-regulate innate immune 
NALP3 inflammasome activation22. This will lead to diminished availability of 
caspase cleaved cytokines, IL-1β and IL-18, and thereby potentially alleviate 
the induction of Th1 and Th17 populations. This epitomises the far reaching 
capabilities of the IL-12 family members in regulating immune responses, 
and demonstrates the importance of the knowledge that can be gained from 
fully understanding the regulation, expression and function of all its members, 
particularly the most recently identified, anti-inflammatory member, IL-35.
Unlike IL-12, IL-23 and IL-27, production of IL-35 has not been demonstrated 
in APCs. However in light of the expression of all chains by DCs, one could 
speculate that these cells may produce this potent anti-inflammatory cytokine. Our 
work focused on tolerogenic DCs generated in the presence of dexamethasone. 
Over the last decade a consensus has developed that tolerogenic DCs should 
lack IL-1217. We and others have shown that DCs generated in the presence of 
dexamethasone fulfil this requirement23,24, but for the first time we have identified 
that these cells maintained, and had elevated transcriptional levels of IL27B 
and IL12A, together making the potent regulatory cytokine IL-35 (chapter 
2). Notably, it appeared that this cytokine was not constitutively produced by 
tolDCs, but was inducible upon challenge with TLR agonists, CD40L and most 
strikingly, IFNγ. Considering that Ebi3 is part of IL-27 and IL-35 and that the 
tolDC we generated were completely devoid of IL-12p40, we silenced IL-12p35 
as a means of silencing IL-35 and found that tolDCs required IL-35 to elicit 
their full tolerogenic potential. This opens up an exciting opportunity to study the 
expression of IL-35 in other regulatory APCs including type II anti-inflammatory 
macrophages and myeloid derived suppressor cells. Although limited to murine 
data it has been shown that intracellular Ebi3 expression can block LPS induced 
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M1 to M2 transition and IL-12p70 production25. We have also observed elevated 
basal Ebi3 levels in M-CSF generated human M2 compared to GM-CSF generated 
M1 macrophages (Fig.1, unpublished data), although this difference normalised 
upon activation. Therefore, it would be interesting to extrapolate on the possible 
role of Ebi3 in maintaining the regulatory functions of M2 macrophages.
 Figure 1: IL27B expression in M1 and M2 macrophages. 
Advances in our understanding of the role of cytokines in inflammatory diseases 
has led to a growing field of cytokine driven therapies aimed to either block or 
restore the activity of a particular cytokine. We have seen through the use of 
Anakinra26,27, Etanercept28,29 and recombinant IFNα30 and IFNβ31,32 that cytokine 
based therapies have proven successful. However, one of the major pitfalls with 
cytokine therapy, and what has laboured progress, is that in healthy individuals 
there is equilibrium between inflammatory and regulatory cytokines. This balance 
becomes disturbed in chronic inflammatory states, such as autoimmunity and 
transplant rejection. However the required action to restore balance is not to just 
simply block inflammatory cytokines or treat systemically with anti-inflammatory 
cytokines. For the latter it is difficult to determine how much and what cocktail of 
anti-inflammatory cytokines to administer. Additionally, giving too much could 
render an individual susceptible to viral and bacterial infection and may even 
promote the development of tumour growth.
Ideally one would not want systemic suppression, but rather specific regulation 
directed against the offending antigen at the level of the affected organ or tissue. 
In this way tolDCs would be the ideal vehicle, not only have they the ability to 
directly suppress and induce antigen specific regulatory T cells, but the inducible 
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production of regulatory cytokines e.g. IL-10, IL-35, would infer tolDCs with a 
second wave of immunosuppressive potential e.g. through the action of regulatory 
T cells. IL-35 has already been proven to be a broad regulatory cytokine with 
the ability to promote tolerance and immune suppression in an array of disease 
models (Table I). 
Table I: In-vivo studies evaluating the effect of IL-35 induction in disease 
settings
Although some studies have directly utilised rIL-3535 or induced local ectopic 
expression33, successful suppression has also been obtained by transferring iTr35 
cells36. As of yet, no data has been generated using tolDCs expressing IL-35, 
however Ebi3 expression in tolerised DCs has been implicated as a key mediator 
of allograft acceptance39. In this study the authors could not identify expression of 
either IL-27p28 or IL-12p35 but considering the powerful regulatory potential of 
IL-35, it would be of significant interest to investigate the role of IL-35 expressing 
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tolDCs in such disease settings.  
7.3 Role of apoptotic cell clearance in the regulation of immune responses.
 
When one considers DC activation, the first idea that comes to mind is activation 
in response to invading pathogens and viruses. The general conjecture is that 
under steady state conditions, DCs are quiet sentinels, and that introduction of 
microbial products is required to evoke a response. However this simplified theory 
does not fully address the role and function of DCs under normal physiological 
conditions. In the body, cell death and turnover is an inevitable process and is 
essential to preserve normal homeostasis throughout all our tissues. 
Extensive literature has shown that apoptosis is a controlled physiologic process 
resulting in the generation of  “eat me” signals designed to promote efficient 
uptake of apoptotic cells by phagocytes during the early stage of cell death, 
thereby preventing the release of potentially immunogenic intracellular contents40. 
This so termed `silent removal` of apoptotic cells is well acknowledged, however 
there is an increasing body of evidence that apoptotic cell clearance is not just an 
immunologically inert event41-43, and that active processes must be taking place 
in order to preserve immune tolerance to self and innocuous antigens44-47. In line 
with this, some studies have observed that uptake of apoptotic cells of different 
origins to the ingesting APC (i.e neutrophils, T cells etc) can inhibit up-regulation 
of co-stimulatory molecules on APCs upon subsequent LPS challenge48. In 
addition, murine studies have suggested that uptake of apoptotic cells, by DCs 
leads to up-regulation of TGF-β49. Until recently the only member of the IL-12 
family to be investigated upon apoptotic cell uptake was IL-12. There have been 
conflicting reports about the regulation of IL-12 upon apoptotic cell ingestion 
however the greater body of literature points to decreased IL-12 production upon 
ingestion of apoptotic material. We explored the regulation of IL-12 compared to 
IL-27 and IL-35 and demonstrated (chapter 3) that uptake of apoptotic cells by 
viable DC, in the absence of any exogenous stimuli, led to enhanced transcription 
of IL27B and IL12A. 
As we have mentioned, Ebi3 can also dimerise with IL-27p28 to yield IL-27, 
and an interesting study demonstrated that uptake of apoptotic tumour cells 
by DCs led to IL27B upregulation and IL-27 production50. While we did not 
observe upregulation of IL27A in our study it is intriguing that Ebi3 was up-
regulated in both studies, and notably remained unaffected by necrotic cell uptake 
in our study. An additional hypothesis is that uptake of DCs by DCs51,52 is the 
key determinant for the profound regulatory changes we observed (chapter 3). 
Work by Martin and colleagues has generated some interesting findings that cells 
undergoing apoptosis are capable of producing cytokines and chemokines which 
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they suggest influences the response of the ingesting phagocyte53. The cytokine 
profile of apoptotic cells of diverse lineages has not yet been fully elucidated. 
However, one could imagine that DCs would be particularly adept at secreting 
potent immune mediators that may specifically tailor the immune response in an 
immunogenic or tolerogenic fashion. 
It would be of interest to fully investigate the mechanism of Ebi3 upregulation 
in our experimental setup and to additionally dissect whether pre-stimulated 
apoptotic cells would infer an even better regulatory response. Of course this 
will likely depend on the stimulus used but, based on our findings throughout the 
thesis, IFNγ could be an interesting target.
7.4 IFNγ and immune regulation.
IFNγ is a remarkable cytokine that orchestrates many distinct and complex 
networks through its transcriptional control over large numbers of genes54. Initially 
termed macrophage activating factor (MAF), IFNγ is more often expected to be an 
inflammatory molecule. However, in recent years IFNγ has proven to exert many 
regulatory functions, including the potent upregulation of B7H155 and IDO56. 
Though paradoxical to many, in a study mentioned earlier, Cuturi and colleagues 
demonstrated up to 3 fold higher levels of IFNγ in allograft tolerised rats39. In 
this study the authors investigated the use of autologous DCs as a tolerance 
inducing strategy and found a novel role for Ebi3 in transplant tolerance, whereby 
blockade of Ebi3 resulted in allograft rejection. Notably blockade of Ebi3 also 
resulted in ablation of IFNγ production, indicating a surprising link between 
these two molecules in the induction of allograft tolerance, which is noteworthy 
considering our findings with IFNγ induction of Ebi3 in tolDCs (chapter 2). In 
fact more and more evidence is gathering that IFNγ is an important mediator of 
tolerance induction in both cell and organ transplantation, and in autoimmunity. 
The immuno-modulatory activity of MSCs has been shown to be significantly 
augmented when the cells were first primed with IFNγ57. This presumably depends 
on the duration and concentration of IFNγ. Based on our findings (chapter 2) 
IFNγ treatment would also seem like a potentially useful conditioning strategy 
for tolDCs. We demonstrated that tolDCs expressed high levels of the IFNγ R 
and had higher basal levels of total STAT1 (chapter 4). Additionally it has been 
determined that the promoter region of Ebi3 has a high number of binding sites 
for IRF-158. Together this resulted in a strong and sustained response upon IFNγ 
treatment and yielded many regulatory features including upregulation of co-
inhibitory molecules B7H1 and B7DC and regulatory IL-12 family members IL-
12p35 and Ebi3 (chapter 2).
We demonstrated an additional novel regulatory role for IFNγ in complement 
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regulation (chapter 4). fH and fP are at opposite poles in terms of complement 
regulation with fH being an important negative regulator and fP being the only 
know positive regulator within the entire system. Surprisingly, IFNγ played a 
dual role, with the ability to markedly reduce fP secretion while simultaneously 
increasing fH. As such IFNγ appears to support complement regulation as 
opposed to activation. The combined efforts of DCs and complement in T cell 
activation has recently gained interest with the studies by Heeger and colleagues 
which demonstrated that DCs and T cells secrete complement proteins, express 
C3aR, C5aR and complement regulators on their surfaces59,60. The authors further 
demonstrated that locally produced C3a and C5a influences the strength and 
phenotype of T cell responses. In our work we have shown that DCs produce 
both fP and fH and thereby also possess the tools to potentially regulate the local 
complement activity when encountering T cells. Using RNA interference we 
found that inhibition of fP diminished the allostimulatory capacity of DCs. A 
combination of siRNA directed against fP and IFNγ stimulation, acting as a natural 
inhibitor of fP, resulted in an even more pronounced reduction in allostimulatory 
capabilities. Conversely interference of fH led to enhanced T cell activation by 
DCs thereby demonstrating that the active production of complement regulators 
by DCs does influence T cell activation and cytokine production. This has the 
potential to open up many exciting avenues of research. Information regarding 
the role of local complement synthesis by DCs in determining T helper cell 
skewing is virtually unknown. One could speculate that management of the two 
key regulators of complement activity by IFNγ could serve as a negative feedback 
loop to control cellular immune activation. In view of the established role of 
complement activation in lowering the threshold of B cell activation one may also 
question the contribution of local complement activity, or its absence, in lowering 
or elevating the threshold of naive T cell activation by DCs. Considering the 
many functions of IFNγ in DC activation it will prove difficult to address these 
specific questions in-vitro, but use of IFNγ-/- and IFNγ R-/- mice and BMDCs 
could prove useful.
7.5 Involvement of local tissues in DC regulation.  
As mentioned earlier it is not yet fully clear whether regulatory DCs in vivo 
represent a terminally differentiated DC phenotype, or reflect a transient 
state subject to changes within distinct tissue microenvironments. There is an 
increasing body of evidence to strongly support the latter hypothesis whereby 
several studies focusing on stromal or mesenchymal stem cells61-63 derived from 
various tissues, have been shown to modulate DC function. DC differentiation in 
the presence of tissue-dependent microenvironment leads to a more regulatory 
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cell population with lower expression of co-stimulatory molecules and poor 
induction of T cell proliferation. This process has been described for several 
organs64,65 including the bone marrow, lung66, thymus and intestine67. More 
recently the presence of kidney derived MSC like cells has been identified in 
mouse68. It has been suggested that renal fibroblasts may be a stromal lineage of 
kidney MSCs, thereby warranting further investigation into their immunological 
contribution. We demonstrated (chapter 6) that culture of monocyte derived DCs 
in the presence of renal fibroblasts led to the generation of a more regulatory DC 
population with diminished co-stimulatory molecules and enhanced expression of 
co-inhibitory molecules B7H1 and B7DC. Notably IL-12 was markedly reduced 
in this cell population while IL-23 and IL-27 remained largely unaffected. 
Together this resulted in a DC population with a significantly impaired ability to 
induce IFNγ production in allostimulated T cells. Although the ontogeny of renal 
DCs remains unknown, it is likely that under steady state conditions renal DCs 
do not arise from monocytes69,70. However during periods of stress or injury it is 
widely thought that monocytes function as tissue infiltrating DCs3,4,71-73, thereby 
calling for a deeper understanding of how the local tissue network can influence 
and modulate the development of DCs. In line with some studies investigating 
the mechanisms of stromal cells and DC regulation, we found that IL-6 was at 
least partially responsible for the modulating effect of renal fibroblasts on DC 
generation and subsequent function. The cytokine IL-6 is highly pleiotropic 
possessing both pro74,75 and anti-inflammatory76,77 properties.  Only recently a 
possible explanation for these discrepancies has come to light. All IL-6 family 
members signal via the beta receptor gp130. In addition some members also need 
to bind to a non-signalling alpha receptor in order to facilitate signal transduction. 
In the case of IL-6 this alpha receptor is IL-6R. While gp130 is ubiquitously 
expressed on most cells in the body, expression of the IL-6R is more finite. Cells 
which express both IL-6R and gp130 respond to IL-6 via “classic signalling”. In 
contrast cells which do not typically express the IL-6R may still respond to IL-6 
by engaging with a soluble IL-6 receptor and function via “trans-signalling”78,79.
It is thought that responsiveness to IL-6 via “classic” signalling exerts anti-
inflammatory functions whereas “trans-signalling” exerts pro-inflammatory 
functions. Still there are some caveats with this theory as addition of exogenous 
IL-6R has been shown to further enhance the regulatory potential of dermal 
fibroblast derived IL-6 on human monocyte-derived DCs62. 
We investigated how healthy renal fibroblasts regulate DC generation. One could 
question what happens in organs undergoing chronic inflammation. Considering 
the central location of fibroblasts within the kidney it is reasonable to postulate 
that these cells themselves are functionally affected in periods of inflammation or 
upon injury. This is likely to impair their ability to regulate local and infiltrating 
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DC populations, thereby potentially exacerbating the inflammatory response. 
Little is known about the expression and responsiveness of renal fibroblast to 
DAMPs but research into this field could prove invaluable in fully understanding 
local DC responses. With a view to expand our knowledge on the immunological 
contribution of the kidney we investigated the expression of IL-12 family 
members within normal human kidney (chapter 5). Unlike other subunits of the 
IL-12 family whose expression is largely restricted to haematopoietic cells, Ebi3 
expression has been demonstrated in placental synctiotrophoblasts80, endothelial 
cells, intestinal mucosa81,82 and aortic smooth muscle cells83. We observed a 
surprisingly abundant expression of Ebi3 within the glomeruli of normal kidney, 
and in distal tubuli. We could confirm the expression of IL27B transcripts within 
the glomeruli, but further work will be needed to establish whether the tubular 
cells are actively producing Ebi3 or are possibly endocytosing the protein from 
the lumen. We provided strong indications that podocytes were the source of Ebi3 
in the kidney and observed a marked reduction in IL27B expression during acute 
allograft rejection. Ebi3 is known to have two isoforms and aside from IL-27p28 
and IL-12p35, Ebi3 can interact with Calnexin84, Golgi SNAP receptor complex 
member 185, MyoD family inhibitor, and SMAD family member 386. It remains 
to be seen whether Ebi3 expressed within human kidney is functioning as a 
cytokine, or if it is remaining as an intracellular molecule and interacting with the 
aforementioned proteins. Additionally, the possibility that Ebi3 is functioning as a 
homodimer cannot be excluded. Nevertheless is it intriguing that Ebi3 expression 
was so abundant in human kidney and further investigation into the role of this 
molecule may shed light on previously unidentified regulatory pathways within 
the kidney.
7.6 Looking ahead...
As we look towards the future of immune regulation and tolerance, it is imperative 
to focus not only on identifying novel mediators of tolerance, but also how these 
regulatory cell populations can be identified. This is particularly relevant with the 
generation of tolerogenic or regulatory DCs, as the plastic nature of DCs makes 
them challenging to identify and track over time. Even in vitro generated tolDCs, 
which we and others have shown to be a highly stable regulatory cell population, 
would undoubtedly prove challenging to identify once injected in vivo. If we 
want to try to identify populations of endogenous regulatory DCs expressing 
IL-35 in vivo then a daunting task lies ahead. As we have demonstrated in this 
thesis, the extensive chain sharing within the IL-12 family means that one must 
assess all 5 chains of the family before beginning to interpret any data. The use 
of knockout mice for studies in this area are limited as mice deficient in one 
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chain can obviously lack multiple cytokines. As we have already seen in the early 
data regarding IL-12 and IL-2387-89, this complicates data interpretation and often 
leads to false conclusions. 
Unfortunately IL-35, unlike IL-23, does not express a unique chain so the 
generation of knockout mice specific for IL-35 will be challenging. Perhaps the 
most feasible way will be through the generation of specific neutralising antibodies 
that target a unique epitope only found in the Ebi3: IL-12p35 heterodimer. These 
antibodies would also prove invaluable for in-vitro assays, as currently one must 
combine anti-Ebi3 and anti IL-12p35 to try and block IL-35. This works relatively 
well for T cell populations36,90, however considering DCs express all chains this 
method is not useful for investigating the presence and function of IL-35 in DC 
populations and further complicates an already complex relationship that exists 
between the opposing roles of IL-12 and IL-35. In our experience there is also a 
degree of difficulty in generating rhu-IL-35 that is functionally active in terms of 
T cell suppression and iTr35 induction. In time these reagents will surely be more 
robustly developed which will open up many avenues in IL-35 research. 
In light of the function of IL-35 in the generation of a unique inducible regulatory 
T cell population, it is possible that IL-35 may also generate a regulatory DC 
population, as DCs do express relatively abundant transcript levels of the IL-35R 
(Fig. 2). IL-35 is promiscuous in that it can exert its activity via three different 
receptor combinations, thus potentially facilitating IL-35 with a wide berth of 
activity. As mentioned earlier in this thesis, IL-27 can up regulate the expression 
of IL-12Rβ2 and thereby sensitise naive T cells not only to IL-12 but also IL-35. 
It may well be that some of suppressive action of IL-27 is in fact mediated by the 
priming of iTr35 cells, though this remains to be proven experimentally. 
Figure 2: IL-35 receptor expression  on DC and tolDC
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With all of this in mind it makes the finding of the abundant expression of Ebi3 
in the kidney very intriguing. This is one area where Ebi3 knockout mice could 
prove very useful. Expression of IL27B or Ebi3 protein has not been previously 
explored in murine kidney but if it is indeed expressed, then Ebi3-/- mice would 
be a useful tool to fully investigate the role of Ebi3 in renal immunology. During 
periods of inflammation, one could wonder if local IL-35 production helps to 
maintain a regulatory environment for resident DCs. Although cytokine mRNA 
transcripts are typically transient it would also be interesting to utilise in-situ 
hybridisation to explore the expression of IL-12 family transcripts within 
interstitial DCs of the kidney to evaluate if these cells may be primed to produce 
the regulatory cytokines IL-27 or IL-35. Concerning the IL-12 family as a whole, 
many fundamental questions remain unanswered. For example what dictates the 
heterodimerisation of IL-12p35 with IL-12p40 in some conditions, and IL-12p35 
with Ebi3 in others? This competition extends beyond the chains themselves as 
the receptor subunits are also shared between cytokines. For example IL-12 and 
IL-23 both utilise IL-12Rβ1.Can one cytokine out-compete the other? Or if IL-23 
is bound by its receptor does this affect availability of IL-12Rβ1 for IL-12 and 
thus reduce the potency of IL-12? 
It is clear that the IL-12 family and DCs together provide a fertile ground for 
future research but more importantly together have the potential to expand our 
understanding of regulatory cytokines beyond IL-10 and TGF-β and enable us to 
get a wider and deeper look into the regulation of immunity and immunological 
tolerance.
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Summary
Dendritic cells (DCs) are antigen-presenting cells of the immune system. Their 
main function is to process antigenic material e.g. from pathogens or malignant 
cells, and present it on their cell surface to the T cells of the immune system. 
As such, DCs act as a bridge between the two arms of the immune system; the 
innate and the adaptive immune responses. DCs belong to the former but play 
a key role in orchestrating the adaptive immune response, on the one hand to 
promote immunity to pathogens and on the other to maintain tolerance to self 
or innocuous antigens. Consequently there is a great deal of interest in how 
DCs might be exploited as a form of immunotherapy e.g. to induce immunity to 
cancers or to promote graft acceptance in transplantation. 
Soluble factors secreted by DCs are crucial mediators in determining this balance 
between the immunogenic and regulatory arms of the immune system and one 
such group of factors is cytokines. These cytokines are small proteins which can 
be released by cells and subsequently influence the behaviour of other cells. The 
cytokine network is a highly integrated and complex system which is generated 
in response to immune challenge. The overall balance between immunogenic 
and regulatory cytokines is what determines the nature of a particular immune 
response. Advances in our understanding of the role of cytokines in inflammatory 
diseases has led to a growing field of cytokine driven therapies aimed to either 
block or restore the activity of a particular cytokine. We have seen through the 
use of Anakinra, Etanercept and recombinant IFNα and IFNβ that cytokine 
based therapies have proven successful. However, one of the major pitfalls with 
cytokine therapy, and what has laboured progress, is that in healthy individuals 
there is an equilibrium between inflammatory and regulatory cytokines. This 
balance becomes disturbed in chronic inflammatory states, such as autoimmunity 
and transplant rejection. However the required action to restore balance is not 
to just simply block inflammatory cytokines, or treat systemically with anti-
inflammatory cytokines. For the latter it is difficult to determine how much and 
what cocktail of anti-inflammatory cytokines to administer. Additionally, giving 
too much could render an individual susceptible to viral and bacterial infection 
and may even promote the development of tumour growth.
Ideally one would not want systemic suppression to treat autoimmunity and 
transplant rejection, but rather specific regulation directed against the offending 
antigen at the level of the affected organ or tissue. In this way DCs generated in 
a tolerogenic manner would be the ideal vehicle, not only have they the ability to 
directly suppress and induce antigen specific regulatory T cells, but the inducible 
production of regulatory cytokines e.g. IL-10, would infer tolDCs with a second 
wave of immunosuppressive potential e.g. through the action of regulatory T 
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cells. 
An individual cytokine can be produced by multiple cell types and can exert a 
broad array of functions. As a result of this, cytokines are often grouped into 
different families based on structural similarities rather than cellular origin or 
function. One family which is gaining increasing attention is the IL-12 family. 
It is composed of four members; IL-12 and IL-23 are immunogenic and their 
expression has been very well characterised in DCs. The other two, IL-27 and 
IL-35, are regulatory, but relatively little is known about their regulation and 
expression by DC populations. Promisingly, IL-35 has already been proven to be 
a broad regulatory cytokine with the ability to promote tolerance and immune 
suppression in an array of disease models including IBD, autoimmune diabetes 
and arthritis. In this thesis we aimed to give a comprehensive overview of the 
expression and regulation of IL-12 family members in human DCs, with a 
particularly emphasis on the IL-12, IL-27 and IL-35. 
There has been much speculation as to whether DCs, particularly tolerogenic 
DCs could produce IL-35. We generated tolerogenic DC in vitro using the 
immunosuppressive agent Dexamethasone. In Chapter 2 we presented data 
regarding the ability of these human tolDCs to produce IL-12p35 and Ebi3, the 
alpha and beta chain of IL-35, respectively. In this chapter we demonstrated, for 
the first time, that abrogating the production of IL-12p35 in tolDCs diminished 
the immunosuppressive capability of these cells and points to IL-35 as being a 
novel mediator of immune suppression by tolDCs. 
Once thought of as a lack of a response, tolerance is now understood to be the 
result of many complex active processes that take place in order to preserve 
immune tolerance. This shift in rationale has extended to the field of apoptosis 
where an increasing body of evidence exists to support the idea that the so termed 
“silent removal” of apoptotic cells in the body is in fact a series of active processes 
that culminates in the maintenance of tolerance to self and innocuous antigens. 
As such, uptake of dying cells by DCs is considered to contribute to induction 
and maintenance of immunological tolerance in vivo. Many groups in the area 
of transplantation are striving to identify the best way to induce tolerance in 
allograft recipients. A promising strategy may be to culture tolDCs of recipient 
origin and feed them with donor apoptotic cells. Indeed it has been shown in a 
murine model that targeting of DCs with donor apoptotic material can restrain 
indirect allorecognition, a major hurdle in the quest for transplant tolerance. In 
Chapter 3 we investigated how uptake of dead cells affected the production and 
expression of different members of the IL-12 family by either immature DC 
or tolDC. We demonstrated how phagocytosis of apoptotic (cells that die from 
programmed cell death) or necrotic cells (cells that die in an uncontrolled or 
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unregulated manner) by immature DCs or tolDCs modulated the release and 
expression of IL-12 cytokine family members, particularly the IL-12/IL-35 axis. 
We found that apoptotic cell uptake resulted in diminished production of IL-12p40 
and IL-12p70, while simultaneously increasing expression of IL12A and IL27B. In 
addition we addressed an important question; which is that tolerogenic DCs are 
efficient at ingesting apoptotic material and that their regulatory cytokine profile 
is maintained even when challenged with necrotic material. In this chapter we 
conclude that ingestion of apoptotic versus necrotic cells by DCs differentially 
regulates the IL-12 family members thereby playing a role in determining the 
immune response in such events.
One of the most renowned pathways associated with apoptotic cell clearance is 
the complement system. The complement system is composed of a number of 
small proteins found in circulation and was first discovered by its ability to assist 
or “complement” the bactericidal activity of blood. Since its initial discovery, the 
complement system has established itself as an important mediator of apoptotic 
cell and immune complex clearance, pathogen eradication and lowering the 
threshold of B cell activation and antibody production. Considering the increased 
and accelerated clearance of dying cells by tolDCs in chapter 3 we began 
investigating the production and regulation of complement factors by DCs and 
tolDCs, with a particular focus on the lesser studied of the three complement 
pathways; the alternative pathway. In Chapter 4 we described the production of 
two key regulators of the alternative pathway of complement by DCs and tolDCs. 
Factor H (fH) and properdin (fP) are at opposite poles in terms of complement 
regulation with fH being an important negative regulator and fP being the 
only known positive regulator within the entire system. We showed that IL-27 
and members of the Interferon family differentially regulated the expression 
of fH and properdin. Surprisingly, IFNγ played a dual role, with the ability to 
markedly reduce fP secretion while simultaneously increasing fH. As such IFNγ 
appears to support complement regulation as opposed to activation. We further 
demonstrated how alteration in the balance between properdin and fH affected 
the allostimulatory capabilities of DCs with reduction of fH leading to increased 
T cell stimulation and reduction of fP resulting in diminished stimulation of T 
cells by DCs. 
The work demonstated in chapters 5 & 6 largely stemmed from the pioneering 
work by Matzinger and colleagues who put-forward the idea that the local organ 
or tissue in which an immune cell resides can possess enormous influence 
in determining the fate of that particular immune cell. In the last decade the 
kidney has come to light as being a hive of immune activity with many renal 
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cells possessing immunologically active molecules including B7H1, CD40 and 
MHC class II among others. In view of previous reports that Ebi3 expression is 
not restricted to haematopoietic lineages we investigated whether Ebi3 and other 
members of the IL-12 family could be identified within normal human kidney. 
In Chapter 5 we analysed the expression of Ebi3 and related partners, IL-12p35 
and IL-27p28, within normal human kidney, and found abundant expression of 
Ebi3 and IL-12p35 within the glomerular region. In-vitro experiments strongly 
suggested that podocytes were the source of this abundant Ebi3 expression. 
Analysis of an acute rejection patient cohort demonstrated that compared to 
the pre-transplant biopsies, Ebi3 transcripts were down-regulated during acute 
rejection. This data suggests a possible role for Ebi3 and Ebi3-related cytokines 
in allograft rejection that requires further investigation. Finally in Chapter 6 
we described that generation of DCs in the presence of healthy renal fibroblasts 
led to the development of a DC population with regulatory properties. These 
DCs displayed a reduced capacity to produce IL-12 but maintained normal levels 
of IL-23 and IL-27, while IL-10 production was elevated. Further experiments 
demonstrated that IL-6 was at least partially responsible for the ability of human 
renal fibroblasts to generate this regulatory DC population. One could question 
what happens in organs undergoing chronic inflammation. Considering the 
central location of fibroblasts within the kidney it is reasonable to postulate that 
these cells themselves are functionally affected in periods of inflammation or 
upon injury. This is likely to impair their ability to regulate local and infiltrating 
DC populations, thereby potentially exacerbating the inflammatory response. 
Little is known about the expression and responsiveness of renal fibroblast to 
DAMPs but research into this field could prove invaluable in fully understanding 
local DC responses.  
In conclusion, one could argue that many of the remaining caveats in our 
understanding of the immune system relate in one way or another to the question 
of immune regulation and immune tolerance. This thesis highlights that the IL-
12 family and DCs together can be harnessed to control and completely direct 
the adaptive immune response. Much remains to be seen in terms of the potential 
use for IL-35 therapeutically but in light of its clear immunoregulatory properties 
it could prove invaluable to expand our current knowledge on immune tolerance 
in vivo. Furthermore this thesis emphasises that the responsibility of immune 
homeostasis lies far beyond the professional immune cells (neutrophils, DCs, 
T and B cells) and that the local cellular and tissue environment should be 
considered in order to get a true perspective on local immune responses. The IL-
12 family and DCs, either as individual entities or together, have the potential to 
lead to the development of specific immune based therapies, ultimately yielding 
sustained and targeted immune regulation.
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Achoimre 
Is iad na cealla dendritic (DC) na cealla a thugann antaigíní faoi deara sa chóras 
díolúine. Is é a bpríomh fheidhm ná ábhar antaigín a phróiseáil mar shampla ó 
cealla díobhálacha nó patalgin, agus taispéanann siad ar dhromchla na cealla do 
dtí na cealla T den gcóras díolúine. Mar sin gníomhann DC`s mar droichead idir 
an dhá ghéag den gcóras díolúine; na freagraí solúbtha díolúine agus dúchasacha. 
Is cuid den chéad géag dúchasach ach tá ról speisialta acu sa mheádú den freagra 
solubtha díolúine, ar lámh amháin chun díonacht ar phatalgin a chur chun 
cinn agus ar an lámh eile chun caoin-fhulaingt a choimeád ar féin nó antigíní 
neamhúrchóideacha. De bharr sin tá suim ar leith in conas ar féidir leas a bhaint 
as DC`s mar fhoirmde teiripe dhíonachta mar shampla chun díonacht ar ailse a 
fheidhmiú nó chun glacadh greamacht i nódú a chur chun cinn. Is idir gabhálaithe 
rí thábhachtach na fachtóiri inthuaslagtha atá curtha amach ag na DC`s, chun 
cothromacht a chinneadh idir géaga rialaithe agus immunogenic sa chóras 
díolúine agus grúpa amháin de na fachtóirí sin is ea cytokines. Is proitéin beaga 
iad na cytokines seo a féidir a ligeadh amach ag na cealla agus ina dhiaidh sin 
chun tionchar a bheith acu ar iompair na cealla eile. Is féidir saghasanna eágsúla 
cealla cytokine singil a thairgeadh agus is feídir réimse leathan feidhmiúcháin a 
bheith aige. De thoradh ar seo go minic cuirteac na cytokines isteach I ngrúpaí 
éagsúla bunaithe ar struchtúir ionanais in áit dúchas nó feidhmiú na cealla. Tá 
aire faoi leith á dhíriú ar ghrúpa IL-12. Tá sé déanta suas de cheithre bhaill; IL-12 
agus IL-23, is iad sin na cealla immunogenic agus leíriódh an carachtéir atá acu 
ins na DC`s. Is rialaitheoirí iad an dá cheann eile IL-27 agus IL-35 ach níl mórán 
ar eolas faoina rialacháin nó a leíriú daonra DC. Ins an tráchtas seo sé an aidhm 
a bhí again ná forbhreathnú cuimsitheach de leíriú agus rialú na baill den IL-12 
ins na DC`s daonna le béim faoi Leith ar an IL-12, IL-27 agus IL-35.
Is iomaí tuairmíocht atá déanta ar na DC`s, go háirithe DC`s tolerogenic ar an 
féidir leo IL-35 a thairgeadh. Rinneamar DC tolerogenic a ghiniúnt in-vitro ag 
baint úsáid as gníomhaire coscaithe imdhíonachta dexamethasone. I gcaibidil 2 
léiríomar sonraí maidir le cumas le na tolDC`s daonna seo chun IL-12p35 agus 
Ebi3 a thairgeadh, an slabhra alpha agus beta de IL-35 fach seach. Ins an cáibidil 
seo thaispeánamar don chéad uair mair a aisgairiú an tairgeadh de IL-12p35 i 
tolDC`s gur laighdigh sé an cumas cosceadh imdhíonachta de na cealla agus 
taispeánann sé gur idirgabhálaí úr é IL-35 de coisceadh imdhíonachta ag tolDC`s.
Uair amháin ceapadh gur de bharr easpa freagrachta ach anois tuigtear go bhfuil 
an lamháltas ann de thoradh próiséisí casta gníomhachtaithe a tharlaíonn chun 
lamháltas imdhíonachta a chaomhnú. Tá an t-athrú seo I réasunaíocht a leathrú 
go dtí an reímse apoptosis áit a bhfuil corp fianaise atá ag méadú ann chun cuidiú 
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leis an barúil gur próiséisí gníomhachta iad sin atá ainmnithe mar proiséisí 
bainte go riúin do na cealla apoptotic sa cholann a chríochnaíonn i gcothabháil 
na caoinfhulaingthe chun féin antaigíní agus antaigíní neamhúrchóideacha. Mar 
sin tuigtear go gcuidíonn an tabhairt suas de na cealla DC`s atá ag dul in éag leis 
an ionduchtú agus an cothabháil den lámhaltas imdhíoneolaíochta in-vivo. Tá 
an-chuid grúpaí maidir le nodaíocht ag déanamh iarracht fáil amach an bealach 
is fear chun lamháltas a thosnú I bhfaighteoirí allograft. Is straitéis geallúnach é 
tolDC`s de bhfaighteoirí bunúsacha a shaothrú iad a bheathú le cealla apoptotic 
bronnta. Taispeánadh gur sa samhail murine nuair a dírítear ar DC`s le ábhar 
apoptotic bronnta gur féidir srian a chur le allo-recognition indíreach, bac mhór 
é sin lamháltas nodaíochta. I gcaibidil 3 scrúdaíomar an tionchar a bhí ag an 
tabhairt de cealla marbha ar gheiniunt agus léiriú de na baill éagsúla den aicme 
IL-12 le DC anabaí nó tolDC. Léiríomar an tslí a dhéanann phagocytosis de cealla 
apoptotic nó necrotic trí DC`s anabaí nó tolDC`s athrú ar an scoileadh agus ar an 
gcur in iúl de IL-12 cytokine, go háirithe den ais IL-12/IL-35. Fuaireamar amach 
gur laighdaíodh ar thairgeadh de IL-12p40 agus IL-12p70 le tabhairt suas ar na 
cealla apoptotic agus necrotic ag an am chéanna ag méadú ar chur in iúl de IL12A 
agus IL27B. Chomh maith le seo thugamar aghaidh arc heist thábhachtach; sé sin 
go bhfuil na DC`s tolerogenic éifeachtach ag tabhairt ábhar apoptotic isteach sa 
cholann agus go gcoimeádann siad a bprofíl cytokine rialaithe le ábhar necrotic 
fiú amháin. Sa chaibidil seo thángamar ar an dtuairim go rialaítear an aicme IL-
12  go dfréalach nuair a itheann DC`s cealla apoptotic i gcoinne cealla necrotic, 
dá bhrí sin na baill ag imirt ról ag cinneadh an freagra imdhíonachta ar imeachtaí 
den sórt sin.
Ceann de na cosáin is cailiúla atá ag baint le imreitiú cealla apoptotic is ea an 
córas comhlánú. Nuair a mheastar an méadú agus an imreitiú sciopa de na cealla 
atá ag dul in éag leis an tolDC`s i gcaibidil 3, thosuaíomar ag déanamh inscrúdú 
ar tairgeadh agus rialú na fachtóir comhlánú ag DC`s agus tolDC`s, le béim faoi 
leith ar an gcosán is lú a rinneadh staidéar air de na trí cosán comhlánú: an cosán 
malartach. I gcaibidil 4 rinneamar cur síos ar tairgeadh an dá phríomh rialaitheoir 
den cosán malartach den chomhlánú ag DC`s agus ag tolDC`s. Tá fachtóir H (fH) 
agus properdin (fP) mar chuaillí urchomhaireacha maidir le rialú comhlánú ag 
fH an rialaitheoir tábhachtach diúltach agus fP an rialaitheoir dearfach amháin 
atá ar eolas taobh istigh den córas ar fad. Thaispeánamar go ndearna IL-27 agus 
baill eile den aicme interferon (IFN) rialú difréalach ar an dtaispeántas de fH 
agus properdin. Mar ábhar iontais, bhí ról dúbailte ag IFNγ, agus an cumas aige 
laghdú suntasach a dhéanamh ar cur amach FP agus san am ceánna, ag méadú 
fH. Mar sin is cosúil go gcuidíonn IFNγ le rialú comhlánú in ait gníomhachas. 
Thaispeánamar freisin conas mar a bhfuil tionchar ag athrú an iarmhéid idir 
properdin agus fH ar chumas allostimulatory de na DC`s agus laghdú den fH ag 
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díriú ar mhéadú gníomhachas T cell agus laghdú de fP agus mar thoradh ar sin 
go bhfuil laghdú spreagadh ar na cealla T ag na DC`s.
Tá an meid oibre i gcaibidil  5,6 tagtha ón saothar oibre atá déanta ag Matzinger 
agus a chomhghleacaithe a luaigh an barúil gur féidir leis an organ áitiúil nó 
fiochán áit ar féidir ceall imdhíon conaí tíonchar an-mhór a bheith aige i gcinneadh 
a chinniúnt den ceall imdhíon sin. Le deich mbliana anuas is léir gur látháir 
gníomhachta díolúine an duán, agus go bhfuil an-chuid moilíní gníomhachtaithe 
imdhionealaíochta ins na cealla duáin mar atá B7H1, CD40 agus MHC ranna 
II agus cuid eile. Nuair a chuirtear reámhthráchtas san áireamh nach bhfuil cur 
amach Ebi3 srianaithe le línte haematopoeitic rinneamar inscrúdú ar ar féidir Ebi3 
agus baill eile den aicme IL-12 a aithniú taobh istigh den ghnáth duán daonna. 
I gcaibidil 5 rinneamar anailís ar thaispéantas an Ebi3 agus comhpháirtithe 
gaolmhara, IL-12p35 agus IL-27p28, taobh istigh den ghnáth duán daonna agus 
fuaireamar an-chuid taispeántas de Ebi3 agus IL-12p35 taobh istigh den réigiún 
glomerular. Thug turgnamh in-vitro faoi deara go láidir gurb iad na podocytes 
foinse an taispeántas Ebi3 fhúirseach seo. Anailís a rinneadh ar ghrúpa othair a 
dhiúltaigh go gear a thaispeán i gcomparáid le bithopsí reámh nódaithe, go raibh 
athscríbhinní Ebi3 rialaithe síos le linn diúltú gear. Léiríonn na sonraí seo gur 
féidir le Ebi3 agus cytokines gnolaithe Ebi3 rol a bheith aige in diúltú allograft 
agus go bhfuil stáideár níos faide ag teastáil ar an méid seo.
Ar deireadh i gcaibidil 6, léiríomar nuair a geintear na DC`s mair atá fibroblasts 
dúanacha sláintiúla i láthair gur dhírigh sé seo ar daonra DC a bhfuil tréithe 
rialachas acu. Thaispeáin na DC`s seo cumas laghdaithe IL-12 a thairgeadh ach 
choinnigh siad leibhéal normálta de IL-23 agus IL-27 ach san am gcéanna nuair 
a bhí tairgeadh IL-10 ardaithe. Thaispeáin tuilleadh turgnamh go raibh IL-6 
ciontach sa pháirt as an gcumas atá ag fibroblasts diánacha sláintiúla an daonra 
rialaithe DC seo a gheiniúnt. Is féidir ceist a chur faoi mar cad a tharlaíonn in 
orgáin atá faoi athlasadh ainsealach. Nuair a thugtar faoi deara an ionad lárnach 
a bhfuil ag na fibroblasts taobh istigh den duán is rud reásúnach é a rá go bhfuil 
na cealla seo iad féin faoi thionchar feidhmiúl nuair atá réimsí athlasadh ann nó 
gortú. Mar sin, is dócha go gcuireann sé seo srian lena gcumas chun daonra DC 
áitiúl agus ón dtaobh amuigh a rialú agus de bharr sin ag cur méadú le freagracht 
athlasadh. Níl mórán ar eolas faoin freagrúlacht agus taispeántas de fibroblasts 
duánacha go DAMPs ach bheadh sí rí-thábhachtach taighde a dhéanamh chun 
tuiscint ceart a fháil ar fhreagrúlacht DC áitiúl.
Mar fhocail scoir, d`fhéadfadh duine a mhaíomh go mbaineann alán de na caveats 
atá fágtha inár dtuiscint ar an chóras imdhíonachta ar bhealach amháin ná eile le 
ceist na rialacháin imdhíonachta agus caoinfhulaignt imdhíonachta. Aibhsíonn 
an tráchtas seo gur féidir leis an aicme IL-12 agus DC`s gafa le chéile chun rialú 
agus stiúradh iomlán a dhéanamh ar an bhfreagra imdhíonachta oiriúnaitheach. 
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Tá i bhfad níos mó fós le feiceáil i dtearmaí úsáid féideartha le haghaidh IL-
35 teiripeach, ach mar gheall go bhfuil tréithe dearfa rialaithe imdhíonach aige, 
ba rud an-thábhachtach é an t-eolas atá againn faoi láthair ar chaoinfhulaignt 
imdhíonachta in-vivo a mheadú. Níos mó ná sin, cuireann an tráchtas seo béim ar 
chúrann de imdhíonacht homeostasis i bhfad lasmuigh de na cealla imdhíonachta 
profisiúnta (neutrophils, DC`s, cealla T agus B) agus gur ceart barúil a dhéanamh 
den imshaoil cealla agus fiocháin áitiúla chun fíor léargas a fháil ar freagrachtaí 
imdhíonacha áitiúla. Tá cumas ag an aicme IL-12 agus DC`s ag obair ina aonair nó 
le chéile, treoir a thabhairt do fhorbairt teiripí sonracha,imdhíonachta bunaithe, i 
na dála ag tabhairt rialachán imdhíonachta leanúnach agus spriocdhírithe. 
Nederlandse samenvatting
Dendritische cellen zijn de antigeen presenterende cellen van het immuunsysteem. 
Hun belangrijkste functie is om antigeen materiaal zoals pathogenen of tumor 
cellen, op te nemen, te processen en op hun oppervlak te presenteren aan T 
lymphocyten. Op deze manier zijn DCs de brug tussen de twee armen van het 
immuun systeem, het aangeboren (innate) en verworven (adaptieve) immuun 
systeem. DC behoren tot het aangeboren systeem, maar zijn in feite de dirigenten 
van de adaptieve response, zowel voor het induceren van immuniteit tegen 
pathogenen, maar ook om tolerantie in stand te houden tegen onschuldige 
antigenen, bijvoorbeeld die van het eigen lichaam. Als gevolg hiervan is er grote 
aandacht hoe DCs gebruikt kunnen worden als vorm van immuno therapie, bv 
om een response tegen tumoren te induceren of juist transplantaat acceptatie te 
verhogen. 
Oplosbare factoren uitgescheiden door DCs zijn cruciale mediatoren om de 
balans tussen immuniteit en tolerantie te bepalen, en dan met name de familie 
van cytokinen. Deze cytokinen zijn kleine eiwitten die geproduceerd door een 
cel de functie van andere cellen beïnvloeden. Een individueel cytokine kan door 
meerdere cel typen gemaakt worden en daarnaast ook verschillende activiteiten 
uitoefenen, kortom ze vormen een complex netwerk. Gebaseerd op de structuur 
en/of functie kunnen verschillende families van cytokinen onderscheiden 
worden. Een familie die de laatste jaren veel aandacht heeft gekregen is de IL-12 
familie. Het bestaat uit 4 leden; IL-12 en IL-23 zijn imunogeen en hun productie 
en regulatie in DCs is uitgebreid beschreven. De twee andere leden, IL-27 en 
IL-35 zijn meer regulerend, en van deze factoren is relatief minder bekend, zeker 
wat betreft de productie en regulatie in DC populaties. Studies in dit proefschrift 
concentreren zich met name op de regulatie van de IL-12 familie in menselijke 
DCs met een nadruk op IL-35.
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Er is enige speculatie geweest over de capaciteit van DCs, en dan met name van 
tolerogene DCs (tolDCs), om IL-35 te kunnen produceren. In onze studies is 
gebruik gemaakt van tolerogene DCs die met behulp van het immunosuppressieve 
medicijn dexamethason gemaakt werden van perifeer bloed monocyten. In 
hoofdstuk 2 presenteren we de data betreffende de capaciteit van humane tolDCs 
om IL-12p35 en Ebi3,de respectievelijk alpha en beta keten van IL-35. We 
tonen aan dat een blokkade van de IL12-p35 keten in deze cellen de regulerende 
werking van deze cellen verminderd. Een dergelijk rol in de reguleren de wering 
van tolDCs is niet eerder aangetoond.
Hoewel vroeger vooral aangenomen werd dat tolerantie staat voor de afwezigheid 
van een immuun response, is steeds duidelijker geworden dat het behoud van 
tolerantie een veel actiever en complex proces is. Dit wordt het best geillustrrerd 
met de kennis over het opruimen van apoptotische cellen (cellen die via een 
natuurlijk proces dood gaan). Het opruimen hiervan is niet per se een inert proces, 
maar gaat juist gepaard met het activeren van allerlei regulerende processen en 
lijkt daarmee van groot belang te zijn om tolerantie tegen eigen cellen/weefsel 
in stand te houden. In het veld van transplantatie zijn meerdere groepen op zoek 
naar methoden om experimenteel, maar uiteindelijk ook in patienten, actief 
transplantatie tolerantie te induceren. Een veel belovende techniek lijkt hierbij te 
zijn om tolerogene DCs van de ontvanger te kwekken, bloot te stellen aan donor 
cellen (en deze te laten opnemen en presenteren) en dan weer terug te geven 
aan de ontvanger. In hoofdstuk 3 hebben we onderzocht hoe de opname van 
dood celmateriaal van invloed is op de expressie en productie van verschillende 
leden van de IL-12 familie door zowel DCs als tolDCs. We vonden dat opname 
van apoptotische cellen door DCs de productie van IL-12p70, het actieve IL-
12 molecuul, sterk verminderde, terwijl tegelijkertijd de expressie van de alpha 
keten van IL-12 (IL-12p35) en IL-27 beta keten verhoogde. Kortom, normale 
DCs lijken door deze opname hun immunogene cytokines te remmen terwijl 
de expressie van de regulerende familie leden juist omhoog gaat. Voor tolDCs, 
waar de balans al in het voordeel van de regulerende cytokines ligt, had de 
opname van apoptotische cellen geen verder positief effect, maar belangrijk ook 
geen remmende werking. Ten slotte werd gevonden dat de manier van celdood 
ook nog van belang was. Wanneer de studies werden verricht met necrotische 
cellen, gaf dit juist aanleiding tot de activatie van IL-12 productie, en dus niet de 
remming zoals gezien met apoptische cellen. Kortom de balans van immunogene 
en regulerende cytokine door DCs wordt zowel bepaald door het type DC als 
door het type celdood.
Een belangrijke proces waarvan al langer bekend is dat dit bij het opruimen 
van apoptotisch materiaal betrokken is , is het complement systeem. Hoewel 
de meeste complement eiwitten met name door de lever geproduceerd worden, 
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wordt steeds duidelijk dat er ook een lokale productie van complement kan plaats 
vinden, onder andere door antigeen presenterende cellen. Gezien het feit dat we 
in hoofstuk 3 ook aantoonden dat tolDCs efficiënter waren in het opruimen van 
apoptotisch materiaal, hebben we de productie van complement factoren door 
DCs verder bestudeerd. Daarbij hebben we ons geconcentreerd op twee factoren 
die van groot belang zijn voor de alternatieve route van activatie. Factor H (fH) 
en properdine (fP) zijn twee eiwitten die een tegenovergesteld effect hebben op 
de alternatieve route; fH is een belangrijke remmer van dit systeem, terwijl fP 
de enige positieve regulator is die de stabiliteit van het C3 convertase complex 
verhoogt. In hoofdstuk 4 toonden we aan dat beide factoren verschillend 
gereguleerd werden door IL-27 en leden van de interferon familie, een ander 
groep cytokinen. Met name IFN-gamma speelde een dubbele rol, waarbij de 
productie van fP geremd werd, terwijl tegelijkertijd de productie van factor H 
juist omhoog ging. Dit suggereert dat IFN-gamma een netto negatief effect heeft 
op de lokale complement activatie. Recent is aangetoond dat tijdens de interactie 
tussen T cellen en antigeen presenterende cellen, deze lokale alternatieve route 
activatie positief bijdraagt aan de activatie van de T cellen. Door middel van 
specifieke remming van de productie van fH of fP door DCs, met behulp van 
siRNA interferentie, toonden we aan dat  verminderde fH expressie resulteerde 
in een verhoogde T cel proliferatie, terwijl een verminderde fP productie juist 
aanleiding gaf tot een verminderde proliferatie. Deze data tonen aan dat ook fH 
en fP een rol spelen bij de alloimmuun respons.
Het werk in hoofdstuk 5 en hoofdstuk 6 bouwt voort op het idee van Matzinger 
dat de lokale conditie in een orgaan of weefsel van groot belang zijn voor de 
kwaliteit van een immuunrespons. Wat betreft de nier is intussen aangetoond dat 
verschillende moleculen met een actieve rol in het sturen van immunologische 
reacties, zoals B7H1, CD40 en MHC klasse II, op verschillende cellen in de nier 
voor komen. Gezien het feit dat de expressie van Ebi3, een onderdeel van IL-35, 
niet beperkt blijft tot hematopoietische cellen, is de expressie van deze en andere 
IL-12 familieleden in de onder verder onderzocht. In hoofdstuk 5 toonden we 
aan dat zowel Ebi3 als de geassocieerde ketens IL-12p35 en IL-27p28 in de nier 
tot expressie kwamen, en dan met name in de glomerulus van de nier. Zowel 
dubbelkleuringen als in vitro experimenten met geweekte niercellen suggereerden 
dat podocyten de meest waarschijnlijk bron waren van deze Ebi3 productie. De 
expressie van Ebi3 werd ook onderzocht in een cohort van afstotingsbiopten, 
waarbij de expressie heterogeen was, maar de indruk bestond dat deze expressie 
verlaagd was ten tijde van afstoting. Deze bevinding zal verder onderzocht 
moeten worden om de functie van dit Ebi3 nader te onderzoeken.
In hoofdstuk 6 ten slotte hebben we onderzocht in hoeverre in vitro de 
ontwikkeling en functie van DCs beïnvloed wordt door de aanwezigheid van 
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nierfibroblasten. Deze DCs vertoonden een verminderde capaciteit om IL-12 te 
produceren, terwijl de hoeveelheid IL-23 en IL-27 niet beïnvloed werd en de 
hoeveelheid IL-10 zelfs hoger was. Verder onderzoek toonde dat IL-6 gedeeltelijk 
verantwoordelijk was voor het ontstaan van deze DCs met een meer regulerende 
functie. Deze veranderde functie werd bevestigd door het feit dat ook de T cel 
activatie door deze cellen sterk geremd was. Gezien de uitgebreide aanwezigheid 
van dit fibroblast netwerk in het interstitium van de nier, de locatie waar ook de 
DCs zich voornamelijk bevinden, levert vele vragen over hoe in situaties van 
chronische ontsteking en reactie op weefselschade en dit zal verder onderzocht 
moeten worden.
In conclusie kan gesteld worden dat de vraag hoe tolerantie gereguleerd wordt nog 
altijd een belangrijk thema binnen de immunologie is. Het huidige proefschrift 
heeft zich toegespitst op de IL-12 familie en DCs, twee belangrijke spelers in het 
aansturen van de adaptieve immuun respons. We toonden een potentiele rol voor 
IL-35, geproduceerd door dendritische cellen, in dit proces. Verder werd uit het 
werk in dit proefschrift duidelijk dat naast de cellen van het immuunsysteem, 
ook andere parenchymale of stromale cellen, direct of indirect, van belang zijn 
voor het lokale milieu en met elkaar de immuun homeostase bepalen. Het begrip 
in de functie van DCs en de IL-12 familie zullen bijdragen aan de ontwikkeling 
van nieuwe therapieën die kunnen bijdragen aan langdurige en specifieke 
immuunregulatie en tolerantie, het ultieme doel in orgaan transplantatie.
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Abbreviations
Ag   Antigen
AP   Alternative Pathway
APC   Antigen Presenting cell
C3aR   C3a Receptor
C5aR   C5a Receptor
CPM   Counts per minute
CTLR   C-type lectin Receptor
Ctrl   Control
CFSE   Carboxyfluorescein diacetate succinamidyl ester
DAB   3,3’-diaminobenzidine
DAMP   Danger-associated molecular pattern
DAF   Decay accelerating factor (CD55)
DC   Dendritic cell
DC+Fibro Sup  Monocyte derived DC generated in the presence of cell    
   free renal fibroblast supernatant
Dex   Dexamethasone
Ebi3   Epstein Barr Induced Gene-3
ELISA   Enzyme linked immunosorbent assay
fH   Complement Factor H
FHL-1   fH like protein-1
FHR   fH related protein
Fibro-DC  Monocyte derived DC generated in the presence of  
   renal fibroblasts
FITC   Fluorescein isothiocyanate
fP   Complement factor P (Properdin)
GAS   Gamma interferon activation site
HMGB1  High mobility group box 1
HRP   Horseradish peroxidase 
ISRE   IFN-stimulated response elements
LPS   Lipopolysaccharide
mAb    monoclonal antibody
NLR   NOD-like receptor
OD   Optical Density
PDGFRβ  Platelet-derived growth factor receptor beta
PI   Propidium Iodide
PRR   pattern recognition receptors
RLR   RIG-I like receptors
siRNA   silencing RNA
TLR   Toll-like receptor
tolDC   tolerogenic Dendritic cell
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